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The epicardium is a single layer of epithelial (mesothelial) cells that covers the entire heart 
surface, but whose function in adult mammals is poorly understood. Defining the role of 
epicardial cells during homeostasis, growth and injury has potential to provide new treatment 
strategies for human diseases that result in heart failure, due to extensive loss of viable cardiac 
tissue. We hypothesized that epicardial cells contribute to repair as transplantable progenitor 
cells for cellular regeneration and as a source of secreted growth factors for cell protection 
after myocardial infarction. 
Adult epicardial cells were prospectively isolated as uncommitted epithelial cells 
using epithelial-specific beta-4 integrin (CD104). These cells underwent epithelial to 
mesenchymal transformation in culture to generate epicardial cell derivatives (EPDCs). We 
demonstrate that the C-terminal peptide from Connective Tissue Growth Factor (CTGF-D4), 
when combined with insulin, effectively primes EPDCs for robust cardiac engraftment in rats 
and contributes to improvement in cardiac function at one month after MI. Furthermore, we 
define a signaling axis comprised of CTGF-D4, low density lipoprotein receptor-related 
protein 6 (LRP6), sex determining region Y-box 9 (Sox9) and Endothelin Receptor B (ETBR) 
that controls several key processes that impact EPDC graft success: cell survival, proliferation 
and migration. Interestingly, conditional deletion of ETBR using epicardial-specific transgenic 
mice prevented epicardial cell proliferation and migration into myocardium after MI. We 
therefore observed a congruence in the signals and signaling pathways that control the 
proliferation and migration of endogenous EPDCs after MI and EPDCs that can be generated 
in cell culture and grafted back to the heart.  
To gain additional insight into the cellular contribution of the epicardium, we 
utilized a non-injurious running exercise model to evaluate epicardial activity as a 
consequence of cardiac hypertrophy (i.e. myocardial growth model). We employed an 
inducible lineage-tracing system to specifically label and track epicardial cells by GFP 
expression. Prolonged exercise resulted in a significant number of GFP-positive proliferating 
epicardial cells and epicardial-derived GFP-positive endothelial cells and few GFP-positive 
smooth muscle cells in the heart. These observations highlight the cellular plasticity of the 
adult epicardium and its function as a cardiac progenitor cell niche, maintaining a source of 
replacement cells.  
To investigate the paracrine properties of adult epicardial cells for their role in 
cell protection after MI and reperfusion, human epicardial cells were isolated from donor 
atrial tissue explants. We predicted that medium conditioned by cultured epicardial cells (EPI 
CdM) contained secreted reparative factors that would promote endothelial cell survival. 
Administration of EPI CdM promoted endothelial cell survival in culture and in vivo, 24 hours 
after ischemia-reperfusion injury. By screening EPI CdM, we detected protein complexes 
containing hepatocyte growth factor (HGF) with polyclonal IgG that imparted vascular 
protection in vivo in a manner similar to EPI CdM.  
Overall, the studies presented here illustrate the unique biology of epicardial cells, 
their signaling networks, and their contribution to cardiac cell protection and regeneration. 
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CHAPTER I. INTRODUCTION  
 
Clinical need for translational research 
Cardiac ischemia or myocardial infarction in humans  
Ischemic heart disease that includes myocardial infarction (MI) is a leading cause of 
death worldwide among both men and women. In 2012, there were an estimated 7.4 
million deaths due to ischemic heart disease, three quarter of which occurred in low and 
middle income countries (http://www.healthdata.org/gbd). In the United States there are 
an estimated 735,000 people that have an MI every year, with 120,000 cases resulting in 
death. Despite an about 40% fall in mortality rates due to MI over the last decade, it 
remains the leading cause of morbidity and healthcare burden on the surviving population 
(AHA Report, 2015). The risk factors for MI are prevalent at alarmingly high rates across 
multiple countries, thereby highlighting the paramount need for effective prevention and 
treatments.   
Myocardial ischemia occurs during interruption of blood flow to the myocardium 
(heart muscle, cardiomyocyte), creating a mismatch between the myocardial oxygen 
demand and supply in the tissue. Ischemia is often caused by atherosclerotic plaque 
formation in the large coronary arteries. Plaque formation is a slow and chronic process 
responsible for narrowing of the coronary blood vessels and consequent decrease in blood 
flow through them. Myocardial infarction (MI) refers to the necrosis (death) of the 
cardiomyocytes as result of a sudden and profound ischemia (www.mayoclinic.org).  An 
MI results when there is a sudden disruption of an atherosclerotic plaque that results in 
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lodging of plaque material (thrombotic occlusion) in the coronary artery. This occlusion 
causes severe ischemia and subsequent necrosis (infarction) of the myocardium.  
Ventricular remodeling and cardiomyopathy  
An MI creates a central zone of necrotic non-viable myocardium with a surrounding peri-
infarct region consiting of viable, but ischemic tissue. The peri-infarct region represents 
myocardium that can be salvaged by timely restoration of blood supply though the 
occluded vessels (reperfusion). A greater time delay between an infarction event and 
reperfusion results in a corresponding increase in the expansion of the area of necrosis 
into the bordering ischemic but viable peri-infarct regions (Lamas, 1993; Litwin et al., 
1994; McCormick et al., 1994; Nakamura and Tohma, 1991). A single event of MI can 
result in the death of around a billion cardiomyocytes (Sabbah et al., 1998).  Widespread 
cardiomyocyte cell death causes the left ventricle (LV) wall to thin, thereby increasing 
the pressure and volume load on the heart. To compensate for this structural change, the 
LV wall undergoes dilatation that originates from the infarct region and spreads though 
the chamber.  
The formerly healthy, contractile cardiomyocytes are replaced by noncontractile, 
akinetic fibrotic scar tissue comprised of myofibroblasts, which are beneficial to maintain 
the pumping efficiency of the heart and cardiac output in the early phase after MI (Bryant 
et al., 2009; Freed et al., 2005; Vasquez et al., 2010). However, over time increasing 
stress on the surviving cardiomyocytes and extensive scarring results in compensatory 
changes in shape, size, mass, volume and physiology of the LV. This is referred to as 
“negative” LV remodeling because it adversely affects cardiac function. Though 
3 
 
cardiomyocyte necrosis is the major cause of negative remodeling, death of blood 
vessels, fibroblasts and other cell types also contribute to subsequent changes in 
physiology (Roberts et al., 1984). Treating the natural progression of this disease remains 
a major clinical challenge and demands development of new therapies to preserve or 
replace of viable tissue.  
Clinical diagnosis of MI 
MI can be categorized on a clinical basis or on an anatomical and histological basis. In 
the clinic, MI is classified based on the electrical activity in the heart from 
electrocardiographic (ECG/EKG) measurements. These clinical classifications provide 
guidelines for the course of treatment and patient management. Anatomically, MI can be 
either transmural or non-transmural. A transmural infarct spreads across the 3 main heart 
layers in a cross section: the outermost epicardium, the middle myocardium (thickest 
layer) and the inner endocardium. A non-transmural MI is limited to the endocardium and 
inner myocardium, which are also morphologically the least vascularized regions in the 
heart (Figure 2) (www.mayoclinic.org). Echocardiography (ECHO) is a commonly used 
diagnostic tool for visualizing cardiac function using two- or three-dimensional and 
Doppler ultrasound visualizations. Of note, in addition to its clinical usage, ECHO is a 
commonly used method for evaluating the efficacy of basic and translational research 
discoveries.  
Current treatment for MI 
The current standard of care is determined on a patient-to-patient basis with the common 
goals of: (a) rescuing as much of the jeopardized myocardial tissue as possible, (b) relief 
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from angina (pain) and (c) prevention of further injury or related complications.  
Reperfusion therapy for the prompt restoration of blood flow and oxygenation to provide 
relief from symptoms is performed in patients by mechanical or chemical interventions. 
Percutaneous coronary intervention (PCI) is a commonly performed non-surgical 
procedure for the re-canalization of macroscopic coronary arteries. In certain severe 
cases, Coronary Artery Bypass Grafts (CABG) are performed to restore cardiac flow by 
creating new routes of blood flow through vascular grafting (Lamas et al., 1995; Pfeffer 
et al., 1992; Rutherford et al., 1994). Patients are also administered thrombolytic drugs 
which chemically dissolve a clot to release the occlusion and prevent further thrombosis 
(e.g. asprin, IV unfractionated heparin, tissue Plasminogen Activator, IV streptokinase) 
and drugs for symptom relief and prevention of further infarctions (e.g. nitroglycerides, 
beta-blockers, ACE inhibitors) (Lamas et al., 1995; Pfeffer et al., 1992; Rutherford et al., 
1994).  In the USA, these mechanical and chemical interventions combined with 
improved emergency response and primary care have thus far achieved over a 95% 
survival rate for any given individual arriving to the hospital after an MI.  Still, however, 
1 out of every 5 survivors develops chronic heart failure (CHF) in the long-term and 
faces a 5-year mortality rate of around 50% (AHA, 2015 Report).  
Heart Failure 
Congestive heart failure (ischemic cardiomyopathy) results from necrosis of myocardial 
tissue after recurrent bouts of myocardial ischemia with infarctions. The current clinical 
treatment for CHF is limited to administration of pharmacologics that manage disease 
progression and extend patient life span (Atkinson and Robertson, 1979). Heart 
5 
 
transplantation is a strategy to replace a damaged organ with newer and more viable one, 
however this option is available to less than 0.1% of heart failure patients. Treatment of 
CHF to arrest the progression of heart disease or to completely eliminate it is therefore of 
critical importance. Cardiovascular disease has become a global epidemiologic issue due 
to the extent of the affected population, its life-long impact, and its social and financial 
demands for patient management.  
Cardiac cell replacement by transplantation and engraftment of reparative cells           
Early work on myocyte cell engraftment for MI 
Over the last 2 decades, strategies to replace damaged cells in the heart with newer ones 
to prevent or slow the progression of heart failure after MI have received much attention 
and investment. The successful transplantation of skeletal myoblasts into damaged 
muscle of rats, mice and pigs inspired the possibility of providing healthy myocytes after 
MI, by direct cell injections into the heart (Schwarz et al., 1998). Experimental subjects 
were immunosuppressed for allogenic transplantation in different animal models. Direct 
delivery of myocytes or skeletal myoblasts was performed in rabbit and pig models of MI 
(Atkins et al., 1999; Azarnoush et al., 2005), as was delivery of postnatal or fetal 
myocytes (to harness their superior proliferative ability), into rats with MI (Azarnoush et 
al., 2005; Reffelmann et al., 2003). In theory, the best strategy would provide a cell 
source that could: (a) stabilize the existing tissue and prevent remodeling, (b) provide 
regional or global improvement in cardiac function by supporting myocyte contractility, 
and/ or (c) serve as a carrier for drugs or growth factors for molecular support to the host 
myocardium (Schwarz et al., 1998).  However, transplantation of myocytes required their 
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survival and integration with the existing network of electrically coupled myocytes and 
the formation of intracellular connections gap junctions. In certain instances, engraftment 
of mature myocytes resulted in subsequent arrhythmias due to failure of the grafted cells 
to couple to the existing myocardial network. Altogether, outcomes from human clinical 
trials using muscle cells and fetal-derived cells did not generate much enthusiasm, but did 
open avenues for new treatment strategies (Hagege et al., 2006; Ozbaran et al., 2004; 
Patel et al., 2005). Identifying alternate cell sources for repair became an immediate need 
for the advancing field of cardiac cell therapy. 
Stem cells as candidates for cell therapy 
The myoblast transplantation trials coincided with developments in the field of stem cell 
biology, an area that was being explored for its massive potential for regenerative 
medicine. In general, stem/progenitor cells have properties of self-renewal, proliferation, 
migration and differentiation, which make them favorable candidates for cell therapy. For 
instance, using a well-defined cell surface marker profile (Visser et al., 1984), the 
hematopoietic stem cell (HSC) from the bone marrow could be isolated and expanded 
clonally ex vivo and in vivo (Dexter et al., 1977; Morrison and Weissman, 1994). By the 
1970 and 80s, clinical allogenic and autologous bone marrow transplants with HSC were 
being carried out after complete irradiation. The HSC could self-renew (divide to replace 
itself while maintaining its differentiation potential), give rise to a population of fate-
committed progenitors, and repopulate all lineages of the hematopoietic system due to its 
property of multipotency (Weissman and Shizuru, 2008). Accordingly, the administration 
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of naïve, undifferentiated stem/progenitor cells from bone marrow with benefit of 
differentiation into desired cell types gained interest for cell therapy of other organs.  
Stem cell therapy for MI  
Bone marrow-derived cells, circulating progenitors and MSCs for cardiac repair 
In cardiology, numerous clinical trials were initiated using multiple candidate 
stem/progenitor cell types for engraftment. Cells were delivered to subjects either 
intravenously, through injections into the main coronary arteries, or by direct injection 
into the myocardium. Some moderate success was achieved after injection of bone 
marrow derived mononuclear cells. Success of these clinical trials was measured by 
improved cardiac function of patients early after cell administration (Klein et al., 2007; 
Pompilio et al., 2004; Stamm et al., 2003). Unfractionated bone marrow mononuclear 
cells were used due to ease of isolation, in addition to their capability of differentiating 
into vascular endothelial cells to restore perfusion and rebuild areas damaged by 
infarction. Improved methods to isolate, expand and culture other bone marrow-derived 
subpopulations such as vascular progenitor cells also initiated other clinical trials for 
cardiac regeneration in the heart. Another population, namely, Mesenchymal Stromal 
Cells (MSC) from the non-hematopoietic compartment gained widespread popularity in 
cardiac cell transplantation, in addition to their use in other organs (Amado et al., 2005; 
Chen et al., 2004; Giordano et al., 2007; Hare et al., 2009; Luan et al., 2010; Strioga et 
al., 2012). MSCs were particularly interesting because they could be propagated ex vivo 
to provide a source of multiple beneficial reparative secreted factors that were identified 
from their cell culture media (Boyle et al., 2010; Pittenger and Martin, 2004). 
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ES cells and iPSC cells for MI  
Embryonic Stem cells (ES cells) which were first isolated in 1998 from the inner cell 
mass of the blastocyst during embryogenesis (Thomson et al., 1998). These cells retain 
the ability to differentiate into any desired cell type when exposed to appropriate 
hormones and growth factors (Ladd et al., 1998). Early transplantation studies with ES 
cells into animal models of MI resulted in teratoma formation and immune complications 
(Nussbaum et al., 2007). Further understanding of human ES cell biology helped to 
establish protocols for deriving cardiomyocytes ex vivo and in vivo, and coupling them 
with the existing myocardial structures after transplantation. These advances resulted in 
reports of 20-40% improvement in cardiac function for animal models of MI (Caspi et al., 
2007; Laflamme et al., 2005; Shiba et al., 2012; Swijnenburg et al., 2005). To date, 
pluripotent cells or their derivatives have not been approved for cardiac clinical trials in 
the USA. However, one trial has begun in France using ES cell derivatives that are 
Islet1+/ CD15+ progenitors derived from committed ES cells (www.clinicaltrials.gov).  
A landmark discovery in 2006 by researchers in Japan (that was awarded the 
Nobel prize within 7 years) described methods to reprogram differentiated skin fibroblast 
cells into Pluripotent Stem Cells (induced PSC) by expressing 4 transcription factors (c-
Myc, Klf4, Oct-3/4, Sox2) (Takahashi and Yamanaka, 2006). Eventually, these cells 
could be efficiently differentiated into highly pure cardiomyocytes using chemicals, gene 
expression or unique culture conditions and provided a valuable new resource for cell 
replacement (Pasha et al., 2011; Yu et al., 2007). iPSCs derived from mouse, human 
(Ieda et al., 2010) and several other organisms are now available to treat animal models 
and for preclinical and clinical testing for MI. Engraftment studies with iPSC in animal 
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models showed cardiac function benefits in addition to preservation of existing structures 
and coupling with myocytes (Dai et al., 2011; Mauritz et al., 2011).  These cells 
overcome many of the limitations of ES cells for treating adults, while at the same time 
have numerous other applications (Guha et al., 2013). They can be used to create 
cardiomyocyte lines from different donor-derived iPSCs for genetic studies, drug 
screening and for creating patient-specific cell banks. For review, see (Lalit et al., 2014). 
However, utilization of iPSCs for clinical applications demands a significantly deeper 
understanding of cellular properties including clonal capacity, signals that control their 
proliferation and differentiation and their immune modulatory effects, among others.  
 
Challenges to stem cell therapy after MI  
Our ability to evaluate stem cell contribution in terms of direct cell replacement and 
benefit for cardiac function is currently limited. This is due to the low number of cells 
that initially engraft and survive, and that can be detected in the few months or even 
weeks after MI. In fact, thus far, in terms of cell engraftment and survival, poor results 
have been obtained with all candidate cell-types. Important ‘issues’ affecting cell survival 
and engraftment include the death of transplanted cells by apoptosis or necrosis, cell 
escape to extra-cardiac regions (this is of greater risk in the case of systemic cell 
injections) or mechanical loss from areas bordering the infarct due to constant pumping 
action of the heart (Wu et al., 2011). Although multiple clinical trials have reported 
modest improvement in cardiac function in patients after different times of follow-up, 
clear understanding of whether such functional improvements result from cell 
engraftment is lacking (Refer Table 1). To correlate the effects of cell engraftment 
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directly with cardiac function requires robust levels of initial engraftment, survival, 
proliferation, migration and (or) differentiation of the cells, and in some cases, their long 
term persistence in the heart.  A recent report from 2014 in macaques showed modest cell 
survival at 1 month after MI (Chong et al., 2014). However, this was not a significant 
improvement in the level of engraftment over that achieved in prior pre-clinical studies in 
2005 in sheep (Menard et al., 2005). Low engraftment and survival remains a major 
challenge for cell replacement after MI, as infarct necrotic zones are saturated with cell 
death signals, immune infiltrates, cell debris, redox mediators and extracellular exudates. 
Therefore, new strategies are required to promote cell survival and engraftment after MI.   
Strategies to improve engraftment of transplanted cells in hearts with MI      
Amongst various criteria, method of delivery is critical to determining the success of 
engraftment. To improve the efficiency of cell delivery, survival and persistence, 
additional manipulations are currently being tested prior to cell engraftment (Wu et al., 
2011). For instance, any potential candidate cell can be preconditioned or primed by heat 
shock (Suzuki et al., 2000) or exposure to hypoxia, often termed “ischemic 
preconditioning” prior to engraftment (Chacko et al., 2010; Niagara et al., 2007).  Grafted 
cells might also be genetically modified to express of pro-survival factors such as Akt 
(Kofidis et al., 2004; Kutschka et al., 2006; Mangi et al., 2003), or conjugated to 
magnetic beads to increase early retention (Cheng et al., 2010). Bioengineering material 
to serve as carriers and scaffolds for cell delivery has gained massive momentum to 
support cell therapy for MI.  Grafted cells are frequently prepared by microencapsulation 
into degradable microbeads prior to engraftment (Paul et al., 2009). Alternatively, cells 
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are arrested in scaffolds where they are physically coupled to artificial or natural 
substances that form matrices, prior to injections. These matrices can either be injected as 
gels or deposited as patches on the heart surface (Guo et al., 2011; Wang et al., 2010). 
Most of these methods have shown promise in animal models of MI, where investigators 
have detected beneficial differences in cell injections  with cells combined with 
engineered formulations versus cells alone (Bel et al., 2010; Hu et al., 2008; Huang et al., 
2010; Tao et al., 2011; Yu et al., 2010). Notably, however, such constructs do have 
potential to interfere with the natural disease environment and to alter tissue in ways that 
could impede the natural course of remodeling and repair. Furthermore, the sustainable 
and practical aspects of these formulations have to be formally characterized prior to their 
use in humans.  
An effective approach to improve cell delivery methods would likely benefit from 
the identification of biological signals in the cell’s natural environment (niche) that 
supports its native survival and functions. As elaborated in this dissertation, providing 
sufficient or excess amounts of these endogenous signals during the process of 
engraftment supports cell survival and can foster their natural course of action. These 
signals can be delivered in controlled amounts, for specific periods of time, and in a cell-
specific manner. Consequently, this directed approach eliminates the need to modify 
candidate cells genetically or by other means that risk abnormal behavior (e.g., 
unexpected tumors arising from primary cells due to gene overexpression). Harnessing 
cell signals from the injury environment has great potential to ensure predictable, safe 
and consistent outputs from grafted cells engraftment based on fundamental biological 
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properties, and may eliminate the variability and risks associated with grafting with 
artificial methods and products.  
The second chapter of this dissertation presents new methods for successful 
grafting of cells to the adult heart after MI. The methods involve screening of niche 
regulating factors from cultures of mesenchymal stromal cells, and the ability of these 
factors (together or in defined, purified combinations) to prime cardiac stem/progenitor 
cells to promote robust cell engraftment. Our results demonstrate dramatic improvements 
in graft success obtained with any cell type to date, particularly for initial engraftment, 
proliferation, migration and differentiation of cells long-term after MI. Of note, cell 
engraftment into the subepicardial regions (beneath the activated epicardium) bordering 
the infarct was found to confer a unique advantage to cell survival and proliferation after 
engraftment. The new engraftment procedures were initially demonstrated with a 
population of widely-used c-Kit+ cardiac stem/progenitor cells, which can be isolated and 
propagated in culture to perform ex vivo studies to study mechanisms of cell signaling 
(Davis et al., 2010; Messina et al., 2004; Mishra et al., 2011). A cell surface glycoprotein, 
c-Kit (a.k.a. CD117), was a marker first used to prospectively isolate bone marrow stem 
cells (Ikuta and Weissman, 1992; Morrison and Weissman, 1994). In 2003, this marker 
was also first described  to isolate a multipotent adult cardiac stem cell with the ability to 
proliferate and differentiate into multiple cardiac cell types including cardiac myocytes 
(Beltrami et al., 2003). These cells gained popularity from observations of repair in 
animal models following in vivo cell transplantation (Beltrami et al., 2003; Cimini et al., 
2007; Fazel et al., 2006; Limana et al., 2005)  and were quick to find their way into 
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Figure 1- 1. Diagramatic representation of the cross section of a mammalian heart 





Connective tissue growth factor in injury repair  
CTGF is a 37 kDa protein first isolated in 1991 from cDNA expression libraries of 
human endothelial cells using anti-PDGF antibodies (Bradham et al., 1991). It has a 
widespread mRNA expression pattern as a single 2.4 kb transcript in heart, brain, kidney, 
placenta, liver and muscle  (Surveyor and Brigstock, 1999) of adults. Within the heart, 
CTGF is produced mainly by myocytes and myofibroblasts (Ohnishi et al., 1998). Our 
group also detected transcripts for CTGF in purified epicardial cells. Although CTGF has 
been detected inside the cytosol of some cells, the majority of CTGF is secreted into the 
extracellular microenvironment (Brigstock, 2010). It can also be detected in plasma, 
serum and urine. The half-life of CTGF is not known, however its uptake was shown to 
be mediated by low-density lipoprotein receptor (LRP) (Brigstock, 2010).  
CTGF is an unconventional growth factor, with a structure comprised of 4 distinct 
domains: an insulin-like growth factor binding protein (IGFBP) domain (module I), a 
Von Willebrand factor domain (module II), a thrombospondin-homology domain 
(module III), and a cysteine knot, heparin-binding domain (module IV). Each of these 
domains interact with multiple different extracellular matrix proteins and growth factors 
outside the cell, as well as integrins and receptors on the cell surface (Abreu et al., 2002; 
Grotendorst and Duncan, 2005; Tong and Brigstock, 2006; Yoshida and Munakata, 
2007). Based on its numerous interaction partners, it is important to consider the activity 
of CTGF in a context-dependent manner (Brigstock, 2010). Angiopoietin II and 
Endothelin-1 induce CTGF expression during cardiac repair and potentially also function 
as downstream mediators of CTGF functions in angiogenesis (Leask and Abraham, 
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2006). Among its multi-faceted roles, there is growing evidence that CTGF promotes the 
process of epithelial to mesenchymal transformation (EMT) and coordinates receptor 
affinity and feedback signaling for BMP,  and TGF-beta signaling and phosphorylation of 
SMADs (Leask, 2010). CTGF has been widely studied in the process of tissue fibrosis. 
While CTGF not capable of initiating fibrotic responses on its own, based on its 
interaction with TGF-beta it may function as a fibrotic “signal amplifier” (Accornero et 
al., 2015; Leask, 2015). 
 
Cardiac Stem Cells  
Does the heart have a bona fide stem cell? Questions and Controversies 
The choice of cell to be grafted is a major consideration for success in cell therapy. The 
heart requires myocytes for contractile and electrical conduction, adventitial and 
interstitial fibroblasts for structural integrity, and vascular smooth muscle and endothelial 
cells to maintain perfusion. Engraftment of each of these cell types individually present 
unique issues, and engraftment of all differentiated cell types is complex and not feasible 
to perform clinically. As such, stem/progenitor cell sources that can provide multiple 
desired fates are more attractive for engraftment to the heart. While we are currently not 
limited by the available options for candidate stem/progenitor cell types for engraftment, 
advances in cell therapy with adult cells suggest that tissue-specific cell types will have 
the most benefit. Several stem/progenitor cell populations have been described in the 
heart that express c-Kit, Sca-1 (Oh et al., 2003), ATP binding transporter (Pfister et al., 
2008) and that form cardiospheres that putatively mark a stem cell clone (Masuda et al., 
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2012; Smith et al., 2007). However, none of these markers or properties are unique to the 
heart, nor are the methods such as cardiospheres isolation a reliable or specific way to 
obtain stem cells.  
More recently, many have challenged the validity of c-Kit as a marker of a true 
stem or progenitor cell in the adult heart (Servick, 2014). Early reports demonstrating 
their ability to differentiate into cardiac myocytes, albeit in low numbers, helped them to 
rapidly enter into human to clinical trials (Beltrami et al., 2003).  However, many 
investigators eventually failed to detect significant proliferation of c-Kit cells in the heart 
after MI. Combined with the absence of detectable myocytes that derived from c-Kit+ 
cells, further studies contradicted what was previously reported (van Berlo et al., 2014). 
To date, as the field has still been unable to reach a consensus regarding a true adult 
cardiac stem cell marker, and the opportunity for discovery remains.  
Epithelial stem cells 
A unique stem cell has not been identified for several adult tissues or organs in mammals. 
In fact, emerging reports are now challenging the existing dogma that proposes a true 
stem cell (by definition) exists in every organ. Instead, evidence from multiple organs 
indicates that a differentiated cell within some organs has the ability to dedifferentiate 
into a more primitive stem or progenitor-like phenotype and function in organ repair after 
injury (Blanpain and Fuchs, 2014). For instance Clevers et. al. identified a cell surface 
marker “Troy” that marks a specific subset of chief cells in the intestine that display 
plasticity (i.e. they serve as quiescent reserve stem cells and can replenish the entire 
gastric unit at the tissue level upon dedifferentiation) (Stange et al., 2013). Studies in the 
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lung demonstrated the ability of a committed epithelial cell to dedifferentiated and 
function as a stem cell in vivo after injury (Tata et al., 2013), while differentiated kidney 
epithelial cells were shown to participate in kidney repair after proximal tubule injury 
(Kusaba et al., 2014). These observations challenge the notion that stem cell hierarchies 
are represented by a unidirectional model for differentiation, and that committed cells 
can, in part, serve to be a part of the homeostatic and eventual tissue regeneration 
programs in the body.  
Interestingly, the above examples also allude to the theme of epithelial cells 
serving as putative stem cells in multiple organs after injury reviewed by Blanpain and 
Fuchs (Blanpain and Fuchs, 2014). This review details the remarkable plasticity of 
epithelial cells that were thought to be lineage-restricted and their ability to acquire stem 
like properties during physiological or regenerative conditions. In the heart, among 
various differentiated cell types, the epicardium, an epithelial layer covering the entire 
heart surface has marked potential for dedifferentiation. Epicardial cells are promising 
candidates for engraftment based on myriad properties that include their role as a 
progenitor cell source in development, their direction of tissue morphogenesis by 
protein/peptide secretions, and emerging evidence for functions in modulation of 
inflammation after an injury (Smart and Riley, 2012). 
Epicardial cell biology in development and disease 
Epicardium forms the cover of the heart 
 
The epicardium is a single layer of epithelial (mesothelial cells) that covers the entire 
heart surface. It plays key roles in signaling to the myocardium and also as a progenitor 
19 
 
cell source for different cardiac lineages. Physical removal of the epicardial layer in 
developing avian hearts resulted in arrest of cardiomyocyte growth, leading to a thin-
walled ventricle, and the arrest of coronary vessel development (Gittenberger-de Groot et 
al., 2000; Pennisi et al., 2003). Likewise, knockout of genes required for epicardial 
survival and function in mice [e.g., beta-catenin (Zamora et al., 2007), Wt1 (Guadix et 
al., 2011), Vcam1 (alpha4beta1 integrin) (Sengbusch et al., 2002) , Gata4 (Watt et al., 
2004), Notch (del Monte et al., 2011; Loomes et al., 2002)] resulted in similar 
phenotypes.  
Epicardium during development 
During cardiac development, the epicardium serves as an important signaling center to 
ensure myocyte development and a cellular source for formation of the coronary 
vasculature. Lineage-tracing studies in developing chick and quail embryos have 
provided insights into the origin and fate of the epicardium. It derives from the 
proepicardial organ (epithelium attached to the embryonic diaphragm), and in mice, 
around embryonic day 9.5 (E9.5) it migrates to completely engulf the myocardial and 
endocardial layers. Around E10.5 it forms an epithelial covering around the entire 
developing structure, termed the epicardium. From this stage onwards it is responsible for 
directing events that help to complete cardiac development.  
Between E11.5 and 13.5, epicardial cells undergo epithelial to mesenchymal 
transformation, providing a population of subepicardial mesenchymal cells and 
precursors that migrate into the myocardium. Retinoic acid (RA) and erythropoietin 
(Epo) signaling within the epicardial cells stimulates them to secrete mitogens that are 
required for myocyte proliferation and maturation; this induces maximal heart growth. 
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Mice deficient in RA or Epo signaling were reported to have severe myocyte hypoplasia. 
In turn, it has been shown that epicardial PDGF, FGF9, FGF16 and FGF20 signaling to 
myocyte FGFR1 and 2 receptors mediates myocardial growth (Lavine and Ornitz, 2008; 
Lavine et al., 2005; Vega-Hernandez et al., 2011).  
Epicardium in lower vertebrates 
In lower vertebrates, which share conserved features of cardiac development with 
mammals, the role of the epicardium has been extensively studied. These organisms 
provide excellent model systems for genetic manipulations and real-time visualization of 
in vivo processes. The zebrafish heart is capable of completely regenerating damaged 
cardiac tissue (similar to many other organs), to provide a functionally perfect structure, 
identical to the former one. Resection of a piece of zebrafish ventricle leads to production 
of a blastema structure; this is then followed by activation of the localized epicardium (by 
re-expression of embryonic transcription factors). The activated cells then make a new 
epicardial covering around the blastema and then undergo EMT to provide progenitors 
for formation of vasculature in the repair area. FGF17 signaling from the disrupted 
myocytes through FGF receptors on the epicardium coordinated the repair process 
(Lepilina et al., 2006). More recently the same group of investigators used a similar 
transgenic zebrafish model that expressed bacterial nitroreductase (catalyzes conversion 
of a non-toxic substrate to cytotoxic product) in a cell-specific manner. This was used to 
ablate (deplete) the epicardial layer after myocyte injury (Wang et al., 2015). Compared 
with the course of repair in normal animals, in the transgenic animals, cardiomyocyte 
proliferation was inhibited, and long term regeneration of the cells was delayed.  
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Epicardium in mammals 
During adulthood, the mammalian epicardial layer is thought to remain quiescent. 
Although the role of the epicardium after injury to the heart has garnered much interest, 
our understanding of its function is quite poor. Thus far, after injury it is clear that a 
population of epicardial cell become activated and gain the expression of embryonic 
epicardial markers such as Wt-1,Raldh2, Tbx18 and Gata4, factors not expressed in the 
normal adult heart. Lineage-tracing studies using these activated transcription factors as 
markers demonstrates migration of a subset of these cells into the myocardium. Winter et. 
al. (2007) defined “spindle-like cells” obtained by removing the epicardial layer from 
human atrial tissue explants as “epicardial-derived cells” (EPDC) (Lie-Venema et al., 
2007; Winter and Gittenberger-de Groot, 2007). These cells were cultured and 
transplanted into the hearts of immnuodeficient mice using a permanent ligation model of 
MI. They observed differences in various parameters of cardiac function up to 6 weeks 
after MI, however, they failed to detect engrafted cells at that time point (Winter et al., 
2007). Several studies in mice have demonstrated that after experimental MI, epicardial 
cells become activated to proliferate, undergo EMT, migrate into the myocardium and 
secrete factors that promote angiogenesis and fibrosis within and adjacent to areas with 
infarction (Gittenberger-de Groot et al., 2010; Masters and Riley, 2014; Smart et al., 
2013; Zhou et al., 2011).  
Utilizing epicardial cell biology for cardiac cell transplantation  
Based on our current understanding of organ resident adult stem cells and the known 
roles of the epicardium, this cell population satisfies certain key criteria to be defined as 
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stem/progenitor cells for the heart. Therefore epicardial cells and their derivatives can 
potentially be a source of cell replacement cells after MI or of mitogens that preserve 
and/or repair tissue after injury. To date, few studies have explored the potential of 
epicardial cells and their derivatives as candidates for cell engraftment. This is due, in 
part to, limitations in knowledge and lack of appropriate tools for epicardial cell-specific 
isolation and in vivo experimentation. In order to reproducibly isolate a pure population 
of cells from donors, epicardial cell-specific surface markers or epitopes need to be 
identified. These markers have to be unique to this population in the heart, similar to 
methods that identified progenitor cells in other organs (Prockop et al., 2003; Wang et al., 
2015). Additionally, we need to investigate key changes in epicardial cells including 
signals received and emitted by the epicardial cells in an injury environment. Currently, 
understanding of intracellular and extracellular epicardial signaling has been limited to 
embryonic studies. However, there is need for a comprehensive examination of signaling 
events and pathways that control epicardial cell proliferation, EMT and migration in the 
adult, which can be eventually targeted to improve or modify injury repair. The third 
chapter of this dissertation focuses on answering key questions in adult epicardial cell 
biology that may help to utilize epicardial cells for effective cell replacement therapies. In 
order to assess the importance of epicardial cells in repair, our approach in these studies 
was focused on enhancing benefit from epicardial cells by means of cell transplantation 
and engraftment. This focus helped us identify a novel molecular target and signaling 
axis that controlled epicardial cell migration. Overall, our studies present an exciting 
research opportunity to determine mechanisms that advance therapeutic use of epicardial 
cells and their derivatives.        
23 
 
Epicardial progenitor cells  
The fate of epicardial-derived cells after migration into the myocardium is the subject of 
numerous debates that stem from conflicting observations in different experimental 
models (Lie-Venema et al., 2007; Rudat and Kispert, 2012). Various lineage-tracing 
studies demonstrate that the majority of epicardial cells differentiate into cardiac 
interstitial fibroblasts and vascular smooth muscle cells that line large cardiac arteries and 
arterioles (Gonzalez-Rosa et al., 2012; Mikawa and Gourdie, 1996; Rudat and Kispert, 
2012; van Tuyn et al., 2007). The epicardium has not been directly shown to contribute 
endothelial cells to the heart, but lineage-tracing studies report a population of cells from 
the proepicardial organ that differentiated into endothelial cells (Perez-Pomares et al., 
2002; Wada et al., 2003). This raises the possibility that a second progenitor exists in the 
proepicardium that migrates separately and is distinct from epicardial-derived progenitor 
cell, based on its ability generate endothelial cells. By contrast, other experiments 
performed with quail and chick chimeras during embryogenesis suggest that the 
epicardial mesothelium itself is a source of endothelial progenitor cells. In these studies, 
retroviral and fluorescent reporter labeling comparing the derivatives of the proepicardial 
and epicardial compartments suggests that a portion of the population of coronary 
endothelial cells derive from the epicardial cells, after they undergo EMT (Perez-Pomares 
et al., 2002). An additional issue concern whether epicardial-derived progenitor cells can 
differentiate into cardiac myocytes (Cai et al., 2008; Kruithof et al., 2006; Zhou et al., 
2012; Zhou et al., 2008) (Figure 2).  
The fourth chapter of this dissertation addresses the cellular requirements of the 
adult heart in a running exercise model of cardiac tissue growth. We employed a cell 
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growth or hypertrophic model because it creates demand for additional perfusion and 
capillary formation. By exercising epicardial-specific linage-tracing mice over a 
prolonged time period, we were able to track labeled cells as they migrated through the 











Epicardial cells undergo epithelial to mesenchymal transformation to generate a population EPDCs in the 
subepicardial mesenchyme. These cells proliferate here prior to their migration into the myocardium where 
they function as progenitor cells. They differentiate to generate adventitial fibroblasts and vascular smooth 









Figure 1- 2. Epicardial Epithelial to Mesenchymal Transformation 
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Vascular damage and protection as a target for paracrine biology 
The phenomenon of “no-reflow” 
In certain instances, reperfusion therapy after MI does not completely restore perfusion to 
regions of ischemia, especially to the inner myocardium lying closest to the endocardial 
layer (French et al., 2010; Zaman et al., 2011). Despite nearly complete restoration of 
blood flow through the major coronary arteries, areas downstream from the site of 
occlusion do not re-oxygenate. These areas of poor blood flow are referred to as regions 
of “no- reflow” or “low-reflow” and are also described during ischemia in other organs 
and tissues including brain, skeletal muscle, skin and kidney (Rezkalla and Kloner, 
2002). The phenomenon of no reflow in the heart was first demonstrated experimentally 
in dogs in 1974 by performing proximal coronary artery ligation followed by reperfusion 
at 40 minutes or 90 minutes after ligation (Kloner et al., 1974). Whereas restoration of 
flow after 40 mins provided complete perfusion to the damaged areas, restoration of flow 
after 90 minute ischemia period resulted in only partial perfusion. Anatomical 
examination of these sites of “no-reflow” suggested significant microvascular cell death 
(i.e., vessels around 200 microns), breakdown of the endothelial barrier, and vascular 
leak. Such structural damage prevents localized blood circulation, causing edema and 
accumulation of toxic metabolites and immune infiltrates. Furthermore, dyes that were 
injected to record perfusion through myocardial tissue failed to trace into regions of no-
reflow. This indicated definitive damage to the vasculature and uncoupling of the 
microvascular circulation from the systemic circulation.  
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No-reflow is associated with adverse clinical events and is now believed to affect 
later processes such as scar formation, ventricular remodeling and the development of 
future collateral flow (Rezkalla and Kloner, 2002). Although a complete understanding of 
the causes and effects of no-reflow on the heart is lacking, numerous theories have been 
put forth to explain the process. More recently, the TAPAS clinical trial has proven that 
prevention of angiographic microvascular damage during an MI may reduce overall 
cardiac injury and improve clinical outcomes (Vlaar et al., 2008). It has also been 
established that the extent of the area at risk of no-reflow directly correlates with 
increased times of ligation, and extent of initial tissue damage from ischemia. This has 
important clinical implications in that the damaged tissue that fails to receive blood will 
remain inaccessible to drugs or recovery by mechanical intervention (Tarikuz Zaman et 
al., 2013). Various interventions for reversing no-reflow following MI have been 
reported, including pharmacological drugs for vasodilation and mechanical devices for 
protection from embolisms. To date, however, no controlled randomized trials have been 
performed to determine the clinical benefit of these therapies. Therefore, there remains a 
great need to develop interventions that protect the structural and functional integrity of 
the microvasculature early after MI, which can potentially limit the extent of damage. 
One strategy gaining importance is the direct targeting of tissues with vaso-protective 
treatments to activate survival pathways in the endothelial cells. This approach has 
potential to salvage large areas of surrounding myocardial tissue at risk and to provide to 
long-term preservation of cardiac function (Tarikuz Zaman et al., 2013).  
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Paracrine effects of cell therapy 
One important role for stem cells in tissues that has been extensively studied is their role 
as a source of paracrine factors. These cells secrete factors within their local environment 
to influence processes like tissue morphogenesis, preservation, and the activities of other 
stem or differentiated cells during tissue repair (Anthony and Shiels, 2013; Shimada and 
Spees, 2011).  The role of paracrine factors in the injury microenvironment has been 
well-studied in the bone marrow. In adults, the bone marrow is the main center for 
hematopoiesis (i.e., formation of all blood cells), as it contains niches for the 
Hematopoietic Stem Cell (HSC). HSC survival, proliferation, differentiation and 
migration are controlled by niche factors in the bone marrow microenvironment. HSC 
niche factors are secreted primarily by the mesenchymal stromal cells (MSC) that reside 
in close physical proximity to the HSC (Anthony and Shiels, 2013; Ehninger and 
Trumpp, 2011; Gregory et al., 2005; Jones and Wagers, 2008; Phinney and Prockop, 
2007; Prockop et al., 2010).   
The niche factors produced by MSC can be harnessed for developing therapeutics 
because we can isolate, expand and cultivate them ex vivo. We then analyze and purify 
factors from their secretions and test them in large scale screens to identify drug 
candidates. These purified factors can be directly administered at optimal concentrations. 
This approach provides multiple advantages in terms of approval by FDA, controlled 
amounts for administration, and ease of storage and handling and administration. An 
important advantage of paracrine therapy over cell therapy is the ability to elicit acute 
treatment effects when compared to the long-term cell replacement or sustained effects of 
cell therapy, in addition to overcoming challenges of immune-mismatch (Gnecchi et al., 
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2008). The paracrine role of stem cells is valuable for cell therapy applications, both to 
protect jeopardized tissue and to rebuild damaged structures.  
Harnessing the paracrine biology of epicardial cells to treat MI 
Beginning with the use of bone marrow-derived mononuclear cells, patients in many cell 
therapy trials for MI showed modest improvements in cardiac function including 
increased ejection fraction, fractional shortening, stroke volume and cardiac output (Kang 
et al., 2004; Wollert et al., 2004). The initial excitement over these improvements 
motivated numerous debates concerning the safety of autologous transplantation, benefit 
of intracoronary versus systemic delivery, and the logistics of isolating and expanding 
large cell populations to derive optimal benefit from the interventional procedure that the 
treatment demanded (Da Silva and Hare, 2013; Karantalis and Hare, 2015; Suncion et al., 
2012). Among these concerns, the question regarding mechanism of action for cardiac 
cell therapy or, specifically, the changes at the cellular and molecular levels that 
influenced function has been an expanding field of investigation (D'Souza et al., 2015; 
Dai et al., 2007; Gnecchi et al., 2008; Haider et al., 2008; Mirotsou et al., 2007). Since 
myocytes are the cellular functional units of the heart, the overt expectation was that cell 
therapy worked to improve cardiac function by differentiation of stem cells into 
cardiomyocytes, thereby increasing their numbers. However, most trials failed to detect 
significant engraftment of transplanted cells. Furthermore, stem cell transplantation did 
not stimulate the proliferation of myocytes at numbers adequate to improve cardiac 
function. It should be noted that transplantation of myocytes alone has been performed by 
many investigators, but presents a formidable challenge in terms of ensuring in vivo 
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survival, proliferation and integration of grafted cells within the existing network of 
myocytes and electric coupling to prevent fatal arrhythmia. In the absence of large 
numbers of transplanted cells to account for the observed functional benefits, the 
paracrine hypothesis became a more plausible and accepted mechanism for stem cell 
function (Avolio et al., 2015; D'Souza et al., 2015; Dai et al., 2007; Mazhari and Hare, 
2007; Menasche, 2015; Quijada et al., 2015; Wollert and Drexler, 2005, 2006; Yannarelli 
et al., 2014). The paracrine study of epicardial cells has been largely inspired by research 
of developmental processes where available literature indicates numerous paracrine 
signals from the epicardium guide myocardial development (Bochmann et al., 2010; 
Bollini et al., 2014). Gene expression changes also suggest that the epicardium is a 
notable source of cytoprotective and angiogenic factors (Huang et al., 2012; Lui et al., 
2014; Velecela et al., 2013; Zhou et al., 2011). From the standpoint of MI, early therapies 
to limit infarct area and expansion by treating the extent of no-reflow can be a suitable 
treatment strategy for early vascular protection and to control late tissue remodeling 
(Tarikuz Zaman et al., 2013).  
The fifth chapter of this thesis focuses on treatment of low- or no-reflow after an 
MI. The chapter introduces methods to evaluate endothelial damage that occurs due to 
no-reflow early after ischemia/reperfusion injury, followed by treatments to minimize 
this damage. Screens of epicardial cells isolated from human donors, to identify secreted 
repair and angiogenic factors, are also presented. One screen identified a powerful growth 
factor and its biochemical interacting partner that enhance vascular protection early after 




Statement of specific aims  
The process of cardiac regeneration involves coordinated changes in multiple cell-types 
in the heart, and occurs during tissue growth, after injury and during disease or ageing. 
Among the various cells that have been studied, the role of epicardial cells in adults, 
especially during regeneration is poorly understood. The overall goal of my dissertation 
was to investigate novel functions of the adult epicardium and demonstrate the important 
contributions of epicardial cells in cardiac regeneration. In each chapter, I focused on 
studying a distinct aspect of epicardial cell signaling and biology in a specific 
physiological context (e.g., during repair after MI or hypertrophic growth). In order to 
address specific research questions, my primary experimental objectives in this 
dissertation included: i] understanding endogenous epicardial cell biology, ii] 
identification of epicardial markers and signals to promote their utility for cell 
replacement therapy after MI, and iii] screening epicardial cells for secreted factors for 
early treatment of MI, in a manner which can restore cardiac function. 
Significance of the models and experimental approach  
Work carried out in this dissertation integrates the use of multiple animal species for in 
vivo studies combined with work on primary cells isolated from several different 
mammalian species including human. This approach has been adopted to overcome the 
apparent technical limitations of each model. Rat models are larger in size, facilitating 
engraftment and treatment studies requiring coarse manipulations, whereas mouse models 
are better established for performing genetic manipulations and studies that evaluate 
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endogenous cells. Notably, a variety of transgenic mouse models allowed us to perform 
genetic manipulations, and to evaluate the role of specific, novel factors in epicardial cell 
biology. The different animal models of injury and physiology enabled us to model both 
the onset and progression of cardiac injury through various stages, and the effects of 
different treatments at different time points.  Evidence from multiple model systems 
increases confidence that our findings provide fundamental insight into the cell biology 
of multiple mammalian species and highlights shared similarities in key cellular 
properties. In addition, results from our studies highlight the power of using animal 
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Transplantation of culture-expanded adult stem/progenitor cells often results in poor 
cellular engraftment, survival, and migration into sites of tissue injury. Mesenchymal 
cells including fibroblasts and stromal cells secrete factors that protect injured tissues, 
promote tissue repair, and support many types of stem/progenitor cells in culture. We 
hypothesized that secreted factors in conditioned medium (CdM) from adult bone 
marrow-derived multipotent stromal cells (MSCs) could be used to prime adult cardiac 
stem/progenitor cells (CSCs/CPCs) and improve graft success after myocardial infarction 
(MI). Incubation of adult rat CPCs in CdM from human MSCs isolated by plastic 
adherence or by magnetic sorting against CD271 (a.k.a., p75 low-affinity nerve growth 
factor receptor; p75MSCs) induced phosphorylation of STAT3 and Akt in CPCs, 
supporting their proliferation under normoxic conditions and survival under hypoxic 
conditions (1% oxygen). Priming CSCs with 30x p75MSC CdM for 30 min prior to 
transplantation into sub-epicardial tissue 1 day after MI markedly increased engraftment 
compared with vehicle priming. Screening CdM with neutralizing/blocking antibodies 
identified Connective Tissue Growth Factor (CTGF) and Insulin as key factors in 
p75MSC CdM that protected CPCs. Human CTGF peptide (CTGF-D4) and Insulin 
synergistically promoted CPC survival during hypoxia in culture. Similar to CdM 
priming, priming of CSCs with CTGF-D4 and Insulin for 30 min prior to transplantation 
promoted robust engraftment, survival and migration of CSC derivatives at 1 week and 1 
month after MI. Our results indicate that short-term priming of human CSCs with CTGF-




Poor graft success is a common problem after transplantation of cultured cells into 
injured tissues and occurs with transplants of adult stem/progenitor cells, embryonic stem 
(ES) cells, and ES cell derivatives [1-3]. Despite rapid progress in methods to identify, 
isolate and culture candidate cells for tissue repair, the inability to effectively graft 
culture-expanded cells to diseased or injured adult tissues remains a challenge for many 
anticipated forms of cell therapy. Cell grafts for solid, non-hematopoietic tissues and 
organs such as the heart are particularly inefficient, especially after ischemic injury. Upon 
transplantation, culture-expanded cells can exhibit low adhesion to host tissue, low 
survival, and/or low levels of migration [2,3]. Improving these stages of cell engraftment 
is critical because they typically precede differentiation and functional integration of 
transplanted cells into host tissue. Recent efforts to improve graft success have utilized 
genetic manipulation to over-express pro-survival factors such as Akt in transplanted 
cells or co-administer cells with accessory materials/scaffolds to support the graft [4,5]. 
Paracrine activity from mesenchymal cells such as fibroblasts and other stromal cells 
promotes tissue repair after injury [6,7] and also regulates, in part, stem cell niches [8]. In 
the bone marrow, endothelial cells and stromal derivatives from non-hematopoietic 
progenitor cells (multipotent stromal cells, MSCs) support hematopoietic stem cells 
(HSCs) by providing critical structural and regulatory components of the hematopoietic 
niche. The niche components include cellular substrate, e.g. extracellular matrix, as well 
as multiple growth factors, cytokines, and hormones that influence HSC self-renewal, 
proliferation, survival, and function [8-12].  Due to their supportive roles, feeder layers of 
52 
 
stromal cells (e.g. MSCs or fibroblasts) are commonly used to support the culture of 
HSCs, other types of adult stem/progenitor cells, and ES cells [12-15]. 
MSCs are typically isolated from total bone marrow mononuclear cells simply based on 
their adhesion to tissue culture plastic. To standardize isolation methods, several 
investigators have sorted human MSCs from bone marrow aspirates based on cell surface 
epitopes such as CD271 (p75 low-affinity nerve growth factor receptor, p75MSCs) or 
CD133 (Prominin-1, CD133MSCs) [16-18]. In some cases, sorting MSCs based on 
markers appears to enrich subpopulations of MSCs that differ in terms of paracrine 
activity. Of clinical interest, the different repertoires of secreted proteins/peptides may 
enhance particular therapeutic applications. For example, secreted factors from the 
CD133MSC subpopulation was shown to provide greater protection of cerebral tissue 
after stroke compared with those from the p75MSC subpopulation [18]. In transplantation 
studies, co-infusion of human HSCs and p75MSCs into immunodeficient mice provided a 
10 to 23 fold improvement in multi-lineage engraftment of bone marrow compared with 
co-infusion of HSCs and typical (non-selected) human MSCs [19]. 
CD271+ cells characteristic of bone marrow p75MSCs are rapidly mobilized into 
the blood of patients with acute MI [20]. We hypothesized that marrow-derived 
CD271+cells participate in cardiac repair/remodeling after MI, in part, through paracrine 
activity. We investigated the effects of stromal cell-derived ligands on cardiac 
stem/progenitor cells (CSCs/CPCs) and found that conditioned medium (CdM) from 
human p75MSCs, but not from CD133MSCs, supported the proliferation and survival of 
adult rat CSCs/CPCs. Furthermore, priming of CSCs in p75MSC CdM for 30 min prior 
to transplantation markedly improved CSC grafts after MI. By screening p75MSC CdM 
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for molecules that protected CPCs under hypoxic conditions, we identified two ligands 
with synergistic effects on CSC survival and developed a novel priming tool to enhance 
graft success. 
Results 
CdM from human stromal cells induces proliferation of rat CPCs  
CdM was collected from human MSCs, p75MSCs, and dermal fibroblasts. CdM from 
each of the cell types supported CPC proliferation (Figure 1A and Supplemental Figure 
1). We observed a concentration-dependent increase in CPC number when CPCs were 
incubated in 10x-concentrated CdM (10x CdM) from MSCs or p75MSCs (Supplemental 
Figure 2A). In contrast, when CPCs were incubated in CdM vehicle (serum-free α-MEM, 
SFM), their numbers gradually decreased (Figure 1A and B). To confirm DNA synthesis 
and active cell cycle status, we quantified incorporation of BrdU into CPCs 24 hrs after 
exposure to CdM. The percentage of BrdU-positive CPCs in CdM from MSCs, p75MSCs 
or fibroblasts was significantly greater than that for SFM-treated CPCs (Figure 1B). 
Immunoblotting demonstrated that Ki67 was expressed in CPCs treated with CdM but 
not in CPCs treated with SFM (Figure 1B). In contrast to its effects on CPCs, CdM from 
MSCs or p75MSCs did not support the proliferation of cardiac fibroblasts (Figure 1C).  
CdM from human MSCs activates STAT3 and Akt in CPCs. STAT3 activation is critical 
for self-renewal of ES cells, adult HSCs, and adult neural stem cells [22-24]. 
Accordingly, we assayed levels phosphorylated-STAT3 (p-STAT3; Tyr705) in CPCs 
exposed to CdMs from MSCs, p75MSCs, or fibroblasts.  Levels of p-STAT3 were 
significantly higher in CPCs at 1 and 2 days after CdM treatment compared with SFM 
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(Figure 2A). Immunocytochemistry demonstrated that p-STAT3 (Tyr 705) localized to 
the nuclei of CPCs treated with CdM (Figure 2B). In addition to p-STAT3, we observed 
phosphorylation of Akt (p-Akt; Ser473) after incubation of CPCs in CdM from each of 
the stromal cell types (Figure 2C). However, we also observed p-Akt in CPCs incubated 
in SFM alone (Figure 2C). Notably, auto-phosphorylation of signaling molecules 
affecting cell survival such as Akt, ERK1/2, and mTOR occurs in diverse cell types 
during serum or nutrient deprivation [25]. 
To determine whether p-STAT3 and/or p-Akt mediated the effects of CdM on 
CPCs, we treated CPCs with pharmacological inhibitors. AG490, the Jak2/STAT3 
pathway inhibitor, reduced the number of CPCs treated with MSC CdM in a dose-
dependent manner: control (CdM+DMSO), 100 ± 1.5%; 1 µM, 96.3 ± 0.9 %; 5 µM, 89.5 
± 0.9 %; 10 µM, 43.4 ± 2.4 % (cell number ratio to control cell number [121,863 cells], 
mean ± SEM, n = 3 to 6). The inhibitory effect of AG490 was also observed for CPCs 
treated with CdM from p75MSCs or fibroblasts (Figure 2D).  LY294002, the 
phosphatidylinositol 3-kinase (PI3K)/Akt pathway inhibitor, decreased CPC number in 
CdM but to a lesser extent than did AG490 (Figure 2E). Combined treatment with 
AG490 and LY294002 was most effective in reducing CPC number in CdM (Figure 2E). 
Incubation of CPCs in “Stattic”, an inhibitor specific to STAT3, confirmed the role of 
STAT3 activation in CdM-mediated effects on CPC proliferation (Supplemental Figure 
2B). AG490 treatment also significantly reduced the number of CPCs incubated in 
serum-free medium, however, the effect of the AG490 was nearly equal to that of 
LY294002 treatment (Supplemental Figure 2C). Of interest, LY294002 but not AG490 
significantly diminished CPC numbers in growth medium, indicating that the factors 
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promoting CPC growth in growth medium differed from the active factors in CdM that 
were STAT3-activating (Supplemental Figure 2C). 
Insulin and Insulin-like growth factor 1 (IGF-1) bind to tyrosine kinase 
holoreceptors and promote cell survival and proliferation by signaling through the 
PI3K/Akt and Ras/MAP kinase pathways. Partial functional redundancy for Insulin and 
IGF-1 signaling is evidenced by signaling through IR/IGF-1R receptor heterodimers and 
bidirectional cross-talk by ligands and receptors [26]. Adult CPCs express the receptor 
for Insulin-like growth factor 1 (IGF-1) and injection of biotinylated IGF-1 nanofibers 
was shown to improve CPC grafts as well as endogenous myocardial regeneration after 
MI [27].We observed that CSCs/CPCs did not proliferate in the absence of medium 
supplements containing Insulin (e.g. Insulin-Transferrin-Selenium [ITS] or fetal calf 
serum), even when in the presence of other mitogenic components from CSC/CPC 
growth medium such as LIF, EGF or bFGF (Supplemental Figure 3); this suggested that 
CdM from human stromal cells contained Insulin, IGF-1, or both. 
CdM protects CPCs exposed to hypoxia 
Because cells transplanted to the heart after MI may encounter hypoxic environments, we 
examined whether CdM could protect CPCs during exposure to 1% oxygen for 48 hrs ex 
vivo. Compared with cell survival in CPC growth medium (positive control; 100 ± 
3.01%), survival of CPCs in SFM was 48.63 ± 21.13%, whereas that of CPCs incubated 
in MSC CdM was 87.515 ± 3.97% (P< 0.01 vs SFM), and in p75MSC CdM was 83.215 
± 4.005 % (P< 0.01 vs SFM). Survival of CPCs incubated in 1x CdM from MSC donors 
and p75MSC donors was not significantly different (n=4 donors per cell type, P= 0.206). 
Of note, CdM produced from a different subpopulation of MSCs, CD133MSCs, did not 
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protect CPCs during culture under hypoxic conditions (P= 0.160 vs SFM). Fibroblast 
CdM significantly protected CPCs (70.79 ± 1.91%,  P< 0.05 vs SFM), although both 
MSC CdM and p75MSC CdM were more protective than fibroblast CdM (each P< 0.01 
vs fibro). Inhibition of STAT3 abolished CdM-mediated protection of CPCs under 
hypoxic conditions (AG490, Figure 3B; Stattic, Figure 3C). 
CPCs incubated in CdM retain their multipotent differentiation capacity 
Differentiation assays were performed under normoxic conditions. Control CPCs cultured 
in CPC growth medium were negative for α-smooth muscle actin and von Willebrand 
Factor staining, whereas about 60% expressed α-sarcomeric actin (Supplemental Figure 
4A, left and B). In contrast, clones of CPCs exposed to 1x CdM in culture for 4 days 
stained positively for α-sarcomeric actin, α-smooth muscle actin, and von Willebrand 
Factor (Supplemental Figure 4A and B). After 4 days in CdM, CPC-derived cells no 
longer expressed the CSC antigen, c-Kit, suggesting progress toward differentiation. 
Effects of intra-arterial infusion of p75MSC CdM after MI. Based on our results with 
CdM and cultured CPCs, we examined whether infusion of CdM after MI would increase 
the number of endogenous CPCs. MI was produced in C57bl6 mice by permanent 
ligation of the left anterior descending coronary artery (LAD). The following day, mice 
were randomized to receive treatment with intra-arterial infusion (left ventricle lumen) of 
30x p75MSC CdM or vehicle (SFM).  Mice from each group were euthanized at 1 day or 
1 week after treatment. Hearts obtained 1 day after treatment were sectioned and 
processed for TUNEL and immunohistochemistry to detect c-Kit. TUNEL assays showed 
that CdM infusion significantly reduced cardiac apoptosis/necrosis (SFM, 17.2 ± 8.1%; 
CdM, 3.7 ± 2.2%; P< 0.05, Supplemental Figure 5). Intra-muscular injection of porcine 
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MSCs from bone marrow, but not their conditioned medium, was reported to increase the 
number of c-Kit+ cells in the hearts of pigs after MI [28]. After intra-arterial infusion of 
CdM from human p75MSCs, we detected rare c-Kit+ cells in heart sections from both 
CdM- and SFM-treated mice. However, because c-Kit+ cell number was variable and did 
not appear differ between mice that received CdM or SFM, we did not quantify c-Kit+ 
cells. Biochemical assays for residual myocardial Creatine Kinase (CK) activity in left 
ventricular (LV) homogenates indicated that CdM- and SFM-treated mice had similar 
size infarcts at 1 week after MI (Anterior LV, SFM, 4.66 ± 0.40; CdM, 5.00 ± 0.43, 
P=0.21; Posterior LV, SFM, 6.59 ±0.32; CdM, 6.34 ± 0.33, data expressed as IU CK/mg 
protein, mean ± SD, P=0.23; SFM, n=6; CdM, n=5). 
Priming of CSCs with CdM from p75MSCs improves graft success after MI 
Based on our observations with p75MSC CdM and its ability to increase proliferation and 
survival of cultured CSCs/CPCs, we next determined whether prior exposure of CSCs to 
p75MSC CdM could foster the grafting of CSCs to the injured heart. MI was produced in 
Fischer rats by permanent ligation of the LAD. One day after MI, syngeneic GFP-
positive rat CSCs were primed for 30 min on ice in p75MSC CdM (30x CdM, n=6 rats) 
or vehicle (SFM, n=5 rats). The chest wall was re-opened and rats were randomized to 
treatment with co-injections of CSCs/CdM or CSCs/SFM (125,000 cells/5 µl injection, 2 
sub-epicardial injections, 1 per border zone; please refer to Supplemental Figure 6 to 
view injection site). At 1 week and 1 month after MI, rats were euthanized and their 
hearts were processed as frozen serial-sections from apex to base. For each heart, we 
quantified GFP+ cells in the tissue section with the most GFP+ cells. At 1 week after MI, 
for 2 rats in the CSCs/SFM co-injection group, we did not detect GFP+ cells. 
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Furthermore, hearts from CSC/SFM rats with the highest level of engraftment contained 
less than 40 GFP+ cells/section (Figure 4A). In contrast, many sections from rats co-
injected with CSCs/CdM contained several thousand GFP+ cells (Figure 4B-E). After 
priming of CSCs in p75MSC CdM, GFP+ cells grafted into sub-epicardial locations, 
proliferated (see Ki67 stain, Figure 4C), and migrated into zones with infarction (Figure 
4C-E and Supplemental Figure 6). Furthermore, after 1 week, derivatives from CSCs 
primed in CdM engrafted into blood vessel walls as CD31-positive endothelial cells 
(Figure 4F).  They also generated smooth muscle cells and myofibroblasts (smooth 
muscle alpha actin-positive, Figure 4G). Although they grafted into sub-epicardial 
locations after MI, GFP+ cells derived from vehicle-primed CSCs did not stain for Ki67 
and had not entered myocardial tissue from sub-epicardial tissue at 1 week after MI and 
treatment (Figure 4A). At 1 month after MI, GFP+ cells were detected in infarct and 
border zones in multiple tissue sections and differentiated to CD31-positive endothelial 
cells. Whereas engraftment was extensive in 4 out of 4 animals that were injected with 
CSCs primed in p75MSC CdM, only 1 out of the 5 control animals had detectable cell 
engraftment at 1 month after MI. However, similar to control cell grafts at 1 week after 
MI, this animal had only a few GFP+   cells in the sub-epicardial tissue and none in the 
myocardial tissue. (Supplemental Figure 7A-C’’).    
CdM contains human CTGF and bovine Insulin that activate CSCs/CPCs 
To identify factors in p75MSC CdM that promoted the proliferation and survival of 
CPCs, we examined Affymetrix gene expression profiles from human p75MSCs that 
were freshly sorted from marrow aspirates and from p75MSCs cultured adherently for 2 
passages [18]. Antibody blocking/neutralization studies for selected secreted factors were 
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carried out with 10x p75MSC CdM and CPCs exposed to hypoxic conditions (1% 
oxygen, 48 hrs). Under hypoxia, neutralizing antisera specific to human CTGF prevented 
CdM from protecting CPCs (P< 0.001, Figure 5A). Of interest, addition of human CTGF 
alone to SFM containing 1% BSA significantly induced p-STAT3 in CPCs (See inset, 
Figure 5B). By ELISA, 10x p75MSC CdM contained significantly more CTGF than did 
CD133MSC CdM (p75MSC, 1.29 ± 0.03 ng/ml; CD133MSC, 0.59 ±  0.13 ng/ml; P< 
0.01), but did not differ in CTGF levels in comparison to MSC CdM  (0.81 ± 0.14 ng/ml) 
or fibroblast CdM (1.1 ± 0.36 ng/ml). To our surprise, we did not detect IGF-1 in CdM, 
but we did detect Insulin. The amount of Insulin was not significantly different for CdMs 
from MSC, p75MSC, CD133MSC, or fibroblasts (about 2-3 ng/ml). Since the growth 
medium for MSCs and fibroblasts contained FCS (with bovine Insulin) and we did not 
detect human mRNA for Insulin by gene chip or by RT-PCR with cDNA from MSCs, we 
expect that the Insulin present in CdM was bovine in origin. Neutralizing antibodies 
specific to Insulin significantly reduced CdM-mediated protection of CPCs during 
hypoxia exposure, albeit not as much as did blocking CTGF (MTS assay[Abs490]: non-
specific IgG, 0.378 ± 0.021; anti-Insulin, 0.270 ± 0.034; mean ± SD, n=4, P< 0.05). 
Addition of recombinant human Insulin to CPCs induced p-Akt in a dose-responsive 
manner and increased also CPC survival and proliferation under hypoxic conditions 
(Figure 5C). Notably, CPC protection assays with human Insulin or IGF-1 alone (30 
ng/ml, each) demonstrated that they were equivalent in their ability to rescue CPCs 
exposed to hypoxia (control [SFM with 1% BSA]: 9004 ± 12 cells; Insulin: 13,507 ± 
1,473 cells; IGF-1, 14,894 ± 559 cells; mean ± SD, n=3, P= 0.24).  
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CTGF (CCN2, IGFBP8) consists of 4 domains and the C-terminal (4th) domain alone was 
reported to increase cell adhesion and proliferation [29,30]. In experiments with 
recombinant peptides, we found that combined treatment with human C-terminal CTGF 
(CTGF-D4) and Insulin had synergistic effects on CPC survival and proliferation under 
hypoxic conditions. For example, CTGF-D4 or Insulin alone (1 ng/ml in SFM, each) did 
not protect CPCs against 48 hr of hypoxia (Figure 5D). In contrast, addition of both 
CTGF- D4 and Insulin to SFM (1 ng/ml, each) provided significant protection of CPCs 
against hypoxia (P< 0.05, Figure 5D). CTGF-D4/Insulin-mediated protection of CPCs 
was enhanced by including 1% BSA as a carrier (P< 0.01, Figure 5D). Clones of CPCs 
exposed to CTGF-D4 (3ng/ml) and Insulin (30ng/ml) in culture for 4 days stained 
positively for α-sarcomeric actin, α-smooth muscle actin, and von Willebrand Factor at 
ratios similar to those observed after 4 day CPC differentiation in 1x CdM (Supplemental 
Figure 4B). These results indicated that the multipotency of CPCs was retained after 
exposure to CTGF-D4 and Insulin. 
A defined combination of CTGF-D4/Insulin promotes CSC grafts after MI  
Having observed synergistic protective effects after CTGF-D4/Insulin treatment of 
cultured CPCs exposed to simulated ischemia, we hypothesized that a priming mixture 
based on the CTGF-D4/Insulin ratio found in 30x p75MSC CdM would promote CSC 
engraftment when using to prime CSCs. One day after MI, GFP CSCs were incubated on 
ice with SFM containing 1% BSA, CTGF-D4 (3 ng/ml), and Insulin (30 ng/ml), or with 
vehicle (SFM with 1% BSA) for 30 min prior to co-injection into border zone areas of 
rats randomized to treatment (125,000 cells/5 µl injection, 2 sub–epicardial injections, 1 
per border zone). As before, all rats were euthanized 1 week after MI and their hearts 
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were processed as serial sections. Whereas few rats that received co-injections of 
CSCs/vehicle had detectable GFP+ cells after 1 week (1/7 rats, Figure 6A and A’), all rats 
that received CSCs/CTGF-D4/Insulin exhibited a level of engraftment consistent with 
results obtained by priming with 30x p75MSC CdM (5/5 rats, Figure 6B-C’). Similar to 
CSCs primed in CdM, CSCs primed in CTGF-D4/Insulin grafted into sub-epicardial 
locations, proliferated, and provided GFP+ CSC derivatives that migrated into host 
myocardium, reaching areas of infarction with few remaining viable myocytes (Figure 
6B’-C’). At one month after MI, 4 out of 5 rats that received CSCs primed in CTGF-
D4/Insulin exhibited widespread engraftment cells of GFP+ derivatives. Similar to 
priming of CSCs in CdM, CTGF-D4/Insulin priming facilitated survival, migration and 
differentiation of CSC derivatives to CD31-positive and smooth muscle actin positive 
cells in infarct area at 1 month (Supplemental Figure 7D-E’). 
Discussion 
Pre-conditioning strategies that expose cells to hypoxia, heat-shock, protein/peptide 
growth factors, chemicals and drugs have been shown to increase the survival of adult 
stem/progenitor cells, ES cells, and ES cell-derivatives after transplantation to the heart 
[31-36]. Although significant in terms of effect, many reported strategies result in modest 
cell grafts that are unlikely to repair the large tracts of necrotic tissue generated after MI. 
Our results indicate that short-term priming in p75MSC CdM or CTGF-D4/Insulin may 
boost graft success for clinical application of CSCs and perhaps also cultured 
stem/progenitor cells derived from other tissues or sources.  
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Priming in IGF-1 was reported to improve the survival of cardiac cell grafts with adult 
and embryonic stem cells [36]. We found that adult rat CPCs were protected equally-well 
by Insulin or IGF-1 during hypoxia in culture. Although human p75MSC CdM did not 
have detectable IGF-1, we found that it contained sufficient residual bovine Insulin to 
significantly improve CPC survival under hypoxic conditions. CdM contains Insulin 
because MSCs internalize fetal calf serum components such as albumin, IgG, and Insulin 
from their growth medium. Even after multiple washes, they can release some 
components back into the base medium used for CdM production [37]. 
CTGF is a secreted “matricellular” protein with multiple functions in mammalian 
development and tissue remodeling/repair after injury, including angiogenesis and 
fibrosis [38-41]. During pancreatic development, CTGF promotes the proliferation of 
beta cell progentitors in islets [42]. Cardiac expression of CTGF increases significantly 
after MI and it is expressed by interstitial fibroblasts and cardiac myocytes [43]. By 
interacting with the extracellular matrix, integrins and several cell surface receptors (e.g. 
LRP-1, LRP-6, TrkA), CTGF mediates numerous cellular functions including: adhesion, 
proliferation, migration, differentiation, and survival [44-46]. To regulate coincident 
processes after injury such as angiogenesis and fibrosis, CTGF physically associates with 
numerous other secreted proteins including VEGFA, Slit3, von Willebrand Factor, 
PDGF-B, BMP-4, IGF-1, IGF-2, TGF alpha and TGF beta[30, 38-41]. Although we do 
not identify them here, it will be of great interest to determine which CTGF binding 
partners control graft success. 
CTGF controls fibrosis in multiple tissues after injury, in part, by interacting with 
TGF beta, IGF-1 or IGF-2 and promoting the differentiation of fibroblasts into 
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myofibroblasts. The N-terminal (1st) and 2nd domains of CTGF interact with IGFs and 
TGF beta or BMP4, respectively. Notably, due to its numerous binding partners, the 
effects of CTGF are context-dependent. In the presence of cellular mitogens such as 
EGF, CTGF does not induce fibrosis, even when pro-fibrotic mediators like TGF beta or 
IGF-2 are present [40,41]. Importantly, the CTGF-D4/Insulin priming method reported 
here is unlikely to promote myofibroblast differentiation or fibrosis from transplanted 
CSCs as CTGF-D4 is known to promote cell adhesion and proliferation, but lacks N-
terminal functions in fibrosis [29, 30, 40, 41]. 
To date, clinical trials or animal models designed to graft cells to the heart after 
MI primarily administer cells intravenously, intra-arterially, or intra-muscularly. Here we 
developed a tangential injection method to deliver CSCs to the sub-epicardial space lying 
outside and adjacent to the injured myocardium. In addition to priming CSCs in p75MSC 
CdM or CTGF-D4/Insulin, we found that the border zone sub-epicardial space was 
important for cell injections. Notably, CSCs injected into the sub-epicardial space of 
healthy hearts, or, into the sub-epicardial space lying above normal, uninjured tissue in 
hearts with MI did not proliferate or migrate in the manner observed for border zone 
injections after MI (data not shown).  These observations indicate that the border zone 
sub-epicardial environment may itself contain factors that promote cardiac graft success. 
Whereas our injections were performed in an open-chest fashion, for a less-invasive 
procedure in patients it may be possible to use catheter-based cell injection to reach the 
sub-epicardial space through the myocardium.  
Multiple tissue-specific cell types express integrins and cell surface receptors 
known to interact with CTGF and Insulin, including stem/progenitor cells of adult tissues. 
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In addition to improving cell grafts for the heart, we are hopeful that priming with CdM 
from stromal progenitors or with CTGF-D4/Insulin will promote graft success for other 
solid tissues after injury.  
Materials and Methods 
Preparation of human stromal progenitor cells and fibroblasts 
Human MSCs, p75MSCs and CD133MSCs were prepared with protocols approved by an 
Institutional Review Board. For the experiments outlined here, we used banked vials of 
stromal progenitor cells that were characterized previously for the same human donors 
[18].  Human dermal fibroblasts were obtained from the cell bank of the Tulane Center 
for Gene Therapy; they were isolated from skin punch biopsy samples under a protocol 
that was approved by an Institutional Review Board [18,47]. 
Preparation of serum-free conditioned medium (CdM).  Passage 4 to 8 human MSCs, 
p75MSCs, CD133MSCs, or dermal fibroblasts were cultured in 150 cm2 dishes with 
complete culture medium [18].  For the present study, the various human cell types were 
plated at 1000 cells/cm2 for seeding, underwent about 3 population doublings per 
passage, and were frozen down at each passage. To generate CdM, cells at 80 to 90% 
confluence were washed twice with PBS and incubated with 20 mls of fresh serum-free 
-MEM in standard conditions without any supplements or growth factors for 48 hrs. 
CdM was then collected, filtered, and stored at – 80 C°. For some experiments, CdM was 
concentrated up to 10- or 30-fold with the use of a Labscale™ TFF diafiltration system 
(Pellicon XL 5 kDa cut-off filters, Millipore, Bedford, MA). 
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Isolation and culture of adult rat cardiac stem/progenitor cells 
 Adult CSCs were isolated from the ventricles of Fischer 344 rats and labeled with 
retroviral vector for GFP [21]. CSCs were cultured as floating spheres in DMEM/F12 
supplemented with bFGF (10 ng/ml ), EGF (20 ng/ml), LIF (10 ng/ml) and ITS. To grow 
adherent CPCs, CSCs were plated at 500 cells/cm2 and cultured in CSC medium 
supplemented with 2% FBS (CPC growth medium). 
Short-term priming of CSCs 
CSCs were cultured as spheres in serum-free CSC growth medium. CSC spheres were 
trypsinized and centrifuged at 1000 x g for 8 min. After re-suspension in 1x PBS, cells 
were passed through a 40 micron filter to isolate single CSCs (cell strainer, Fisher 
Scientific). Cells were counted on a hemocytometer, centrifuged again, and re-suspended 
in 30x p75MSC CdM or Alpha-MEM (CdM vehicle control), or CTGF-D4 
(3ng/ml)/Insulin (30ng/ml)/1% BSA in -MEM, or 1% BSA in -MEM (vehicle control 
for recombinant peptides). CSCs were incubated in the above conditions for 30 minutes 
on ice prior to sub-epicardial injection.  
Myocardial infarction surgery and CSC transplantation in rats 
Fischer 488 rats (males, 7 weeks of age) were weighed, shaved, anesthetized under 4% 
isoflurane, and endotracheally-intubated. Rats were ventilated at a respiration rate of 65 
beats per min under a peak inspiration pressure of 15 cm H2O (Kent Scientific). Body 
temperature was maintained at 37°C with a heating pad (Gaymar). Through a dermal 
incision, a blunt dissection of the fascia was performed and the intercostal muscles were 
separated. The heart was exposed by retraction of the pericardium to expose the LAD. 
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The LAD was occluded with a 6-0 nylon suture and occlusion was confirmed by 
blanching of the anterior free wall of the LV. The animals were allowed to recover off the 
ventilator.  
After 24 hours, rats were re-intubated, ventilated, and the chest wall was re-
opened. Hearts were exposed to reveal the border zones of the infarct.  For each rat, we 
performed 2 sub-epicardial injections of CSCs (5 µl each, one per border zone) with a 30 
gauge Hamilton syringe. The needle was introduced tangentially to the wall of the LV 
and with the bevel facing upward. The syringe was advanced only as far as the bevel 
edge to access the sub-epicardial surface of the heart and so as not target the underlying 
myocardium of the LV. After the injections, the chest wall was closed and rats recovered 
for 7 days or 1 month prior to euthanization.  
An expanded Methods section with detailed descriptions for isolation of human bone 
marrow-derived MSCs and p75MSCs, isolation and culture of adult rat cardiac 
fibroblasts, cell culture in CdM and evaluation of cell number, immunocytochemistry, 
DNA replication assays, immunoblotting, ELISAs for IGF-1, Insulin, and CTGF, MI 
surgery in mice, infusion of p75MSC CdM after MI in mice, TUNEL Assay, Creatine 
Kinase (CK) activity assay, immunohistochemistry, and statistical analysis is available in 
the online-only Data Supplement. 
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Isolation of human bone marrow-derived MSCs and p75MSCs. To obtain MSCs, bone 
marrow aspirates were taken from the iliac crest of healthy adult donors. Mononuclear 
cells were isolated with the use of density gradient centrifugation (Ficoll-Paque, 
Amersham Pharmacia Biotech) and resuspended in complete culture medium consisting 
of Alpha-MEM (GIBCO/BRL, Grand Island, NY); 17% FBS (Atlanta Biologicals, 
Norcross, GA); 100 units/ml penicillin (GIBCO/BRL); 100 µg/ml streptomycin 
(GIBCO/BRL); and 2 mM L-glutamine (GIBCO/BRL). Cells were plated in 20 ml of 
medium in a 150 cm2 culture dish and incubated in a humidified incubator (Thermo 
Electron, Forma Series II, Waltham, MA) with 95% air and 5% CO2 at 37°C.  After 24 h, 
nonadherent cells were removed. Adherent cells were washed twice with PBS and 
incubated with fresh medium. The primary adherent cells were cultured and propagated.   
To obtain p75MSCs or CD133MSCs, bone marrow stem/progenitor cells were isolated 
by MACS using antibodies against the p75LNGFR or CD133 (Prominin 1). Freshly 
isolated bone marrow mononuclear cells from the Ficoll gradient were resuspended in 0.4 
ml of PBS containing 0.5% bovine serum albumin and 2 mM EDTA.  After adding 
mouse anti-human antibody conjugated to magnetic beads (CD271, CD133; Miltenyi 
Biotech, Auburn, CA), the sample was incubated for 30 min at 4°C, and then applied to a 
magnetic column (LS Column; Miltenyi Biotech).  The bound fraction was eluted with 5 
ml of MACS buffer and the cells were concentrated by centrifugation at 1000 x g for 8 
min.  After re-suspension, the entire isolate was cultured in complete culture medium. 
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MSC-like cells appeared as small colonies after about 1 week, and the cells were 
expanded.   
Isolation and culture of adult rat cardiac fibroblasts. Procedures conformed to the Guide 
for the Care and Use of Laboratory Animals published by the NIH. The animal protocol 
was approved by the Institutional Animal Care and Use Committee of the University of 
Vermont. Ventricular fibroblasts were isolated from hearts of adult Sprague-Dawley rats. 
The hearts were minced and enzymatically-dissociated into single cell suspension. Non-
myocytes were separated by discontinuous density gradient centrifugation and cultured in 
DMEM/F-12 supplemented with 10 % FCS. Passage 2 cells were used for experiments. 
Cell culture in CdM and evaluation of cell number. Adult rat CPCs and cardiac 
fibroblasts were plated at 500 cells/cm2 and cultured in their respective growth mediums. 
Three days after plating, the medium was removed, the wells were washed twice with 
PBS, and the cells were then exposed to CdM or to fresh serum-free medium (Alpha-
MEM). For time course proliferation studies, CdM and serum-free medium were changed 
every 2 days. In signal transduction inhibitor studies, we used the following 
pharmacological inhibitors: AG490, inhibitor of Jak2/STAT3 pathway; Stattic, inhibitor 
of STAT3; LY294002, inhibitor of phosphatidylinositol 3-kinase (PI3K)/Akt pathway; 
and PD98059, extracellular signal-regulated kinase (ERK) inhibitor. All of the inhibitors 
were purchased from Calbiochem (Darmstadt, Germany) and were dissolved in dimethyl 
sulfoxide (DMSO). CPCs were cultured in CdM with the inhibitors or with the equivalent 
volume of DMSO as a control for 48 hrs. In cell protection studies, 3 days after plating, 
medium was replaced with either the CdM or serum-free medium and the cells were 
exposed to hypoxia in a specialized incubator (1% oxygen) for 48 hrs. The hypoxia 
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incubator was a model that measured both CO2 and O2 (Thermo Electron, Forma Series 
II, model 3130). Oxygen was maintained at 1% by the injection of nitrogen gas and was 
monitored continuously. 
Cell numbers were quantified by the fluorescent labeling of nucleic acids (CyQuant dye; 
Molecular Probes, Carlsbad, CA) and with a microplate fluorescence reader (FLX800; 
Bio-Tek Instruments Inc., Winooski, VT) set to 480 nm excitation and 520 nm emission. 
Each experiment was repeated a minimum of 3 times. 
Immunocytochemistry. CPCs were fixed with 4% paraformaldehyde in 1x PBS. Non-
specific binding was limited by 1 hour incubation in PBS containing 5% goat serum and 
0.4% triton X-100. Primary antibodies were incubated overnight at 4ºC. After washing 3x 
5 min with PBS, secondary antibody that was diluted 1:1000 (Alexa 594, Molecular 
Probes) was applied for 1 h at room temperature (RT). After 3x 5 min washes, slides 
were mounted with Vectashield containing DAPI (Vector Laboratories, Burlingame, 
CA). Epifluorescence images were taken using a Leica DM6000B microscope equipped 
with a CCD camera (Leica DFC350Fx) and FW4000 software. The primary antibodies 
for immunocytochemistry were as follows: phospho-STAT3 (1:50, Tyr705, #9131; Cell 
signaling, Danvers, MA); α-sarcomeric actin (1: 500, clone 5C5, #A2172; Sigma); α-
smooth muscle actin (1: 800, clone 1A4, #A5228; Sigma); and von Willebrand factor (1: 
100, clone 21-43, # AB3442; Chemicon, Temecula, CA). For quantification of 
differentiation, cells positive for α-sarcomeric actin, α-smooth muscle actin and von 
Willebrand factor and total cells were counted at least in three fields per slide. The 
percentage of positive cells was calculated for each slide (n=3 in each group).  
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DNA replication assay. Three days after the plating, CSCs were cultured in growth 
medium, CdM or serum-free medium for 24 h, and BrdU (BD Biosciences) was added at 
a final concentration of 10 µM. Immunocytochemistry was carried out with BrdU 
antibody (1:100 clone BU33, # B8434; Sigma) and BrdU-positive cell numbers were 
quantified as above.  
Immunoblotting. Cells were lysed in a buffer that consisted of 0.1% sodium dodecyl 
sulphate (SDS) and complete protease inhibitor cocktail (Roche, Basel, Switzerland) in 
PBS. Protein concentration was determined by the DC protein assay (Biorad, Hercules, 
CA). Twenty µg of protein was separated by SDS-PAGE. After electrophoresis, the gels 
were electroblotted to polyvinylidene difluoride (PVDF) membranes. All electrophoresis 
and electroblotting used Novex reagents and systems (Invitrogen, Carlsbad, CA). The 
blots were blocked for 1 h at RT in 5% nonfat dry milk in PBS with 0.1% Tween 20 
(PBST), washed 3 × 5 min in PBST, and incubated in primary antibodies in PBST with 
5% BSA overnight at 4ºC. After 3x 5 min washes in PBST, the blots were incubated in 
secondary antibody conjugated to horseradish peroxidase conjugate (1: 2000, Sigma) in 
PBST for 1 h at RT. Unbound secondary antibody was removed and positive bands were 
detected with a chemiluminescent reaction. The primary antibodies for immunoblotting 
were Ki67 (1: 200, clone SP6, Abcam, Cambridge, MA); p-STAT3 (Tyr705, 1: 1000), 
total-STAT3 (1: 1000, #4904, Cell Signaling), p-Akt (Ser 473, 1:1000, # 9271, Cell 
Signaling), total- Akt (1:1000, # 9272, Cell Signaling), Insulin (1:1000, # I2018, Sigma); 
and β-actin (1: 5000, clone AC-15, # A5441, Sigma). 
ELISAs for IGF-1, Insulin, and CTGF. For assay of human IGF-1, we used 1x p75 CdM 
and commercial ELISA reagents with the manufacturer’s protocol (# DY291, R and D 
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Systems). For assay of Insulin and CTGF, high protein-binding plates were incubated 
with 1 or 10x p75 CdM overnight at room temperature to capture antigens from CdM. 
Wells were then washed with mild detergent (0.05% Tween-20 in PBS) followed by 
blocking with 1% BSA in PBS for 1 hour. After blocking buffer was thoroughly washed 
off from the wells, samples were incubated with 100 µl of biotin-conjugated polyclonal 
antibody to CTGF at 5µg/100 µl ( #P252Bt, Peprotech) for 2 hours at room temperature. 
Polyclonal mouse anti-Insulin antibody (Santa Cruz) was incubated for 2 hours at room 
temperature, followed by 3 washes with wash buffer. The wells were then incubated in 
anti-mouse biotin conjugated IgG (B7264, Sigma Aldrich) for 2 hours at room 
temperature. After washing in wash buffer 3 times, samples for CTGF and Insulin ELISA 
were incubated in Streptravidin conjugated HRP (1:2000) for 2 hrs at room temperature, 
followed by washing and addition of 100 µl of substrate ABTS (Thermo Scientific; 
#37615) for 20 minutes. Absorbance was measured (450 nm) on a Synergy HT plate 
reader. 
Myocardial infarction surgery in mice. Male mice at 9-10 weeks of age underwent 
permanent ligation of the Left Anterior Descending Coronary Artery (LAD) to induce 
myocardial infarction (C57bl6 mice, Taconic, Hudson, NY). Mice were not included in 
the study if they did not survive the initial MI surgery, did not achieve a successful MI 
(blanching observed at time of treatment), or died during treatment application.  
Following all procedures, mice were given analgesia (buprenorphine, 0.05-0.1 mg/kg i.p.) 
and monitored for signs of distress until termination of the study.  All procedures were 
done in accordance with the Institutional Animal Care and Use Committee (IACUC) of 
the University of Vermont.  
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For permanent LAD ligation surgery, mice were anesthetized with 2-4 % Isoflurane, 
shaved, weighed, intubated, and then maintained for the duration of the procedure on a 
sterile surgical field with the use of a mechanical ventilation system (MiniVent, Harvard 
Apparatus, Holliston, MA). Throughout the surgery and during the recovery period, body 
temperatures were maintained with a heated water pad system (Gaymar T-Pump TP-500, 
Gaymar Industries, Orchard Park, NY). Viewing the chest through a dissecting microsope 
(Stemi 2000-C, Carl Zeiss MicroImaging, Thornwood, NY) a dermal incision was made, 
the underlying fascia were removed, and the thoracic musculature was retracted to expose 
the left ribcage.  Next the intercostal muscles were retracted and the outer (parietal or 
visceral) pericardium was removed to expose the LAD. The LAD was then ligated (2.0-
3.0 mm from left atrial apex) with 8.0 nylon suture (Henry Schein, Melville, NY) and 
blanching within the myocardium of the left ventricle was noted.  The intercostals were 
rejoined with a 6.0 nylon suture (Henry Schein), the lungs were reinflated, and overlying 
dermis rejoined with a 6.0 nylon suture.  All mice were recovered to an ambulatory state 
prior to any subsequent treatment procedure.  Survival after the MI surgery was > 90%. 
Sham-operated mice underwent all procedures except that the suture was placed under 
the LAD but was not ligated. 
 
Infusion of p75MSC CdM after MI in mice. To evaluate p75 CdM treatment in an 
unbiased manner, all animals were randomized to treatment (after LAD ligation).  
Following 24 hour recovery of an animal after the first surgery, the mouse was then again 
anesthetized, intubated, and the chest opened.  Once the intact suture and area of 
blanching were confirmed, 30x p75 CdM (200 uL) or vehicle (Alpha-MEM, 200 uL) 
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warmed to 37°C was delivered to the entire cardiovascular arterial tree by injecting the 
solution into the lumen of the left ventricle (LV).  Injections were performed slowly (over 
a period of 1 minute) with a 30.5 gauge needle inserted below the great cardiac vein (LV 
apex) at an angle 45° to the myocardium. Following treatment with either CdM or 
vehicle, the needle was removed and the intercostals were rejoined using 6.0 chromic gut 
suture (Ethicon, Johnson and Johnson, Inc., Livingston, UK), lungs then reinflated, and 
overlying dermis rejoined with 6.0 nylon suture.  All mice were then recovered to an 
ambulatory state and transferred to the vivarium for the remaining duration of the 
experiment.   
 
 For CK assays, left ventricular tissue was dissected away from the atria and the 
aorta, further separated into anterior LV and posterior LV/septum, and immediately snap 
frozen by submersion of cryovials in liquid N2.  The LV tissues were maintained at -
80°C until the day of the CK assay (see below). 
 
TUNEL Assay. TUNEL was performed as reported previously.1 Quantification of 
TUNEL- positive cells within zones of infarction was performed in an unbiased fashion 
by a viewer that was blinded to slide (sample) identity. Cells were counted with Image 
Pro Plus Software as reported previously [1]. 
 
Creatine Kinase Assay. The remaining creatine kinase (CK) activity in left ventricular 
tissues was assessed to determine the extent of infarction in mouse hearts as reported 
previously [2,3]. The loss of CK activity directly reflects the loss of viable myocardium 
77 
 
after MI.  The percentage of left ventricle with infarction was calculated based on 
observed total LV CK activity (IU/mg protein) in left ventricles of normal hearts without 
infarction.  The percent of MI = 100 x [NL CK-LV CK] / Δ, where NL CK is the amount 
of CK in tissue from normal LV (IU/mg of soluble protein), LV CK is total remaining 
CK activity in the LV after MI (IU/mg soluble protein), and Δ is the difference between 
the amount of CK in normal zones of myocardium and in zones of myocardium with 
infarction. 
Immunohistochemistry. Rats were euthanized under isoflurane, their hearts harvested and 
washed in PBS to remove remnant blood. Hearts were fixed in 4% paraformaldehyde 
overnight and equilibrated in 15 and 30% sucrose consecutively for cryoprotection. After 
mounting in OCT (Tissue-Tek), serial sections were performed from apex to base at 20 
microns (Leica CM1800 Cryostat) and sections were mounted on glass slides. Slides 
were dried at 37°C and washed twice in 1x PBS. Primary antibodies were against Ki67 
(clone SP6, 1:100; Abcam), CD31, (1:50, #555026, BD Biosciences), and smooth muscle 
alpha actin (1:500, Sigma). Primary antibodies were detected with secondary antibodies 
conjugated to Alexa 574 (1:2000). Slides were mounted in Vectashield with DAPI 
(Vector Labs). Sections were imaged by epifluoresence deconvolution microscopy (Leica 
DM6000B; Leica) with Leica FW4000 software. 
Statistical analysis. Comparisons of parameters among the three groups were made with 
one-way analysis of variance (ANOVA) followed by Scheffé's multiple comparison test. 
Comparisons of parameters between two groups were made by unpaired Student's t-test. 
P< 0.05 was considered significant. 
References for Supporting Information: 
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Figure 2- 1. Human stromal cell CdM induces proliferation of adult rat CPCs 
(A) Time course changes in the numbers of CPCs treated with CdM or SFM. CdM was assayed from 2 
different donors for each cell type. Control cell number (48,896 cells) was regarded as 100%. Data are 
mean ± SEM, n = 3 to 7. *, P< 0.0001 vs baseline; **, P< 0.01 vs baseline; †, P< 0.0001 vs SFM. (B) 
Quantification of BrdU-positive CPCs after immunocytochemistry. Data for 2 human donors are shown for 
each cell type [donor A and donor B]. Inset, Immunoblot for Ki67 in CPCs (molecular weight, 359 kDa: 
lane 1, SFM; lane 2, 1x MSC CdM; lane 3, p75MSC CdM; lane 4, 1x fibroblast CdM). *, P< 0.05 vs SFM; 
**, P< 0.01 vs SFM. (C) MSC CdM does not support cardiac fibroblast proliferation. Control cell number 
(34,606 cells) was regarded as 100%. For B and C, data are mean ± SEM, n = 3. *, P< 0.0001 vs baseline. 
CdM, conditioned medium. SFM, serum-free α-MEM. GM, CPC growth medium (CSC medium with 2% 





Figure 2- 2. STAT3 and Akt activation in CPCs treated with 1x CdM 
 (A) Left, Immunoblotting for phosphorylated STAT3 (p-STAT3) and total STAT3 (T-STAT3) in CPCs 
(molecular weight, 86 kDa). Βeta-actin levels indicate loading. Right, Quantification of p-STAT3 levels (n 
= 3). The corrected values in SFM on day 1 and 2 were designated as “1”. *, P< 0.05 vs SFM. (B) 
Immunocytochemistry for p-STAT3 and T-STAT3. Note: p-STAT3 localizes to CPC nuclei (blue, DAPI). 
Scale bars = 100 μM. (C) Immunoblotting for phosphorylated Akt (p-Akt) and total Akt (T-Akt) in CPCs 
(molecular weight, 62 kDa). (D) Inhibitory effect of AG490 (10 μM) on CPC growth and survival in 
stromal cell CdM for 48 hrs. Control cell numbers (121,863 cells in MSC CdM, 115,342 cells in p75MSC 
CdM, and 118,682 cells in fibro CdM) were regarded as 100%. n= 3 replicates for 1 human donor per cell 
type. *, P< 0.0001 vs control. (E) Inhibitory effects of AG490 (10 μM) and LY294002 (10 μM) on CPCs 
incubated with 1x CdM for 48 hrs. Control cell numbers (121,863 cells) were regarded as 100%. Data are 
mean ± SEM, n = 3 to 6 replicates. *, P< 0.0001 vs control; **, P< 0.01 vs AG; †, P< 0.05 vs LY. Con: 
control, DMSO. AG: AG490, Jak2/STAT3 pathway inhibitor. LY: LY294002, inhibitor of PI3K/Akt 






Figure 2- 3. Protective effect of human stromal cell CdM on rat CPCs exposed to 
chronic hypoxia (1% oxygen for 48 hrs) 
(A) CPC numbers in GM, SFM and CdM after exposure to chronic hypoxia. Control cell number (58,616) 
was regarded as 100%. Data are mean ± SEM. CdM donors assayed for each cell type; n=3 (CD133MSC, 
Fibro), n=4 (p75MSC, MSC). *, P< 0.05 vs SFM; **, P< 0.01 vs SFM; †, P<0.01 vs CD133MSC CdM. 
(B) STAT3 inhibition with AG490 (10 μM) blocks CPC protection conferred by CdM during hypoxia. 
Control cell number (56,559 cells in MSC CdM, 92,120 cells in p75MSC CdM, and 74,511 cells in fibro 
CdM) was regarded as 100%. Data are mean ± SEM, n = 3 replicates for 1 human donor per cell type. *, 
P< 0.0001 vs CdM. AG: AG490, Jak2/STAT3 pathway inhibitor. (C) Survival of CPCs in p75MSC CdM 
and under hypoxic conditions for 48 hrs is dependent on signaling through STAT3 and abolished by 
incubation with the STAT3-specific inhibitor, “Stattic” (10 µM). n = 3 replicates for 1 human donor. **, 
P< 0.001 vs DMSO vehicle with 1x or 10x CdM. CdM, conditioned medium. SFM, serum-free α-MEM. 









Figure 2- 4. Priming of adult rat CSCs with human p75MSC CdM markedly 
improves CSC graft success 1 week after MI 
At 1 day after MI, CSCs were primed in 30x CdM or vehicle (SFM) for 30 min on ice prior to co-injection 
(2 sub-epicardial injections per rat, 1 per border zone). (A) Image of the largest cell graft for control rats (n 
= 5), at 1 week after MI and injections of CSCs/SFM. Yellow autofluorescence indicates host-derived 
myocytes. (B-D) Images of sub-epicardial grafts from three different rats, 1 week after MI and injections of 
CSCs/CdM (n = 6). (C) Ki67 staining (red) of proliferating GFP+ CSC derivatives in sub-epicardial tissue 
after CSC/CdM injections. (D, D’) For hearts treated with CSCs/CdM, GFP+ cells were observed to migrate 
between apparently healthy cardiac myocytes in order to reach distant zones of necrotic myocardium with 
infarction. White arrows in (D) indicate change in CSC orientation during migration from sub-epicardium 
into myocardium after MI; compare to orientation in (B). The dashed white line in D’ indicates edge of 
infarction. (E) After CdM-priming, GFP+ CSC derivatives migrated into areas of necrosis with few 
remaining viable myocytes. (F) CdM-primed CSC derivatives differentiate into CD31-positive (red) 
vascular endothelial cells to repair blood vessels. (G) CdM-primed CSC derivatives differentiate into 
smooth muscle alpha actin-positive (SMA, red) smooth muscle cells and myofibroblasts (arrows indicate 
co-localizations with GFP). (H) Quantification of GFP+ cells from individual tissue sections with the most 
engraftment in hearts that received CSCs/SFM (rats 1 - 5) or CSCs/CdM (rats 6 - 11). Note: We stopped 
counting after 20,000 GFP+ cells for two CSC/CdM-treated rats, but observed thousands of additional GFP+ 




Figure 2- 5. CTGF and Insulin are key factors present in p75MSC CdM that 
promote the survival and proliferation of CPCs 
(A) Incubation of 10x p75MSC CdM with antisera specific to human CTGF ablates its ability to protect 
CPCs during 48 hrs of hypoxia. Non-specific IgG (con IgG) or anti-CTGF was added to separate aliquots 
of CdM (10 μg/ml, each). *** , P< 0.001 vs. con IgG. (B) CTGF (3 ng/ml, 30 min incubation) induces p-
STAT3 in CPCs compared with incubation in vehicle (1% BSA). Levels of p-STAT3 after 30 min 
incubation in 1x CdM are shown for comparison. Inset, Representative blot. (C) Effects of Insulin on 
survival and growth of CPCs under normoxic conditions. Inset, Increasing Insulin concentration has dose-
responsive effect on p-Akt levels in CPCs (30 min incubation). (D) Dual incubation of CPCs with C-
terminal domain 4 peptide (CTGF D4) and Insulin (1 ng/ml, each) has synergistic effects on CPC survival 
during 48 hrs of hypoxia. *, P< 0.05 vs SFM; **, P< 0.01 vs SFM. For A-D, n = 3-5. CdM, conditioned 




Figure 2- 6. Priming of cultured CSCs in CTGF-D4 and Insulin promotes graft 
success after MI 
 (A, A’) Few control rats (1/7) injected with CSCs primed for 30 min in vehicle (SFM with 1% BSA) had 
detectable GFP+ cells at 1 week after MI and sub-epicardial injections. Note: GFP+ cells of control rats do 
not exit sub-epicardial graft site. (B-C’) All rats (5/5) that received CSCs primed with CTGF-D4 (3 
ng/ml)/Insulin (30 ng/ml) demonstrated robust engraftment of GFP+ cells at 1 week after MI. (B, B’) Sub-
epicardial engraftment (B) and extensive migration/integration (B’) of GFP+ cells 1 week after MI in a 
representative animal that received CSCs primed with CTGF-D4/Insulin. (C, C’) Engraftment of GFP+ 
cells 1 week after MI in a second representative animal that received CSCs primed with CTGF-D4/Insulin. 
Image demonstrates integration into area with infarction. FITC channel (C’) shows extent of migration into 
infarct. Note: White dashes in B’ and C’ indicate infarct border. Area beyond dashes has few viable 













Figure 2- S 1. CSC/CPC culture ex vivo 
Top 2 panels: Phase contrast images of CSCs, CPCs in CPC growth medium. Lower 4 panels: CPCs treated 
with CdM from MSCs, p75MSCs, or fibroblasts or SFM for 8 days (magnification, 10x). Please note that 
only the cells in the lower 4 panels were seeded at the same time and at the same density. CPC growth 








Figure 2- S 2. Proliferation of CPCs 
 (A) Dose-dependent effect of 10x-concentrated CdM on CPC proliferation. CPC growth in 1x CdM from 
one MSC donor and one p75MSC donor is shown for reference. Control cell number (60,191 cells) was 
regarded as 100%. Data are mean ± SEM, n = 3. 10x CdM from 2 different donors was assayed for each 
cell type. *, P< 0.0001 vs baseline; **, P< 0.0001 vs day 4; †, P< 0.05 vs day 8. CdM, conditioned 
medium. (B) Growth of CPCs in p75MSC CdM is dependent on signaling through STAT3 and abolished 
by incubation with the specific STAT3 inhibitor, “Stattic” (10 µM). *, P< 0.001 vs DMSO vehicle on day 
2; **, P< 0.001 vs. DMSO vehicle on day 4. (C) Inhibitory effects of AG490 (10 μm) and LY294002 (10 
μm) on CPCs incubated with 1x CdM for 48 hrs. Control cell numbers (99,965 cells in SFM, and 164,614 
cells in GM) were regarded as 100%. For C, data are mean ± SEM, n = 3 to 6. *, P< 0.0001 vs control; **, 
P< 0.01 vs AG; †, P< 0.05 vs LY. Con: control, DMSO. AG: AG490, Jak2/STAT3 pathway inhibitor. LY: 
LY294002, inhibitor of PI3K/Akt pathway. A+L: AG490 + LY294002. CdM, conditioned medium. SFM, 











Figure 2- S 3.Growth factor administration on CPCs 
Time course changes in the numbers of CPCs treated with SFM supplemented with various growth factors 
(EGF, bFGF, and LIF; 10 ng/ml) and in the absence of Insulin-Transferrin-Selenium. Control cell number 
(64,026 cells) was regarded as 100%. Data are mean ± SEM, n = 3. *, P< 0.01 SFM and SFM+EGF+FGF 
vs baseline; **, P< 0.001 SFM, SFM+EGF+FGF, and SFM+LIF+EGF+FGF vs baseline. Data for growth 


















Figure 2- S 4. Differentiation of CPCs expanded in CdM 
 (A) Immunofluorescent staining for α –SA, α-sarcomeric actin; SMA, α-smooth muscle actin; and vWF, 
von Willebrand factor. Left panels (Baseline) show the CPCs in growth medium 3 days after plating, and 
the right panels show CPCs expanded in CdM for 4 days. (B) Quantification of % positive cells for α –SA, 
SMA, and vWF at for cells incubated in growth medium, CdM and CTGF-D4 (3 ng/ml)/Insulin (30 ng/ml). 
Data are mean ± SEM, n = 3. CdM, conditioned medium, Scale bars = 100 μm. Note; the total count for 3 
lineages exceeds a 100% as s portion of CPC-derivatives in culture stain positive for both SMA and α –SA 






Figure 2- S 5. p75CdM in vivo administration 
Intra-arterial infusion of p75MSC CdM 24 hrs after MI significantly reduces the level of cardiac 
apoptosis/necrosis at 48 hrs after MI in adult mice. (A) TUNEL stains of heart sections from vehicle (SFM-
treated) and CdM-treated C57bl6 mice. At 24 hrs after LAD ligation, 200 µl of SFM or 30x p75MSC CdM 
was slowly infused into the left ventricle lumen (intra-arterial delivery). (B) Quantification of TUNEL+ 
cells in heart sections of animals that received intra-arterial infusion of SFM or 30x p75MSC CdM 24 hrs 






Figure 2- S 6. Coronal section after engraftment 
CSCs primed with 30x p75MSC CdM engraft into sub-epicardial tissues after MI and migrate into specific 
zones with infarction. Image shows the localization of CSC-derived GFP+ cells, 1 week after MI and 
CSC/CdM injections. The dashed white arrow indicates the direction of the tangential sub-epicardial 
injection.  The small yellow arrows indicate the direction of cell migration into the myocardium from the 







Figure 2- S 7. One month engraftment data 
CSCs primed with 30x p75MSC CdM survive and differentiate in the heart 1 month following MI and 
transplantation. (A) Few cells survive after vehicle control injection (1%BSA in alpha MEM) 1 month post 
MI. (B, B’) Two different representative animals grafted with GFP-positive CSCs. Cells were primed with 
30x p75MSC CdM and populate the majority of the infarct after 1 month. (B’’) High magnification view, 
highlighting GFP-positive cells in the core of an infarct. (C, C’, C’’) Engrafted CSCs differentiated into 
CD31-positive endothelial cells and contributed to large blood vessels. (D,D’) CSCs and their derivatives, 
engrafted with CTGF-D4/Insulin, 1 month after injury. (E-E’) Engrafted CSCs differentiated into smooth 
muscle actin (SMA)-positive myofibroblasts (E) and CD31-positive endothelial cells (E’) and also 






CHAPTER III. CTGF-D4 ENGAGES AN LRP6/SOX9/ETBR 
SIGNALING AXIS THAT PROMOTES THE EPICARDIAL 
RESPONSE TO INJURY AND GRAFT SUCCESS AFTER 
MYOCARDIAL INFARCTION 
 




































Transplantation of stem/progenitor cells holds promise for cardiac regeneration in 
patients with myocardial infarction (MI). However, low cell engraftment continues to 
present a major challenge and ligands, receptors, and signaling pathways that promote 
graft success remain poorly understood. Here we prospectively isolate uncommitted 
epicardial cells from the heart cover by CD104 (beta-4 integrin) and demonstrate that C-
terminal peptide from Connective Tissue Growth Factor (CTGF-D4), when combined 
with insulin, effectively primes adult epicardial derivatives for robust cardiac engraftment 
after MI.  By neutralization and knockdown studies, we determined that CTGF-D4 
signaled through Wnt co-receptor LRP6, triggering Sox9-dependent expression of 
Endothelin Receptor B (ETBR) and epicardial cell migration. In loss-of-function studies, 
conditional deletion of ETBR in Keratin18-expressing epicardial cells prevented their 
proliferation, EMT, and migration into myocardium after MI. Our results illustrate an 
LRP6/Sox9/ETBR signaling axis that controls the biology of native epicardial cells and 















The limited endogenous regenerative capacity of the adult mammalian heart has 
prompted substantial investment and effort into cell-based therapy for acute myocardial 
infarction (MI) (Laflamme and Murry, 2011; Wadugu and Kuhn, 2012). The ability to 
provide robust, persistent cell grafts in a predictable manner is highly desirable and may 
dramatically improve cardiac regeneration. To date, however, despite numerous animal 
studies and human trials aimed at treating MI and heart failure through direct cardiac cell 
replacement, clinical use of many promising cell types remains hampered by low levels 
of cell survival, engraftment, and differentiation following transplantation.  
Epicardial cells and derivatives from the heart cover are receiving increasing attention as 
a promising cell source for cardiac repair after injury (Bollini et al., 2014; Braitsch et al., 
2013; Gittenberger-de Groot et al., 2012; Gittenberger-de Groot et al., 2010; Gonzalez-
Rosa et al., 2012; Riley, 2012; Ruiz-Villalba et al., 2015; Singh and Epstein, 2012; Smart 
et al., 2013). Adult epicardial cells are multi-potent and undergo proliferation and 
epithelial to mesenchymal transformation (EMT) after MI; this results in subepicardial 
thickening adjacent to areas of injury (e.g. infarct border zones) (Gonzalez-Rosa et al., 
2012; Smart et al., 2013). From there, epicardial-derived cardiac precursor cells migrate 
into injured myocardium and participate in myocardial repair and remodeling (Duan et 
al., 2012; Ren et al., 2013; van Wijk et al., 2012; Zhou and Pu, 2011).  Multiple signaling 
factors such as Retinoic Acid, FGF and Wnt have been shown to regulate the activities of 
epicardial cells during development (Rentschler and Epstein, 2011; Vega-Hernandez et 
al., 2011; Zamora et al., 2007). In contrast, for adults with cardiac injury, extrinsic factors 
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that regulate epicardial cell behavior and/or functions are poorly understood and none 
that mediate epicardial engraftment have been identified. 
Recently, we reported a new biologic grafting drug based on a defined 
combination of human Connective Tissue Growth Factor (C terminal, 4th domain peptide; 
CTGF-D4) and insulin (Iso et al., 2014). This peptide combination effectively primes 
cultured cardiac progenitor cells to graft into subepicardial sites bordering tissue with 
infarction after MI (Iso et al., 2014). Here we identify Wnt-co receptor LRP6 as a key 
target for CTGF-D4 that mediates epicardial graft success and define an 
LRP6/Sox9/ETBR signaling axis that controls multiple aspects of the epicardial response 
to injury. Through loss-of-function studies using inducible, conditional knockout (cKO) 
mice with an epicardial cell-specific promoter (Keratin18CreERT2-ETBR-cKO mice), we 
demonstrate that ETBR is required for epicardial proliferation, EMT and migration into 
the myocardium after MI. Our results illustrate overlap between the signals and signaling 
pathways that regulate injury-induced responses of native epicardial cells and those that 
promote grafting of culture-expanded cells to subepicardial sites after MI. 
Results  
CD104 is a specific marker of undifferentiated adult epicardial cells with an 
epithelial-like (mesothelial) phenotype 
There is growing interest in use of epicardial cells and their derivatives for regenerative 
medicine (van Berlo and Molkentin, 2014; Vieira and Riley, 2011), but lack of defined 
cell surface epitopes unique to adult epicardial cells makes their isolation and enrichment 
difficult. To genetically-label and study epicardial cells in vivo, several studies have 
utilized gene expression of epicardial cell-associated transcription factors such as Wt1 
96 
 
(Zhou et al., 2008), Gata5 (Merki et al., 2005), Tbx18 (Cai et al., 2008) and Tcf21 
(Acharya et al., 2011). While this approach is useful, it is less effective for clinical 
applications due to the requirement for genetic manipulation of the organism and 
overlapping expression of these transcription factors in downstream epicardial derivatives 
and non-epicardial cells (Ali et al., 2014; Kikuchi et al., 2011; Wagner et al., 2008). To 
effectively harness epicardial cells and their derivatives for clinical use, standardized 
protocols for cell isolation and preparation that are less invasive will be necessary. 
Accordingly, we sought to develop methods for direct epicardial cell isolation based on 
differential expression of cell surface epitopes. 
To distinguish them from other cardiac cell types, we focused on the epithelial-
like phenotype of adult epicardial cells and determined that beta 4 integrin (CD104) alone 
could be used to enrich specifically for adult epicardial cells. A transmembrane 
glycoprotein, CD104 forms a heterodimer with alpha 6 integrin, thereby modulating 
epithelial cell proliferation and adhesion to the basement membrane (Kajiji et al., 1989). 
Several reports used CD104 to identify epithelial stem cells from various organs/tissues 
including lung, dental pulp, urothelium and eye (Chapman et al., 2011; Kurzrock et al., 
2008; McQualter et al., 2010; Pajoohesh-Ganji et al., 2006). By immunohistochemistry, 
we found that CD104 was expressed specifically by the epicardium in tissue sections 
from rat, mouse and man (Figures 1A). Furthermore, Magnetic-Activated Cell Sorting 
(MACS) using an antibody to CD104 selectively purified epicardial cells away from 
myocytes, fibroblasts, endothelial and hematopoietic cells, as well as downstream (post-
EMT) epicardial derivatives (Figure 1B). CD104-isolated cells were positive for 
epithelial keratins (intermediate filament proteins) and transcription factors such as 
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Gata4, Wt1, Tbx18, and Tcf21, confirming their epithelial and epicardial identities, 
respectively (Figure 1C-D) (Bochmann et al., 2010). A subset of Wt1-positive cells also 
expressed p63, a marker of epithelial cell activation and proliferation (Figure S1B) 
(McKeon, 2004; Senoo et al., 2007).  
During 3-7 days of culture in medium containing 10% FCS, epicardial cells 
isolated by cell surface CD104 underwent epithelial to mesenchymal transformation 
(EMT) (Figure S1A). Epicardial EMT was confirmed by the appearance of CD90 (Thy-
1), a cell adhesion protein expressed during differentiation (Lennon et al., 1978; Bakondi 
et. al., 2009) (Figure 1E), and concomitant loss of CD104 (Figure 1F).  Hereafter, 
epicardial cells expressing Vimentin (mesenchymal intermediate filament protein, Figure 
1G) and CD90 (Figure 1H) after EMT are referred to as Epicardial-Derived Cells 
(EPDC).  
CTGF-D4 promotes primary EPDC grafts to adult hearts with MI  
Detected by in situ hybridization at 1 week after MI, CTGF mRNA expression was 
reported to increase markedly in subepicardial fibroblasts bordering tissue with infarction 
(Chuva de Sousa Lopes et al., 2004). In agreement, by immunohistochemistry with 
antisera specific to CTGF-D4, we localized CTGF-D4 at 1 week after MI to border zone 
subepicardial regions in hearts from both rats and mice (Figure 2A). In a recently 
published neutralization screen, we identified CTGF and insulin as factors present in 
medium conditioned by human bone marrow progenitor cells that acted synergistically to 
increase the survival of cardiac progenitor cells (CPCs) during simulated ischemia (1% 
oxygen with nutrient deprivation). Furthermore, using a permanent ligation model of MI, 
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we determined that cultured CPCs could be primed with a combination of CTGF-D4 and 
insulin to promote robust graft success with CPCs transplanted into subepicardial sites 
bordering tissue with infarction (Iso et al., 2014). Although our screen identified insulin 
independently, a previous report had shown that insulin-like growth factor (IGF-1) could 
enhance engraftment and differentiation of murine ES cells when co-injected into hearts 
with myocardial infarction.  
The endogenous subepicardial expression pattern of CTGF-D4 and its ability to 
foster cell grafts at subepicardial sites prompted us to investigate the effect(s) of CTGF-
D4 on primary adult epicardial cells. In culture, CTGF-D4 promoted EPDC adhesion to 
fibronectin-coated glass cover slides (Figure S2), suggesting that it might support 
engraftment of transplanted EPDCs. To mimic a clinical scenario in which patients are 
revascularized after acute MI, we used a different MI model with a period of myocardial 
ischemia followed by reperfusion (MI/R) (Rao et al., 2015). To test the ability of CTGF-
D4/Ins to prime EPDC, we performed MI/R surgeries in adult rats (2 h ischemia followed 
by reperfusion), and injected DiI-labeled EPDC into 2 subepicardial sites at the time of 
reperfusion. We evaluated graft success at 1 week or 1 month after cell injection. In 
contrast to vehicle-primed cells, EPDC primed by CTGF-D4/Ins effectively grafted the 
subepicardium in regions bordering the infarct, proliferated (see Ki67+ EPDCs in Figure 
S3B), and migrated into the injured myocardium (Figure 2B). At 1 week after MI/R and 
cell injection, cell counts from selected serial cardiac tissue sections containing the 
highest number of DiI-labeled cells (1 slide per heart) demonstrated a significant increase 
in EPDC engraftment for animals injected with CTGF-D4/Ins-primed EPDC as opposed 
to vehicle-primed EPDC (vehicle, 350 ± 49 cells; CTGF-D4/Ins, 14,868 ± 111 cells; p ≤ 
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0.001, n=6 per group; Figure 2C, Figure S3A). Since DiI-labeling does not persist long-
term after cell proliferation, we repeated the MI/R study with male to female grafts and 
quantified the level of male EPDC engraftment using real-time quantitative PCR (qPCR) 
assays for Y chromosome. After 1 month, we detected significantly more male DNA in 
female hearts that received CTGF-D4/Ins-primed EPDC compared with injections of 
vehicle-primed EPDC (vehicle, .0031 ± .00119%; CTGF-D4/Ins, 0.41367 ± .0244%; p≤ 
0.001, n=4 per group; Figure 2D).  
By echocardiography (ECHO), hemodynamic measurements 1 week after MI/R 
and cell transplantation were similar between the two groups (Figure S3C). However, 
after 1 month we observed a significant improvement in cardiac function for animals 
grafted with CTGF-D4/Ins-primed cells. LV fractional shortening (FS), ejection fraction 
(EF) and anterior wall thickness (AWT) were greater in systole (S) and diastole (D) in 
animals treated with CTGF-D4/Ins-primed cells compared with controls (% FS; sham, 
38.65% ± 3%, vehicle, 30.34 ± 3.4%; CTGF-D4/Ins, 40.81 ± 7.8%; vehicle vs. CTGF-
D4/Ins, p≤ 0.05; % EF; sham, 73.0% ± 7.2%, vehicle, 59.62 ± 6.1%, CTGF-D4/Ins, 
71.91 ± 5.33%; vehicle vs. CTGF-D4/Ins,  p≤ 0.05; AWT (S-D), sham, 0.29 ± .043, 
vehicle, 0.19 ± .03, CTGF-D4/Ins .274 ± .031; vehicle vs. CTGF-D4/Ins, p ≤ 0.05; 
Figures 2E-G).  
Identification of LRP6 as a receptor for CTGF-D4 on epicardial cells 
CTGF-D4 has been shown to interact with integrins, and multiple cell surface receptors 
including TrkA, EGFR, FGFR2, LRP1 and LRP6 (Figure 3A) (Aoyama et al., 2012; 
Kawata et al., 2012; Mercurio et al., 2004; Ren et al., 2013; Wahab et al., 2005) . 
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Exposure of EPDC to CTGF-D4 led to increased expression of CD90 and other 
differentiation markers such as alpha smooth muscle actin (α-SMA, smooth muscle cells 
and myofibroblasts), and von Willebrand Factor (vWF, endothelial cells) (Figure 3B). 
Notably, prior incubation in neutralizing antibodies against LRP6 reduced the 
differentiating effects of CTGF-D4 (Figure 3B). 
We next examined whether CTGF-D4/LRP signaling affected EPDC survival. 
Under conditions of simulated ischemia, blocking antibodies directed to both Wnt co-
receptors (LRP5/6) diminished the protective effects of CTGF-D4. Notably, blocking 
LRP6 alone had the same effect (Figure 3C).  Furthermore, binding LRP6 to its ligand 
Dkk-1 abolished CTGF-D4 mediated EPDC protection, showing that LRP6 regulates 
CTGF-D4-dependent cell survival (Figure S4). Altogether, these results demonstrate a 
role for LRP6 in relaying signals from extracellular CTGF-D4 during EPDC 
differentiation and survival. 
LRP6 signaling is required for EPDC engraftment following transplantation 
To test the hypothesis that CTGF-D4 signals through LRP6 to promote EPDC graft 
success after myocardial infarction, we developed a competitive dual engraftment assay 
(Figure 2D, Methods). At 1 week Following MI/R and cell engraftment, we observed a 
significant reduction in the grafting efficiency of EPDC when blocked with anti-LRP6. 
To further control for the process of dye labeling we performed reciprocal dye labeling of 
EPDC and Fc fragmentation of the blocking antibody prior to engraftment. Importantly, 
we performed the Fc fragmentation step to ensure that the Fc segment of the blocking 
antibody did not activate immune cells and preferentially eliminate epicardial cells that 
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were bound to antibody (see Supplementary methods) (Cell number from best tissue 
section: Control IgG, 29.871 ± 2301 cells; anti-LRP6 3934 ± 100 cells; p ≤ 0.01) (Figure 
3E-E’,F). We next carried out male cell transplants to female donors to confirm results 
from the competitive engraftment assay at 1 month after MI. Assays of genomic DNA 
isolated from whole LV revealed a significant decrease in EPDC engraftment when LRP6 
was blocked, compared with cells incubated in control IgG (Figure 3G). 
CTGF-D4/LRP6/Sox9 signaling targets ETBR to control epicardial cell migration 
To identify other cell surface receptors and pathways that potentially interacted with 
CTGF-D4 signaling and its effects on epicardial cells, we performed an inhibitor screen 
with medium containing CTGF-D4 and normoxic (21% oxygen) or hypoxic (1% oxygen) 
conditions. The results showed that inhibition of either FGFR/VEGFR or Endothelin 
Receptor Type B (ETBR) reduced epicardial cell numbers (Figure S5).  In contrast, 
inhibitors for EGFR, PDGFR, MAPK, Notch signaling (Gamma-secretase) and 
Endothelin Receptor Type A (ETAR) did not (Figure S5). As role(s) for FGFR and 
VEGFR had been established for epicardial cells (Lepilina et al., 2006; Vega-Hernandez 
et al., 2011), we chose to focus on ETBR.  
By antibody staining, ETBR was expressed by native epicardial cells as they 
migrated into the myocardium after MI (Figure 4A). For EPDC in culture, CTGF-D4 
treatment increased ETBR, whereas blocking LRP6 with a neutralizing antibody abolished 
the effects of CTGF-D4 (Figure 4B-C). Furthermore, in a cell migration assay (Figure 
4D), we found that an ETBR agonist (IRL-1620) promoted EPDC migration, while, 
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antagonizing ETBR blocked EPDC migration (Figure 4E-F); these results indicated that 
ETBR signaling could be an important determinant of epicardial cell migration. 
We next sought to identify intracellular factor(s) through which CTGF-D4/LRP6 
signaling could act to promote ETBR expression. Previous reports had demonstrated 
Sox9, a transcription factor, was important for epicardial EMT during development and 
after injury (Hofsteen et al., 2013; Smith et al., 2011). In addition, Sox9 was found to 
control the EMT process in adult cancers of the breast, skin and lung (Capaccione et al., 
2014; Cheng et al., 2015; Guo et al., 2012).  Relevant to our studies, CTGF was shown to 
induce epithelial cell hyperplasia in the lung by increasing Sox9 levels (Sonnylal et al., 
2013). Accordingly, we examined whether primary isolates of EPDC expressed Sox9, 
and they did (Figure 4G). Subsequent treatment of EPDC with CTGF-D4 demonstrated 
increased Sox9 levels, an effect that was diminished by blocking LRP6 prior to CTGF-
D4 treatment (Figure 4H-I).  
Having observed similar changes in Sox9 and ETBR expression after CTGF-
D4/LRP6 stimulation in primary EPDC, we hypothesized that Sox9 controls the level of 
ETBR in response to CTGF-D4/LRP6 signaling. To establish the CTGF-D4/LRP6/Sox9 
signaling axis, we used lentiviral shRNA to knockdown Sox9 in HEK293 cells. 
Coincident with decreased Sox9 levels by shRNA, we observed a corresponding decrease 
in ETBR compared with ETBR levels in cells that received scrambled lentiviral shRNA 
(control) (Figure 5A). By promoter mapping, we determined the EDNRB gene promoter 
contained several Sox9 binding elements (Figure 5B,C). To demonstrate transcriptional 
regulation of EDNRB by Sox9, we transfected control HEK293 cells (scrambled shRNA) 
and Sox9 knockdown HEK293 cells with a pGL4 luciferase reporter construct containing 
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EDNRB promoter DNA (−3,022 bp to +160 bp of the human promoter) (Yokoyama et al., 
2006) (Figure 5D). Following treatment with CTGF-D4, EDNRB promoter activity 
increased in the control cells, but not in the Sox9 knockdown cells (Figure 5E). 
Collectively, these results suggest that CTGF-D4 signals through LRP6 and Sox9 to 
control the levels of ETBR.  
ETBR controls epicardial cell proliferation after MI 
To follow adult epicardial cells and their derivatives in vivo, we produced a lineage-
tracing strain using transgenic Rosa26-mTmG reporter mice, in which a stop codon 
flanked by loxP recombination sites lies between a constitutively-expressed gene for a 
red fluorescent reporter (tdTomato) and an inducible gene that encodes a green 
fluorescent reporter (GFP) (Muzumdar et al., 2007). For cell labeling, the Rosa26-mTmG 
strain was mated to mice that expressed a Tamoxifen (TM)-inducible form of Cre 
recombinase under control of the Keratin18 (K18) promoter, which distinctly labels 
epithelial cell populations throughout the body (Figure S6A) (Ousset et al., 2012; Van 
Keymeulen et al., 2009; Van Keymeulen et al., 2011). In the heart, Keratin18 is 
expressed exclusively by epicardial cells; this is true for multiple species from 
development through adulthood (Figure 6A) (Chen et al., 2002; Eid et al., 1992; Schaefer 
et al., 2004; Thorey et al., 1993; Vrancken Peeters et al., 1995). In confirmation of the 
model, treatment of 1week atrial explant cultures from K18CreERT2-mTmG mice with 4-
hydroxy-Tamoxifen resulted in epicardial cell-specific recombination (Figure 6B). 
Using the K18CreERT2-mTmG mice, we specifically labeled epicardial cells on the heart 
surface (i.e. epithelial phenotype) and then monitored epicardial cell proliferation, 
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epicardial EMT, and EPDC migration after MI (Figures 5B). Tamoxifen (TM) injections 
initiated recombination in 41 ± 3.2% of epicardial cells on the heart surface in healthy 
control mice and in 46.01 ± 4.89% of cells for mice with MI (Figure 6C). As expected, at 
3 days after MI we observed Ki67+ proliferating cells in both subepicardial and 
myocardial regions adjacent to and within the infarct (Figure 6D,D’). In confirmation of 
our inducible transgenic mouse model, at 3 days after MI we observed K18-positive 
epicardial cells that underwent EMT and GFP+ EPDC that subsequently migrated into 
border zone subepicardial sites (Figures 6E).    
To determine whether ETBR had specific role(s) in the proliferation, migration 
and/or function of adult epicardial cells and their derivatives, we generated K18-
CreERT2-ETBR-cKO mice (Figure S6C-D). To measure the effects of ETBR cKO after 
MI/R, we used double immunohistochemistry to develop a simple K18-based cell 
quantification index for both the infarct core and adjacent border zone areas of K18-
CreERT2-ETBR-cKO mice. Importantly, we found that K18 staining persisted in murine 
epicardial-derived CD90+ cells after EMT and thus could be used, in the short-term, to 
track epicardial cells and EPDC after MI/R. At 3 days after TM administration and MI/R 
surgery, we performed blinded counts to ascertain the number of K18+/ Ki67+ 
proliferating epicardial cells and the number of K18+/CD90+ epicardial cells that had 
undergone EMT in the presence/absence of ETBR cKO. As expected, after MI/R we 
observed significant proliferation of subepicardial cells and subepicardial thickening in 
vehicle (oil)-treated animals (Figures 6F-G). Surprisingly, however, K18+ epicardial cells 
in TM-treated animals did not proliferate, nor did they generate a thickened subepicardial 
cell layer (Figures 5F-G). For TM-treated mice, the number of K18+/ Ki67+ epicardial 
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cells in border zone regions was significantly less than that of vehicle-treated mice (Oil, 
43.55 ± 16.48%; TM, 13.35 ± 6.65%; n=5 per group, p ≤ 0.01)(Figure 6F). 
     To evaluate epicardial-specific EMT we analyzed 2 distinct populations of epicardial 
cells at 3 days after MI/R: 1) K18+ only cells (epicardial cells that did not undergo EMT) 
and 2) K18+/CD90+ cells (epicardial-derivatives post-EMT) in regions bordering infarct. 
As expected, within the infarct zones of vehicle-treated animals we observed that the 
majority of epicardial cells underwent EMT by 3 days after MI/R. As reported in patients 
with chronic cardiac failure, these areas were nearly devoid of K18+ epicardial cells 
(Figure 5H). In stark contrast, within the infarct zones of TM-treated K18-CreERT2-
ETBR-cKO mice, we observed a significant percentage of K18
+ epicardial cells that 
maintained an epithelial phenotype (CD90-negative). Intriguingly, these cells had failed 
to undergo EMT and thus now remained on the heart surface (Epicardial K18+ cells 
[infarct zone]: Oil, 11.01 ± 2.67%; TM, 78.45 ± 9.33%; n=5 per group, p ≤ 0.01) (Figures 
5H-I). Additionally, within border zone regions, the number of K18+/CD90+ (double 
positive) cells in TM-treated animals was significantly less than that of vehicle-treated 
animals (Subepicardial K18+/CD90+ cells [border zone]: Oil, 29.99 ± 4.37%; TM, 2.15 ± 
1.98 %; n=5 per group, p ≤ 0.001) (Figure 5H-I). Notably, for regions distal to the infarct 
zone and cell necrosis, the number of K18 cells was similar for both the TM- and vehicle-
treated groups (Epicardial K18+ cells [distal from infarction]: Oil, 62.98 ± 5.31%; TM, 







Here we report multiple effects of CTGF-D4 on epicardial cells that include induction of 
EMT and promotion of differentiation, migration, and survival. By performing cell 
engraftment and ex vivo cell signaling studies, we report that CTGF-D4 engages a 
previously unknown LRP6/Sox9/ETBR signaling axis that appears critical for the 
epicardial response to MI.  
The influence of CTGF in a cardiac injury environment is of great interest and 
needs further investigation. Whereas endogenous cardiac CTGF expression is low or 
absent in healthy myocardial tissue and non-infarcted tissue after MI (Dean et al., 2005), 
it is rapidly expressed in border zone subepicardial tissue early after MI. We found that 
injection of CTGF-D4/Ins-primed EPDCs into border zone subepicardial tissue as 
opposed to sites distal to infarction was necessary for successful cell engraftment. This 
difference in capacity to accept and propagate cellular grafts implies that additional 
extrinsic factors present within activated subepicardial tissue, perhaps even CTGF, are 
necessary for graft success.   
Our studies do not exclude the possible role for CTGF-D4 in stimulating or 
mediating other cellular pathways in primary epicardial cells, aside from the signaling 
axis we report. For instance, during development, in epicardial progenitor cells beta-
catenin is required for epicardial EMT and coronary artery formation during development 
(Zamora et al., 2007). Observations in our lab to detect differences in nuclear localization 
of beta-catenin or using BATGAL mice to detect Wnt pathway activation by beta-catenin 
promoter activity in our lab did not indicate that CTGF-D4 acted on LRP6 like a typical 
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Wnt ligand. Rather, our results in primary adult epicardial cells agree with those of the 
Tallquist group for beta-catenin in epicardial cells during development (Wu et al. 2010). 
Here, they showed that the epicardium is a polarized epithelium and that beta-catenin in 
epicardial adherens junctions and is required for critical epicardial processes including 
EMT and cell division. These effects were independent of beta-catenin transcriptional 
activity (Wu et al., 2010). As such, CTGF-D4/LRP6 signaling in adult epicardial cells 
and EPDC may alter beta-catenin dynamics in a non-canonical fashion, affecting proteins 
involved with cell polarity, cell division and EMT. 
Alternatively or in concert, CTGF-D4/LRP6 signaling may control the movement 
or function of transcriptional coactivators such as Yes-associated protein (YAP) and 
Transcriptional coactivator with PDZ-binding motif (TAZ), key components of the Hippo 
pathway. These proteins form regulatory complexes that interact with TEAD 
transcription factors to promote EMT (Diepenbruck et al., 2014). Of special interest, 
CTGF itself is a direct transcriptional target of YAP and TAZ and TEAD (Zhao et al., 
2008; Zhang et al., 2009).  
Through experiments that combined Sox9 gene knockdown with ETBR promoter 
activity assays, we identified Sox9 as a novel transcriptional regulator of ETBR. 
Interestingly, for mature cardiac myocytes and smooth muscle cells, endothelin (ET-1) 
signaling through ETAR was shown to increase CTGF expression (Rodriguez-Vita et al., 
2005). By contrast, our inhibitor screen with CTGF-D4 and adult epicardial derivatives 
identified FGFR and ETBR, but not ETAR. For pancreas development, Sox9 acts as the 
“centerpiece” in a Sox9/Fgf10/Fgfr2b feed-forward signaling loop that promotes both 
proliferation and fate-commitment of pancreatic progenitor cells (Seymour et al., 2012). 
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Given the known role of Fgfr2b signaling in controlling epicardial movement through the 
myocardium during development (Vega-Hernandez et al., 2011), signaling through 
CTGF-D4/LRP6 and Sox9 may mediate an increase in Fgfr2b to promote EPDC survival 
and/or migration after cardiac injury in adults. In this manner, ETBR and Fgfr2 could act 
as downstream effectors of CTGF-D4 signaling that participate in co-incident or related 
functions during epicardial EMT and/or migration. 
All these observations with regard to its expression pattern after MI and the 
numerous potential roles for CTGF-D4, taken together with our observations suggest that 
exogenous delivery of CTGF-D4 to areas bordering infarction may enhance proliferation 
and/or migration of native epicardial cells to improve cardiac regeneration and function 
after MI. Furthermore, because most adult cell types, including stem/progenitor cells, 
possess the insulin receptor and also receptors and/or integrins that bind CTGF-D4, the 
strategy of CTGF-D4/Ins-mediated priming and transplantation to subepicardial sites 
after MI may promote graft success for other reparative cell types such as adult 
multipotent stromal cells (MSCs), cardiac-specified progenitors (CPCs,), or derivatives 
from embryonic stem cells (ES cells). 
 
Experimental Procedures  
Isolation and short term priming of primary EPDC  
Rat atrial explants were cultured in 10% fetal bovine serum containing medium for 48 
hours, at which point primary epicardial cells were purified from all other cell types by 
magnetic sorting using anti-CD104 antibody. EPDCs were cultured as adherent cultures 
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in 10% complete culture medium. Cells were counted by hemocytometer, centrifuged, 
and re-suspended in CTGF-D4 (40 ng/ml)/Insulin (40 ng/ml)/1% BSA in -MEM, or 1% 
BSA in -MEM (vehicle control for recombinant peptides). 
Myocardial infarction and ischemia reperfusion surgery 
All animal work was approved by the University of Vermont College of Medicine’s 
Office of Animal Care in accordance with the American Association for Accreditation of 
Laboratory Animal Care, as described in (Iso et. al. 2013).   
Quantitative real-time PCR for Y chromosome 
Rat genomic DNA was isolated from the left ventricle homogenates in of rats by 
extraction with SDS/ Proteinase K digestion and Tris buffered phenol at pH 8.0. DNA 
yield and purity were verified then utilized as template for quantification of rat Y 
chromosome by real-time PCR in an automated instrument (ABI Prism 7700 sequence 
detection system, Applied Biosystems). Taqman PCR master mix was used to perform 
PCR reactions as per protocol (ABI Perkin Elmer). Y chromosome probe (5’-FAM CAA 
CAGAATCCCAGCATGCAGAATTCA 3’ -TAMRA) at 250 nM concentration was 
used with the primers (forward 5’ GGAGAGAGG CACAAGTTGGC 3’, reverse 5’ 
CCCCAGCTGCTTGCTGATC 3’; Integrated DNA Technologies, Coralville, IA) at 900 
nM concentrations. Standard curve preparation and analysis were performed as described 
in previously published work (Spees et. al., 2003) 
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Migration assay  
The setup was adopted from a previously described study (McKenzie et. al., 2011). 3000 
Primary EPDC were plated inside the core of a silicone donut, on fibronectin (20µg/ml) 
coated glass cover slips. After overnight adhesion, nuclei were stained using Hoescht 
33342 nuclear stain (Invitrogen, 1∶2000 in media) for 15 min at 37°C. The staining media 
was removed and replaced with either serum free media or serum free media containing 
Endothelin-1 (20 ng/ml, R&D Systems) with drug vehicle control (DMSO) or 
pharmacologic agents IRL-1620 (40 µm, Calbiochem) or BQ-788 (8 µm, Calbiochem).  
Sox9 shRNA knockdown  
Lentiviral transduction with shRNA was used to knockdown Sox9 expression (Mission 
Lentivirus particles; Sigma Aldrich) in HEK293 epithelial cells. For sequence 
information and method, refer supplementary methods.   
Luciferase assay to measure promoter activity 
Human embryonic kidney 293 cells with control scrm shRNA, or Sox9 shRNA 
transfected with the pGL4:hEDNRB promoter construct in 10% CCM with Lipofectamine 
3000 (Life technologies). After 24 hr the cells were seeded into 96-well plates at a 
density of 10,000 cells per well and allowed to adhere overnight. At 45 hr after 
transfection, medium was replaced with MEM containing 1% BSA or 1% BSA and 
CTGF-D4 (40 ng/ml), and CTGF-D4 with control IgG or anti-LRP6 blocking antibody (2 
µg/ml). The plate was allowed to incubate further for 3 hours to the point when promoter 
activity was assessed by luminescence measures with a Synergy HT Multimode 
Microplate reader (BioTek Instruments, Inc.; Winooski, VT). 
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Lineage tracing and conditional knockout mice 
Transgenic mice expressing Cre recombinase enzyme under the human Keratin 18 
promoter were crossed with either mT/mG mice for lineage tracing or to ETBR flox/flox 
mice. Refer supplementary methods for genotyping primers and results. Adult male 
C57BL/6J mice (6–8 wk of age) were obtained from Taconic Farms. Keratin18 Tg mice 
KRT18-cre/ERT2)23Blpn/J (catalog no. 017948), B6; 129-Ednrbtm1Nat/J (EDNRB-flox 
mice; catalog no. 011080), and mT/mG mice Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J 
(catalog no. 0007576) were from JAX. 
Quantification of conditional knockout analysis 
For each animal, 9 sections were analyzed, maintaining the same section position as 
accurately as possible across all animals. In each section, the epicardial region in 6 border 
zone regions to infarct, 3 infarct regions and 3 distal regions of right ventricle were 
captured as high magnification fluorescent images. A blinded operator then quantified the 









Acharya, A., Baek, S.T., Banfi, S., Eskiocak, B., and Tallquist, M.D. (2011). Efficient 
inducible Cre-mediated recombination in Tcf21 cell lineages in the heart and kidney. 
Genesis (New York, NY : 2000) 49, 870-877. 
Ali, S.R., Ranjbarvaziri, S., Talkhabi, M., Zhao, P., Subat, A., Hojjat, A., Kamran, P., 
Muller, A.M., Volz, K.S., Tang, Z., et al. (2014). Developmental heterogeneity of cardiac 
fibroblasts does not predict pathological proliferation and activation. Circulation research 
115, 625-635. 
Aoyama, E., Kubota, S., and Takigawa, M. (2012). CCN2/CTGF binds to fibroblast 
growth factor receptor 2 and modulates its signaling. FEBS letters 586, 4270-4275. 
Bochmann, L., Sarathchandra, P., Mori, F., Lara-Pezzi, E., Lazzaro, D., and Rosenthal, 
N. (2010). Revealing new mouse epicardial cell markers through transcriptomics. PloS 
one 5, e11429. 
Bollini, S., Vieira, J.M., Howard, S., Dube, K.N., Balmer, G.M., Smart, N., and Riley, 
P.R. (2014). Re-activated adult epicardial progenitor cells are a heterogeneous population 
molecularly distinct from their embryonic counterparts. Stem cells and development 23, 
1719-1730. 
Braitsch, C.M., Kanisicak, O., van Berlo, J.H., Molkentin, J.D., and Yutzey, K.E. (2013). 
Differential expression of embryonic epicardial progenitor markers and localization of 
cardiac fibrosis in adult ischemic injury and hypertensive heart disease. Journal of 
molecular and cellular cardiology 65, 108-119. 
Cai, C.L., Martin, J.C., Sun, Y., Cui, L., Wang, L., Ouyang, K., Yang, L., Bu, L., Liang, 
X., Zhang, X., et al. (2008). A myocardial lineage derives from Tbx18 epicardial cells. 
Nature 454, 104-108. 
Capaccione, K.M., Hong, X., Morgan, K.M., Liu, W., Bishop, J.M., Liu, L., Markert, E., 
Deen, M., Minerowicz, C., Bertino, J.R., et al. (2014). Sox9 mediates Notch1-induced 
mesenchymal features in lung adenocarcinoma. Oncotarget 5, 3636-3650. 
Chapman, H.A., Li, X., Alexander, J.P., Brumwell, A., Lorizio, W., Tan, K., Sonnenberg, 
A., Wei, Y., and Vu, T.H. (2011). Integrin alpha6beta4 identifies an adult distal lung 
epithelial population with regenerative potential in mice. The Journal of clinical 
investigation 121, 2855-2862. 
Chen, T., Chang, T.C., Kang, J.O., Choudhary, B., Makita, T., Tran, C.M., Burch, J.B., 
Eid, H., and Sucov, H.M. (2002). Epicardial induction of fetal cardiomyocyte 




Cheng, P.F., Shakhova, O., Widmer, D.S., Eichhoff, O.M., Zingg, D., Frommel, S.C., 
Belloni, B., Raaijmakers, M.I., Goldinger, S.M., Santoro, R., et al. (2015). Methylation-
dependent SOX9 expression mediates invasion in human melanoma cells and is a 
negative prognostic factor in advanced melanoma. Genome biology 16, 42. 
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., 
Deans, R., Keating, A., Prockop, D., and Horwitz, E. (2006). Minimal criteria for 
defining multipotent mesenchymal stromal cells. The International Society for Cellular 
Therapy position statement. Cytotherapy 8, 315-317. 
Duan, J., Gherghe, C., Liu, D., Hamlett, E., Srikantha, L., Rodgers, L., Regan, J.N., 
Rojas, M., Willis, M., Leask, A., et al. (2012). Wnt1/betacatenin injury response activates 
the epicardium and cardiac fibroblasts to promote cardiac repair. The EMBO journal 31, 
429-442. 
 
Dean, R.G., Balding, L.C., Candido, R., Burns, W.C., Cao, Z., Twigg, S.M., and Burrell, 
L.M. (2005). Connective tissue growth factor and cardiac fibrosis after myocardial 
infarction. The journal of histochemistry and cytochemistry : official journal of the 
Histochemistry Society 53, 1245-1256. 
Eid, H., Larson, D.M., Springhorn, J.P., Attawia, M.A., Nayak, R.C., Smith, T.W., and 
Kelly, R.A. (1992). Role of epicardial mesothelial cells in the modification of phenotype 
and function of adult rat ventricular myocytes in primary coculture. Circulation research 
71, 40-50. 
Gittenberger-de Groot, A.C., Winter, E.M., Bartelings, M.M., Goumans, M.J., DeRuiter, 
M.C., and Poelmann, R.E. (2012). The arterial and cardiac epicardium in development, 
disease and repair. Differentiation; research in biological diversity 84, 41-53. 
Gittenberger-de Groot, A.C., Winter, E.M., and Poelmann, R.E. (2010). Epicardium-
derived cells (EPDCs) in development, cardiac disease and repair of ischemia. Journal of 
cellular and molecular medicine 14, 1056-1060. 
Gonzalez-Rosa, J.M., Peralta, M., and Mercader, N. (2012). Pan-epicardial lineage 
tracing reveals that epicardium derived cells give rise to myofibroblasts and perivascular 
cells during zebrafish heart regeneration. Developmental biology 370, 173-186. 
Guo, W., Keckesova, Z., Donaher, J.L., Shibue, T., Tischler, V., Reinhardt, F., Itzkovitz, 
S., Noske, A., Zurrer-Hardi, U., Bell, G., et al. (2012). Slug and Sox9 cooperatively 
determine the mammary stem cell state. Cell 148, 1015-1028. 
Hofsteen, P., Plavicki, J., Johnson, S.D., Peterson, R.E., and Heideman, W. (2013). 
Sox9b is required for epicardium formation and plays a role in TCDD-induced heart 
malformation in zebrafish. Molecular pharmacology 84, 353-360. 
114 
 
Iso, Y., Rao, K.S., Poole, C.N., Zaman, A.K., Curril, I., Sobel, B.E., Kajstura, J., 
Anversa, P., and Spees, J.L. (2014). Priming with ligands secreted by human stromal 
progenitor cells promotes grafts of cardiac stem/progenitor cells after myocardial 
infarction. Stem cells (Dayton, Ohio) 32, 674-683. 
Kajiji, S., Tamura, R.N., and Quaranta, V. (1989). A novel integrin (alpha E beta 4) from 
human epithelial cells suggests a fourth family of integrin adhesion receptors. The 
EMBO journal 8, 673-680. 
Kawata, K., Kubota, S., Eguchi, T., Aoyama, E., Moritani, N.H., Kondo, S., Nishida, T., 
and Takigawa, M. (2012). Role of LRP1 in transport of CCN2 protein in chondrocytes. 
Journal of cell science 125, 2965-2972. 
Kikuchi, K., Gupta, V., Wang, J., Holdway, J.E., Wills, A.A., Fang, Y., and Poss, K.D. 
(2011). tcf21+ epicardial cells adopt non-myocardial fates during zebrafish heart 
development and regeneration. Development (Cambridge, England) 138, 2895-2902. 
Kurzrock, E.A., Lieu, D.K., Degraffenried, L.A., Chan, C.W., and Isseroff, R.R. (2008). 
Label-retaining cells of the bladder: candidate urothelial stem cells. American journal of 
physiology Renal physiology 294, F1415-1421. 
Laflamme, M.A., and Murry, C.E. (2011). Heart regeneration. Nature 473, 326-335. 
Lepilina, A., Coon, A.N., Kikuchi, K., Holdway, J.E., Roberts, R.W., Burns, C.G., and 
Poss, K.D. (2006). A dynamic epicardial injury response supports progenitor cell activity 
during zebrafish heart regeneration. Cell 127, 607-619. 
 
McKenzie, A.J., Campbell, S.L., and Howe, A.K. (2011). Protein kinase A activity and 
anchoring are required for ovarian cancer cell migration and invasion. PloS one 6, 
e26552. 
McKeon, F. (2004). p63 and the epithelial stem cell: more than status quo? Genes & 
development 18, 465-469. 
McQualter, J.L., Yuen, K., Williams, B., and Bertoncello, I. (2010). Evidence of an 
epithelial stem/progenitor cell hierarchy in the adult mouse lung. Proceedings of the 
National Academy of Sciences of the United States of America 107, 1414-1419. 
Mercurio, S., Latinkic, B., Itasaki, N., Krumlauf, R., and Smith, J.C. (2004). Connective-
tissue growth factor modulates WNT signalling and interacts with the WNT receptor 
complex. Development (Cambridge, England) 131, 2137-2147. 
Merki, E., Zamora, M., Raya, A., Kawakami, Y., Wang, J., Zhang, X., Burch, J., 
Kubalak, S.W., Kaliman, P., Izpisua Belmonte, J.C., et al. (2005). Epicardial retinoid X 
receptor alpha is required for myocardial growth and coronary artery formation. 
115 
 
Proceedings of the National Academy of Sciences of the United States of America 102, 
18455-18460. 
Muzumdar, M.D., Tasic, B., Miyamichi, K., Li, L., and Luo, L. (2007). A global double-
fluorescent Cre reporter mouse. Genesis (New York, NY : 2000) 45, 593-605. 
Ousset, M., Van Keymeulen, A., Bouvencourt, G., Sharma, N., Achouri, Y., Simons, 
B.D., and Blanpain, C. (2012). Multipotent and unipotent progenitors contribute to 
prostate postnatal development. Nature cell biology 14, 1131-1138. 
Pajoohesh-Ganji, A., Pal-Ghosh, S., Simmens, S.J., and Stepp, M.A. (2006). Integrins in 
slow-cycling corneal epithelial cells at the limbus in the mouse. Stem cells (Dayton, 
Ohio) 24, 1075-1086. 
Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca, J.D., 
Moorman, M.A., Simonetti, D.W., Craig, S., and Marshak, D.R. (1999). Multilineage 
potential of adult human mesenchymal stem cells. Science (New York, NY) 284, 143-
147. 
Ren, S., Johnson, B.G., Kida, Y., Ip, C., Davidson, K.C., Lin, S.L., Kobayashi, A., Lang, 
R.A., Hadjantonakis, A.K., Moon, R.T., et al. (2013). LRP-6 is a coreceptor for multiple 
fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-
1. Proceedings of the National Academy of Sciences of the United States of America 110, 
1440-1445. 
Rentschler, S., and Epstein, J.A. (2011). Kicking the epicardium up a notch. Circulation 
research 108, 6-8. 
Riley, P.R. (2012). An epicardial floor plan for building and rebuilding the mammalian 
heart. Current topics in developmental biology 100, 233-251. 
 
Rodriguez-Vita, J., Ruiz-Ortega, M., Ruperez, M., Esteban, V., Sanchez-Lopez, E., Plaza, 
J.J., and Egido, J. (2005). Endothelin-1, via ETA receptor and independently of 
transforming growth factor-beta, increases the connective tissue growth factor in vascular 
smooth muscle cells. Circulation research 97, 125-134. 
Ruiz-Villalba, A., Simon, A.M., Pogontke, C., Castillo, M.I., Abizanda, G., Pelacho, B., 
Sanchez-Dominguez, R., Segovia, J.C., Prosper, F., and Perez-Pomares, J.M. (2015). 
Interacting resident epicardium-derived fibroblasts and recruited bone marrow cells form 
myocardial infarction scar. Journal of the American College of Cardiology 65, 2057-
2066. 
Schaefer, K.S., Doughman, Y.Q., Fisher, S.A., and Watanabe, M. (2004). Dynamic 
patterns of apoptosis in the developing chicken heart. Developmental dynamics : an 
official publication of the American Association of Anatomists 229, 489-499. 
116 
 
Senoo, M., Pinto, F., Crum, C.P., and McKeon, F. (2007). p63 Is essential for the 
proliferative potential of stem cells in stratified epithelia. Cell 129, 523-536. 
 
Seymour, P.A., Shih, H.P., Patel, N.A., Freude, K.K., Xie, R., Lim, C.J., and Sander, M. 
(2012). A Sox9/Fgf feed-forward loop maintains pancreatic organ identity. Development 
(Cambridge, England) 139, 3363-3372. 
Singh, M.K., and Epstein, J.A. (2012). Epicardium-derived cardiac mesenchymal stem 
cells: expanding the outer limit of heart repair. Circulation research 110, 904-906. 
Smart, N., Dube, K.N., and Riley, P.R. (2013). Epicardial progenitor cells in cardiac 
regeneration and neovascularisation. Vascular pharmacology 58, 164-173. 
Smith, C.L., Baek, S.T., Sung, C.Y., and Tallquist, M.D. (2011). Epicardial-derived cell 
epithelial-to-mesenchymal transition and fate specification require PDGF receptor 
signaling. Circulation research 108, e15-26. 
Sonnylal, S., Xu, S., Jones, H., Tam, A., Sreeram, V.R., Ponticos, M., Norman, J., 
Agrawal, P., Abraham, D., and de Crombrugghe, B. (2013). Connective tissue growth 
factor causes EMT-like cell fate changes in vivo and in vitro. Journal of cell science 126, 
2164-2175. 
Thorey, I.S., Meneses, J.J., Neznanov, N., Kulesh, D.A., Pedersen, R.A., and Oshima, 
R.G. (1993). Embryonic expression of human keratin 18 and K18-beta-galactosidase 
fusion genes in transgenic mice. Developmental biology 160, 519-534. 
van Berlo, J.H., and Molkentin, J.D. (2014). An emerging consensus on cardiac 
regeneration. Nature medicine 20, 1386-1393. 
Van Keymeulen, A., Mascre, G., Youseff, K.K., Harel, I., Michaux, C., De Geest, N., 
Szpalski, C., Achouri, Y., Bloch, W., Hassan, B.A., et al. (2009). Epidermal progenitors 
give rise to Merkel cells during embryonic development and adult homeostasis. The 
Journal of cell biology 187, 91-100. 
Van Keymeulen, A., Rocha, A.S., Ousset, M., Beck, B., Bouvencourt, G., Rock, J., 
Sharma, N., Dekoninck, S., and Blanpain, C. (2011). Distinct stem cells contribute to 
mammary gland development and maintenance. Nature 479, 189-193. 
van Wijk, B., Gunst, Q.D., Moorman, A.F., and van den Hoff, M.J. (2012). Cardiac 
regeneration from activated epicardium. PloS one 7, e44692. 
Vega-Hernandez, M., Kovacs, A., De Langhe, S., and Ornitz, D.M. (2011). 
FGF10/FGFR2b signaling is essential for cardiac fibroblast development and growth of 
the myocardium. Development (Cambridge, England) 138, 3331-3340. 
117 
 
Vieira, J.M., and Riley, P.R. (2011). Epicardium-derived cells: a new source of 
regenerative capacity. Heart (British Cardiac Society) 97, 15-19. 
Vrancken Peeters, M.P., Mentink, M.M., Poelmann, R.E., and Gittenberger-de Groot, 
A.C. (1995). Cytokeratins as a marker for epicardial formation in the quail embryo. 
Anatomy and embryology 191, 503-508. 
Wadugu, B., and Kuhn, B. (2012). The role of neuregulin/ErbB2/ErbB4 signaling in the 
heart with special focus on effects on cardiomyocyte proliferation. American journal of 
physiology Heart and circulatory physiology 302, H2139-2147. 
Wagner, N., Michiels, J.F., Schedl, A., and Wagner, K.D. (2008). The Wilms' tumour 
suppressor WT1 is involved in endothelial cell proliferation and migration: expression in 
tumour vessels in vivo. Oncogene 27, 3662-3672. 
Wahab, N.A., Weston, B.S., and Mason, R.M. (2005). Connective tissue growth factor 
CCN2 interacts with and activates the tyrosine kinase receptor TrkA. Journal of the 
American Society of Nephrology : JASN 16, 340-351. 
Yokoyama, S., Takeda, K., and Shibahara, S. (2006). SOX10, in combination with Sp1, 
regulates the endothelin receptor type B gene in human melanocyte lineage cells. The 
FEBS journal 273, 1805-1820. 
Zamora, M., Manner, J., and Ruiz-Lozano, P. (2007). Epicardium-derived progenitor 
cells require beta-catenin for coronary artery formation. Proceedings of the National 
Academy of Sciences of the United States of America 104, 18109-18114. 
 
Zhang, H., Liu, C.Y., Zha, Z.Y., Zhao, B., Yao, J., Zhao, S., Xiong, Y., Lei, Q.Y., and 
Guan, K.L. (2009). TEAD transcription factors mediate the function of TAZ in cell 
growth and epithelial-mesenchymal transition. The Journal of biological chemistry 284, 
13355-13362. 
 
Zhao, B., Lei, Q.Y., and Guan, K.L. (2008). The Hippo-YAP pathway: new connections 
between regulation of organ size and cancer. Current opinion in cell biology 20, 638-646. 
Zhou, B., Ma, Q., Rajagopal, S., Wu, S.M., Domian, I., Rivera-Feliciano, J., Jiang, D., 
von Gise, A., Ikeda, S., Chien, K.R., et al. (2008). Epicardial progenitors contribute to the 
cardiomyocyte lineage in the developing heart. Nature 454, 109-113. 
Zhou, B., and Pu, W.T. (2011). Epicardial epithelial-to-mesenchymal transition in injured 






Supplementary Material  
Isolation, culture, and characterization of primary adult epicardial cells and EPDC  
Right and left atrial appendages were dissected from hearts of adult rats (10 to 12 weeks 
of age) and rinsed three times in sterile PBS containing 100 units/ml penicillin and 100 
µg/ml streptomycin. The atrial tissues were minced into 1 mm3 pieces and allowed to 
adhere for 48 hr in 10% complete culture medium (10% CCM) that consisted of α-MEM 
(Gibco) supplemented with 10% fetal bovine serum (FBS lot selected for rapid growth of 
human multipotent stromal cells; Atlanta Biologicals, Lawrenceville, GA), 100 units/ml 
penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine (Mediatech Inc., Hendron, 
VA).  After 48 hours, the explant pieces were lifted (0.25% Trypsin, 2.2 mM EDTA; 
Mediatech Inc.), and trypsin was deactivated with 10% CCM. The resulting cell 
suspension was centrifuged at 800 x g for 6 min and then resuspended in 1 ml of 
Magnetic-Activated Cell Sorting (MACS) buffer (α-MEM containing 1% w/v BSA and 2 
mM EDTA). To isolate CD104+ adult epicardial cells (epithelial), we added anti-CD104 
antibody (1:500, rabbit polyclonal; Bioss) for 30 min at 4ºC and mixed cells every 5 min 
to keep them as a suspension. This was followed by one wash in 25 ml of MACS buffer, 
and incubation in 2 ml of anti-rabbit magnetic microbeads (1:1000) for 10 min at RT. 
Excess microbeads were removing by washing with 25 ml of MACS buffer and 
centrifugation at 800 x g for 6 min. The input bead-conjugated cell population was 
resuspended in 5 ml MACS buffer and filtered through a 40 µm cell strainer to obtain a 
single cell suspension. The cell suspension was then passed through a magnetic column 
(LS-column, Miltenyi Biotech) that had been pre-equilibrated with 5 ml of MACS buffer. 
The column was washed three times and removed from the magnet. The CD104-positive 
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fraction was eluted in 5 ml of MACS buffer, centrifuged at 800 x g for 6 min, 
resuspended in 10% CCM, and plated for characterization by staining, cell culture 
treatment studies, or culture expansion for EMT and subsequent engraftment in vivo.  
Characterization of Cell Surface Epitopes 
Pellets containing 0.5 to 1 x 106 cells were suspended in 0.5 ml of PBS and incubated for 
30 min at 4°C with pre-titered antibodies for flow cytometry: FITC-conjugated anti-CD90 
(BD Biosciences Pharmingen, San Diego, CA) or PE.Cy5-conjugated anti-CD104 (Bioss, 
Germany). After labeling, cells were washed twice with PBS and analyzed by closed-
stream flow cytometry (LSR II, Becton Dickinson, Franklin Lakes, NJ). 
RNA isolation and RT-PCR  
Total RNA was isolated from cell pellets with a commercial kit (RNAqueous, Ambion, 
Austin, TX). To avoid the possibility of contaminating DNA, total RNA samples were 
treated with DNase prior to reverse transcription (TURBO DNase, Ambion). Reverse 
transcription was performed with Superscript III (Invitrogen) in the presence of RNase 
inhibitor (RNaseOUT, Invitrogen). PCR was carried out with an Eppendorf Master 
Cycler EP thermal cycler. Target sequences were denatured at 94ºC (2 min) followed by 
30 amplification cycles of 94ºC (30 s), anneal temp (30 s), and 72ºC (45 s). The last PCR 
step extended the products at 72 C for 2 min.  RT-PCR products were analyzed on 1% 
agarose gels. 
Myocardial infarction and ischemia-reperfusion surgery 
Adult Fischer 488 rats (males, 7 weeks of age) or transgenic mice (7-8 weeks of age) 
were weighed, shaved, anesthetized under 4% isoflurane, and endotracheally-intubated. 
Rats were ventilated at a respiration rate of 65 beats per min under a peak inspiration 
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pressure of 15 cm H2O (Kent Scientific). Body temperature was maintained at 37°C with 
a heating pad (Gaymar). Through a dermal incision, a blunt dissection of the fascia was 
performed and the intercostal muscles were separated. The heart was exposed by 
retraction of the pericardium to expose the left anterior descending coronary artery 
(LAD). The LAD was occluded with a 6-0 nylon suture (or 8-0 nylon suture for mice) 
and occlusion was confirmed by blanching of the anterior free wall of the LV. Animals 
were allowed to recover off the ventilator.  
 Reperfusion in rats was performed 3 hours after ligation. Animals were re-
intubated and the chest wall was reopened to expose the occluded LAD. With a fine pair 
of scissors, the suture was cut to release the ligation and restore blood flow through the 
vessel. Experimental reperfusion was confirmed by the re-pinking of LV tissue. Cell 
transplantation was performed at the time of reperfusion.  
EPDC transplantation  
After 24 hours, rats were re-intubated, ventilated, and the chest wall was re-opened. 
Hearts were exposed to reveal the border zones of the infarct.  For each rat, we performed 
2 subepicardial injections of 125,000 EPDC (5 µl each, one per border zone) with a 30 
gauge Hamilton syringe. The needle was introduced tangentially to the wall of the LV 
with the bevel facing upward. The syringe was advanced only as far as the bevel edge to 
access the subepicardial surface of the heart and so as not target the underlying 
myocardium of the LV. After the injections, the chest wall was closed and rats recovered 
for 7 or 30 days prior to euthanization.   
Competitive dual engraftment  
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To perform in vivo neutralization and engraftment experiments, Fab fragments of LRP6 
and rabbit polyclonal IgG antibody were cleaved and purified away from Fc fragments 
using a Fab fragmentation kit (Thermo Scientific). This step was performed to ensure that 
the Fc segment of the blocking antibody did not activate immune cells to preferentially 
eliminate epicardial cells that were bound to antibody. The neutralizing efficiency of the 
cleaved antibody was confirmed by comparing its ability to block CTGF-D4 mediated 
cell protection under simulated ischemia. Purified CD104 cells after EMT were counted 
and split into 2 populations. One of them was labeled with CMFDA (green dye, 50 
µg/ml; Invitrogen) and incubated with Fab fragments of control IgG (2 µg/ml) while the 
other population was labeled with CMTPX (red dye, 50 µg/ml; Invitrogen) and Fab 
fragments of LRP6 blocking antibody (2 µg/ml), for 30 min at 37ºC. Cells were then 
washed thoroughly 3 times in sterile PBS, mixed together in equal numbers and 
incubated in CTGF-D4 for 30 min on ice. Note: We initially cultured cells from two cell 
populations together for 72 hr to ensure that the dyes did not intermix and were not 
cytotoxic to the primary cells. Given the equal number of red and green cells as the input 
for cell grafting, we could expect 1 of 2 possible outcomes. If LRP6 was an important 
receptor for the process, blocking LRP6 in the red population would affect their ability to 
graft, and we would observe a majority of green cells at 1 week after treatment. In the 
case that LRP6 was not required, blocking it on the red cells would not affect their 
grafting ability and we would observe a similar number of red and green cells engrafted 
at 1 week after treatment. To further control for the process of cell staining, we 
performed control grafts with reciprocal dye-labeling for cells treated with LRP6 




Two dimensional, Doppler, and M-Mode echocardiography was performed with a Vevo 
770 High-Resolution Imaging System (VisualSonics, Toronto, ON, Canada) by an 
operator blinded to the treatment groups.  Data were recorded from sham-operated rats 
and rats with MI/R while under isoflurane anesthesia at 7 or 30 days after cell 
transplantation. All left ventricular dimensions in systole and diastole were measured 
from M-mode images obtained at the mid-papillary muscle level.   
Following ECHO, animals were euthanized and the hearts were removed and 
rinsed in PBS.  For histology, the ventricles were dissected and rinsed in PBS. They were 
fixed for 2 days in 4% paraformaldehyde in PBS at 4°C. The entire heart was cut as serial 
sections (20 µm) from apex to base. 
Immunocytochemistry/ Immunohistochemistry 
Fixed cells or tissue sections were blocked in PBS with 5% normal goat serum containing 
0.4% Triton X-100. Prior to antibody staining, for retrieval of certain antigens, some 
sections were treated with 20 ug/ml Proteinase K. Cells or sections were incubated in a 
humidified chamber with primary antibody at 4°C overnight, washed three times with 
PBS for 5 min each and incubated in secondary antibodies at RT for 1 hour. After 
staining, sections were mounted with DAPI nuclear counterstain (Fluoromount-G with 
DAPI, Southern Biotech). Images were captured on a Leica deconvolution microscope 
(Leica DMI6000B) and analyzed using Leica FW4000 software.  
Immunoblotting 
Cells were homogenized in PBS and lysed in a buffer that consisted of 0.1% sodium 
dodecyl sulphate (SDS) and complete protease inhibitor cocktail (Roche, Basel, 
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Switzerland). Protein concentration was determined by the DC protein assay (Biorad, 
Hercules, CA). Twenty µg of protein was separated by SDS-PAGE. After 
electrophoresis, the gels were electroblotted to polyvinylidene difluoride (PVDF) 
membranes. All electrophoresis and electroblotting used Novex reagents and systems 
(Invitrogen, Carlsbad, CA). The blots were blocked for 1 hr at RT in 5% nonfat dry milk 
in PBS with 0.1% Tween 20 (PBST), washed three times for 5 min each in PBST, and 
incubated in primary antibodies in PBST with 5% BSA overnight at 4ºC. After three, 5 
min washes in PBST, the blots were incubated in secondary antibody conjugated to 
horseradish peroxidase (1: 2000, Sigma) in PBST for 1 hr at RT. Unbound secondary 
antibody was removed and positive bands were detected with a chemiluminescent 
reaction.  
Sox9 shRNA knockdown  
Cells were transduced with 20 µg of 106 cfu of lentiviral particles (Mission, Sigma) in 
10% CCM for 48 hrs. The medium was then replaced with new medium without viral 
particles and puromycin (20 µg/ml) was added for genetic selection of successfully-
transduced cells. The surviving cells were cloned and expanded for further experiments. 
For Sox9 knockdown, we used the following shRNA sequence: 5’ CCG GAC CTT CGA 
TGT CAA CGA GTT TCT CGA GAA ACT CGT TGA CAT CGA AGG TTT TT 3’. 
Genotyping 
Genotyping was performed with the REDExtractN-Amp Tissue PCR Kit (Sigma). We 
used the following primers for genotyping:  
Keratin18, Internal Control (wild type): Forward, 5’ CACGTGGGCTCCAGCATT 3’; 
Reverse, 5’ TCACCAGTCATTTCTGCCTTT G 3’  
Transgenic band: Forward, 5’ GCGGTCTGGCAGTAAAAACTATC 3’;  
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Reverse, 5’ GTGAAACAGCATTGCTGTCACTT 3’.  
 
EDNRB: Forward, 5’ AGGAGACTGAATGCAGACCAGC 3’;  
Reverse, 5’ CATGTTACA GCTTGCTCCTGTG 3’. 
Experiments with conditional knockout (cKO) mice 
Animals were injected intraperitoneally for 3 days with either vehicle (90% v/v oil, 10% v/v 
200 proof Ethanol) or Tamoxifen (20 mg/ml in vehicle). MI surgery was performed the day 
following completion of the last injection. Hearts were harvested 48 hours after MI and fixed 
and processed for serial cryosectioning. For each animal, 9 sections were analyzed, 
maintaining the same section position as accurately as possible across all animals. In each 
section, the epicardial region in 6 border zones adjacent to infarct (left ventricle), 3 infarct 
regions (left ventricle), and 3 distal regions (right ventricle) were captured as high 
magnification epifluorescent images. A blinded operator then quantified the different cell 










Antibody Application Primary Ab Secondary Ab  
Rabbit anti-CD104 
(Bioss, bs10028-R) 
FACS/MACS 1:500 1:1000 anti-Rabbit microbeads  
(Miltenyi Biotech)  
Rabbit anti-WT1 
(Santa Cruz) 
ICC 1:100 1:800 Alexa 594 goat anti-Rabbit  
(Molecular Probes) 
  Rabbit anti-
GATA4  
      (Santa Cruz) 
ICC 1:250 1:800 Alexa 488 goat ant-Rabbit  
(Molecular Probes) 






1:500 Alexa 488 goat anti-Rabbit 
(Molecular Probes) 
1:1000 Biotin conj, goat anti-
Rabbit      (Sigma Aldrich) 
Rabbit anti-Sox9 
(Santa Cruz)  




(Sigma Aldrich)  




ICC 1:250 1:500 Alexa 488 goat anti-Rabbit 
(Molecular Probes) 
Ms anti-Vimentin 
       (Millipore)  
ICC 1:250 1:500 Alexa 488 goat anti-Rabbit 
(Molecular Probes) 
Rat anti-vWF 
         (Dako) 
WB 1:500 1:1000 Biotin conj, goat anti-
Rabbit      (Sigma Aldrich) 
Ms anti-alpha SMA 
(Santa Cruz)  















Figure 3- 1. CD104 identifies epicardial cells prior to EMT 
(A) Immunohistochemistry for beta-4 integrin (CD104) indicating epicardial-restricted expression in the 
adult mammalian heart. Left to right: rat, mouse, human. Scale bars represent 100 µm. (B) By cell surface 
phenotyping, 30% of the mixed cell population from atrial explants express CD104. (C) 
Immunocytochemical characterization of CD104+ cells. Isolated CD104+ cells are proliferative (Ki67) and 
express keratins (epithelial intermediate filament proteins) and transcription factors characteristic of 
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activated epicardial cells (GATA4, Wt-1). Scale bars represent 50 µm. (D) RT-PCR assays for transcription 
factors (Tbx18, Tcf21) and GAPDH. (E-F) Epicardial cell EMT during 1 week in culture is characterized 
by gain of CD90 and loss of CD104 (F) (n=3 donors). (G) EPDC express increased Vimentin levels after 















Figure 3- 2. CTGF-D4 promotes grafts of EPDC into the subepicardium after MI/R  
 
(A) Expression of CTGF-D4 in the subepicardial cell layers and infarct border zone 1 week after MI with 
reperfusion (MI/R). (Left) adult mouse. (Right) adult rat. Scale bars represent 100 µm. (B) Coronal cross 
section of adult rat heart after MI/R depicting engraftment at the subepicardial injection site (note residual 
DiI-labeled EPDC) and migration of DiI-labeled EPDC toward the ischemic myocardium. (C-D) 
Quantification of EPDC engraftment 1 week after transplant by counts of DiI-labeled cells (C) and 1 month 
after male EPDC transplant to female host by qPCR to detect the Y chromosome (D). (E-G) 
129 
 
Echocardiographic measures in animals 1 month after MI/R and EPDC transplant. (E) Fractional 
Shortening, FS. (F) Ejection Fraction, EF. (G) Anterior Wall Thickness, AWT (wall thickness in systole 
minus thickness in diastole). (C-G) Ins = Insulin. Error bars represent SD. Student’s T-test. *p ≤ 0.05, **p 













































Figure 3- 3. CTGF-D4/LRP6 signaling promotes epicardial cell differentiation and 
survival 
 
(A) CTGF has 4 distinct domains that interact with other cell ligands, cell surface receptors, and integrins. 
CTGF binds LRP6 via its N-terminal domain (CTGF-D4).  (B) Treatment with CTGF-D4 promotes EPDC 
differentiation in an LRP-6-dependent manner. CD90 (cell adhesion, differentiation), vWF (endothelial 
cells), alpha-SMA (smooth muscle cells and myofibroblasts). (C) (Left) Exposure of primary EPDC to 
CTGF-D4 increased cell survival during hypoxia (48 hr), an effect blocked by neutralizing antisera to 
LRP6. (Right) Exposure of primary EPDC to Dkk-1 (20 ng/ml) prior to treatment with CTGF-D4 
prevented CTGF-D4 mediated cell protection under hypoxia.  (D) Design for neutralization experiment to 
assay requirement of LRP6 during EPDC engraftment after MI/R. Cultured EPDC from the same 
donor/dish were lifted, split, and separately dye-labeled prior to incubation with blocking antisera (anti-
Lrp6) and CTGF-D4 or non-specific IgG (con IgG) and CTGF-D4. Note: Cells were incubated with 
antibodies prior to CTGF-D4. Equal proportions of EPDC were mixed and grafted together in a 
competitive engraftment assay. (E-E’) Representative tissue sections 1 week after MI/R and cell 
transplantation. (E’) Cell control with reciprocal dye labeling. (F) EPDC counts after 1 week of 
engraftment (n= 11). (G) qPCR data for Y chromosome at 1 month after engraftment (n= 3). Error bars 
represent SD. Student’s T-test. *p ≤ 0.05, **p ≤ 0.01. Scale bar represents 100 µm. 
 









Figure 3-3. CTGF-D4/LRP6 signaling promotes epicardial 





Figure 3- 4. CTGF-D4/LRP6/Sox9 signaling promotes ETBR  and Sox9 expression in 
EPDC 
(A) Epicardial cells on the heart surface express ETBR. Scale bar represents 100 µm. (B-C) CTGF-D4 
treatment increases ETBR levels in an LRP6-dependant manner. (C) Quantification of normalized band 
intensity for ETBR (n=6 donors per treatment group). (D) Design of “donut assay” to measure radial cell 
migration over time in “t” hours, from seeding location inside the donut (see solid line, center) to outside 
the donut (see dotted line, beyond outer edge). (E) Representative images of EPDC migration in donut 
assay (Red, DiI; Blue, DAPI). (F) Quantification of EPDC migration with addition of agonist or antagonist. 
Note: Data are normalized for total cell number. (G) After EMT, vimentin-positive EPDC express Sox9. 
Scale bar represents 50 µm. (H) CTGF-D4 treatment increases Sox9 levels in an LRP6-dependant manner. 





Figure 3- 5. CTGF-D4/LRP6/Sox9 signaling axis controls ETBR levels 
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(A) Sox9 knockdown in HEK293 cells. Sox9 and ETBR levels are decreased in cells expressing Sox9 
shRNA relative to those expressing scrambled shRNA (control). (B,C) Human promoter sequences for the 
EDNRB gene contain multiple putative Sox9 binding sites. Table summarizes the number of sites upstream 
of the transcriptional start site (0 kb) that match Sox9 binding motif AACAAT or its reverse complement 
TTGTTA and motif (T/C)TTG(T/A)G or its reverse complement (A/G)AAC(A/T)C. Arrows in the last 
column of the table in (C) represent direction of promoter sequence in the genome. (D) Schematic of 
reporter construct for the human EDNRB promoter (pGL4-hEDNRB-prom) used for transfection 
experiments and luciferase activity assays. A 3.5 kb span of the human EDNRB promoter was cloned 
upstream of the firefly luciferase gene (LUC). +160bp indicates the position of the start codon. (E) Relative 
luciferase activity (luminescence units) of HEK 293 cells transiently-transfected with pGL4-human 
EDNRB promoter reporter construct. Error bars represent SD. Student’s T-test. *p ≤ 0.05, **p ≤ 0.01.  







Figure 3- 6. ETBR controls epicardial proliferation and migration  
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 (A) In wildtype mouse heart, Keratin18 (K18) is expressed specifically by epicardial cells. Inset: 
Magnified view of epicardial surface. Scale bar represents 100 µm. (B) TM-inducible K18CreERT2-mT/mG 
mice lineage-tag epicardial cells on the surface of the heart (GFP, arrows) and a population of EPDC in the 
myocardium (GFP, circles). Scale bar represents 100 µm. (C) Lineage-tagging efficiency as determined by 
quantification of GFP+ cells (from lineage-tagging), K18+ cells (from immunostaining), and GFP+/ K18+ 
cells under homeostasis and after MI (n=3 animals per group). Note: Negligible recombination from oil 
injection. (D,D’) Proliferating epicardial cells (Ki67+) 3 d after MI in the infarct zone (D, dotted line) and 
in the subepicardial regions bordering the infarct (D’). Scale bars represent 100 µm. (E) Lineage-tagged, 
GFP+ EPDC migrate into the myocardial regions of infarct (left) and border zone subepicardium (right) 3 d 
after MI. (F) Conditional knockout of epicardial ETBR significantly decreased the number of proliferating 
EPDC (K18+/Ki67+) in the subepicardium 3 d following MI (n=6 mice per group). (G) In contrast to oil-
treated controls, with ETBR knockout, many GFP+ cells remained epicardial (on the heart surface) after 
MI/R. Furthermore, with ETBR knockout, the number of migrating EPDC (K18+/CD90+) was significantly 
decreased in the subepicardium bordering infarct (n=6 animals per group). (H) K18+/CD90+ EPDC were 
not affected in either the oil- or in the TM-treated groups in epicardial regions distal to the infarct zone. For 
F-H, scale bars represent 100 µm. TM = tamoxifen. Note: Bright yellow staining in myocardium is 

































Figure 3- S 1. Epicardial EMT 
 
(A) Primary epicardial explants in 10% FBS. (B) (Left) CD104 sorted primary EPDC after 1 day and 7 
























Figure 3- S 2. CTGF-D4 promotes cell adhesion 
 




















Figure 3- S 3. CTGF-D4 promotes Primary EPDC engraftment 
 
(A) Primary EPDC engraftment with 1% BSA (vehicle control). (B) EPDC proliferation at 3 days 
following engraftment in CTGF-D4. Proliferating nuclei can be identified by Ki67 staining. (C) Fractional 














Figure 3- S 4. Pathway inhibitor screen 
 
Cell protection assay in 1% hypoxia for 48 hours under the defined treatment conditions. Inhibitor screen 
treatments included complete culture medium (10% FBS), Serum free medium (SFM), EGF inhibitor (CAS 
879127-07-8), PDGF inhibitor (CAS 347155-76-4), MAPK inhibitor (CAS 331662-51-2), Notch pathway 
inhibitor (gamma-secretase inhibitor: DAPT), Endothelin Receptor A inhibitor (BQ123) Endothelin 





Figure 3- S 5. Transgenic K18CreER mice 
 
(A) Transgenic K18CreER mouse breeding scheme with lineage reporter mT/mG mice. (B) 4-OH-TM 
induction of eGFP (mG) in cultured epicardial cells isolated from K18CreERT2:mTmG mice. Left, Phase 
contrast. Middle, TRITC channel (mT, red). Right, FITC channel (mG, green). Note: Yellow dotted line 
surrounds a group of K18+ mG cells. (C) Genotyping band patterns for K18CreERT2 and Endothelin 










CHAPTER IV. ADULT EPICARDIAL CELLS CONTRIBUTE TO 




During development, a subset of epicardial cells undergo epithelial to mesenchymal 
transformation to provide a population of migratory progenitors or epicardial- derived 
cells (EPDCs) (Lie-Venema et al., 2007; Munoz-Chapuli et al., 2002; Wessels and Perez-
Pomares, 2004). The EPDCs migrate through the developing myocardium and secrete 
signaling factors that play a role in tissue morphogenesis and in ensuing the completion 
of cardiac development, which includes the proliferation and maturation of 
cardiomyocytes (Combs et al., 2011; Vega-Hernandez et al., 2011; Weeke-Klimp et al., 
2010). The epicardial layer also contributes progenitor cells that terminally differentiate 
into a majority of the adventitial fibroblasts and vascular smooth muscle cells (Dettman 
et al., 1998; Gittenberger-de Groot et al., 1998; Perez-Pomares et al., 1998; Vrancken 
Peeters et al., 1999). Both of these cell types are critical to the structural and functional 
integrity of the developing blood vessels. In contrast, the potential of the epicardial 
precursor cells to differentiate directly into cardiac endothelial cells or myocytes 
(cardiomyocytes) is still under debate. Furthermore, contribution of the EPDCs towards 
any of the above differentiated cell lineages in adults needs to be established in a 
definitive manner. 
  To determine whether the epicardial layer functions as a source of progenitor 
cells in adults, we assessed the cellular contribution of EPDCs in response to a 
physiological demand for tissue growth or regeneration. To do so, we generated a novel 
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lineage-tracing mouse model to label and track epicardial cells on the cover of the heart 
and EPDCs that migrate throughout the myocardium. We performed lineage-tracing 
during chronic exercise, in which growth of the myocyte layer and capillary network was 
previously reported. Other groups demonstrated that exercise results in hypertrophic 
growth of the cardiomyocytes (by both enlargement and cell proliferation) (Abrahams, 
1946; Towbin et al., 2015; Van Liere and Northup, 1957; Vanliere et al., 1965). 
Importantly, this form of cardiac hypertrophy is accompanied by an expansion of the 
capillary network due to increased demand for perfusion throughout the heart to meet the 
demand for cardiac output that results from exercise (Anversa et al., 1987; Cosmas et al., 
1997; Laughlin et al., 2012; Mall et al., 1990; Saltin et al., 1986). For lineage-tracing 
epicardial dynamics and fate, we found that the exercise model provides several 
advantages over models of experimental myocardial infarction, where necrotic signals 
and extensive tissue death limit our ability to thoroughly evaluate the cellular 
contribution of the epicardium to regeneration. 
Methods 
 
The Cre-loxP technology was utilized to lineage-tracing adult epicardial cells from the 
cover of the heart. Keratin18 (epithelial intermediate filament protein) is expressed in the 
heart exclusively by epicardial cells and was used to drive the expression of “Cre” a 
bacterial recombinase enzyme. In the transgenic mouse mouse model, Cre remains 
physically associated with estrogen receptor (ER) thereby limiting its expression to the 
cytoplasm throughout the lifetime of the animal (K18CreERT2). Translocation of Cre to 
the nucleus to carry out genetic recombination function was facilitated by administration 
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of Tamoxifen (TM), an estrogen agonist. When K18CreERT2 animals were crossed with 
reporter mice (mT/mG or YFP), in the presence of TM, Cre mediated the excision of a 
STOP codon flanked by loxP sites (its chemical substrate) and enabled the expression of 
a downstream fluorescent reporter gene (GFP or YFP respectively). Subsequently, the 
resulting experimental animals permanently expressed GFP or YFP fluorescent markers 
in epicardial cells and EPDCs throughout the heart.  
 Following three days of TM injection, male mice (6-8 weeks of age) were housed 
in shoe-box sized cages and either provided with a running wheel (exercise) or not (non-
exercise) for the entire duration of the experiment (8 weeks) (n= 20 per group). Animals 
were fed a normal diet and exercised mostly during their wake hours at night. After 8 
weeks, echocardiography was performed, followed by tissue harvest for histology as 
previously described.  
Results   
 
To initially determine that the lineage-tagging system was operational, we examined mice 
early after running, and observed that epicardial cells on the heart covers of K18CreERT2 
:mTmG mice were GFP+. At 8 weeks after exercise, a number of these cells migrated 
through the myocardium were detected in a pattern similar to the capillary network of the 
heart (Figure 1). The vascular-like patterning of the lineage-tagged epicardial derivatives 
was similar through both the ventricular and atrial chambers. 
 Closer examination of tissue from K18CreERT2 :YFP mice and double staining  
CD31, a marker for differentiated endothelial cells, indicated a widespread distribution of 
YFP+/CD31+ cells throughout the heart (Note:  Due to constitutive expression of 
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membrane Tomato in the mT/mG reporter mice, we utilized YFP lineage trace in order to 
be able to use the red fluorescent channel for staining lineage markers). Intriguingly, the 
YFP+/CD31+ cells also appeared as mostly individual capillaries or smaller networks of 
capillaries with short branches with few or no YFP+/CD31+ in the larger arterioles or 
coronary arteries (Figure 2). Quantification of the linage-tagged endothelial cells revealed 
a significantly greater number of epicardial-derived YFP+/CD31+ capillaries in the 
exercised group of animals compared with the group that was not exercised (Figure 3). 
Of interest, we observed only rare epicardial- derived YFP+ cells that differentiated into 
smooth muscle cells, fibroblasts or cardiomyocytes both in the exercised and non-
exercised group of animals.  
 To determine whether there were differences in the proliferation and/or activation 
of the epicardial layer on the surface of the heart in response to running exercise, we 
analyzed the lineage-tagged cells YFP+ cells for expression of Ki67 (proliferation 
marker) (Figure 5; p= 0.71) and WT-1 (activation marker) (Figure 6; p= 0.58). 
Interestingly, we did not observe significant increase in expression of either of markers as 
a result of prolonged exercise over 8 weeks (Figure 4). However, in agreement with 
previous reports (Borer et al., 1983; Nishimura et al., 1980; Perez-Gonzales et al., 1981; 
Perrault et al., 1986), we did observe a significant improvement in cardiac function, 
including parameters of ejection fraction, fractional shortening in the animals that were 






These results demonstrate that the epicardial layer contributes to the capillary network 
after running exercise. In contrast to injury models such as myocardial infarction, where 
fibroblast differentiation predominates, after exercise other differentiated lineage-traced 
cells were rare.  Further understanding of the molecular mechanisms that control 
endothelial differentiation of epicardial cells could have profound impact on the 
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Figure 4- 1. Keratin 18 lineage-labels epicardial cells and its derivatives 
K18CreERT2:mT/mG labels epicardial cells on the surface of the heart as GFP+ at 1 week after TM 
injection. GFP+ cells migrate into the myocardium and demonstrate a capillary network like distribution 








Figure 4- 2. Epicardial-derivatives differentiate into endothelial cells after running 
exercise 
(A,C,D) K18CreERT2:mT/mG labels epicardial cells on the GFP+ through the capillary network in the heart 
that are closely associated with the cardiomyocytes, 8 weeks after running exercise. (B) Few GFP+ cells 











Figure 4- 3. Increase in lineage-labeled capillary density after running exercise 
(Left) High magnification image of K18CreERT2:YFP animals label double positive with endothelial 
marker CD31. (Right) Quantification of the number of lineage-traced capillaries in heart sections in 















Figure 4- 4. Improvement in cardiac function after 2 months of running exercise 
Improvement in cardiac function after 2 months of running exercise. (Left) Fractional shortening. (Right) 












Figure 4- 5. Epicardial proliferation on the cover of the heart does not increase 
during running exercise 
Number of lineage-labeled epicardial cells that are Ki67-positive on the heart cover of exercised animals vs 
non-exercised animals. Note, cells were counted from (n= 10) animals per group, across multiple cross 























































Figure 4- 6. Epicardial cells are not activated on the cover of the heart in response to 
running exercise 
 Number of lineage-labeled epicardial cells that are WT-1- positive on the heart cover of exercised animals 
vs non-exercised animals. Note, cells were counted from (n= 10) animals per group, across multiple cross 




































































CHAPTER V. HUMAN EPICARDIAL CELL-CONDITIONED 
MEDIUM CONTAINS HGF/IgG COMPLEXES THAT 




Krithika S. Rao, Alexander Aronshtam, Keara L. McElroy-Yaggy, Benjamin Bakondi, 






















Aim: Profile paracrine activity of human Epicardial-Derived Cells (hEPDC) to screen for 
secreted vaso-protective factors and develop therapeutics to treat vascular reperfusion 
injury. 
Methods and Results: Epicardial cells support cardiac development, repair and 
remodeling after injury in part, through paracrine activity. We hypothesized secreted 
ligands from hEPDC would protect vascular integrity after MI with reperfusion. During 
simulated ischemia in culture (24-48 hr), concentrated hEPDC-conditioned medium (EPI 
CdM) increased survival of primary cardiac endothelial cells. In a rat MI model, EPI 
CdM treatment reduced vascular injury in vivo after reperfusion. By phospho-Receptor 
Tyrosine Kinase (RTK) arrays, ELISA, and neutralizing antibody screens we identified 
Hepatocyte Growth Factor (HGF) as a key vaso-protective factor in EPI CdM. 
Unexpectedly, we observed that ~30% of HGF in EPI CdM formed complexes with 
polyclonal IgG. Following reperfusion, preparations of HGF/IgG complexes provided 
greater vascular protection than free HGF with IgG. HGF/IgG complexes localized to 
blood vessels in vivo and increased HGF retention time after administration. In 
subsequent screens, we found that “related to tyrosine kinase” receptor (RYK) was 
phosphorylated after exposure of cardiac endothelial cells to HGF/IgG complexes, but 
not to free HGF with IgG. The enhanced protection conferred by HGF/IgG complexes 
was lost after antibody blockade of RYK. Notably, the HGF/IgG complex is the first 
“ligand” shown to promote phosphorylation of RYK. 
Conclusions: Early treatment with HGF/IgG complexes after myocardial ischemia with 





The epicardium, a specialized epithelial cell layer that covers the heart, is essential to 
cardiac development, structure and function.1,2 During development, a subset of 
epicardial cells undergo epithelial to mesenchymal transformation (EMT) into 
EPicardial-Derived Cells (EPDC), precursor cells that invade the subepicardium and 
myocardium and contribute to the subepicardial and coronary vasculature and the pool of 
interstitial fibroblasts.3-5 EPDC interact with neighboring cells such as cardiomyocytes 
and Purkinje fibers and affect their proliferation and function,3,6,7 in part through 
paracrine activity.8 In adults, epicardial cells play important roles in repair and 
remodeling after cardiac injury. Ventricular regeneration in zebrafish requires epicardial 
cell proliferation, EMT, invasion and subsequent neovascularization of myocardium.9 
Factors secreted by EPDC of adult mice were reported to increase angiogenesis after 
myocardial infarction (MI); these paracrine effects correlated with decreased infarct size 
and improved cardiac function. 10 
Historically, the field of cardiac regenerative medicine has focused on 
transplantation of stem/progenitor cells to reduce infarct size and improve cardiac 
function through direct replacement of damaged myocytes and vascular cells. 11,12 
However, numerous reports now indicate paracrine effects were responsible for much of 
the observed benefits of cell therapy. Stimulation of angiogenesis is frequently reported 
due to higher numbers of blood vessels observed in tissues/organs treated with 
stem/progenitor cells13,14, but few studies have considered rescue and/or repair of pre-
existing blood vessels as opposed to angiogenesis. Importantly, secreted factors that 
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protect microvascular endothelial cells early after reperfusion may reduce vascular leak 
and infarct expansion after MI. To better understand the role of vaso-protection (rescue) 
in the paracrine benefits of cell transplantation, we isolated human EPDCs (hEPDC) and 
investigated the ability of hEPDC-conditioned medium (EPI CdM) to protect the 
vasculature early after cardiac ischemia with reperfusion. Through screens of EPI CdM, 
we identified novel HGF/IgG protein complexes that enhance vaso-protection, in part, by 
activating a Wnt co-receptor called “related to tyrosine kinase” (RYK). Our results 
suggest treatment with EPI CdM or HGF/IgG complexes may reduce reperfusion injury 
and infarct expansion in patients with MI. 
Methods 
 
A detailed description of methods is available in the online supplementary materials. 
Human epicardial derived cell-conditioned medium (EPI CdM) 
Conforming with the principles outlined in the Declaration of Helsinki, and with patient’s 
informed consent, right atrial appendages were obtained during cardiac bypass surgery. 
The right atrial biopsies were used to derive primary cultures of hEPDCs. After EMT, 
passage 2 hEPDCs were seeded and grown in 150 cm2 dishes (Nunc) in Claycomb base 
medium supplemented with 10% FCS (lot selected for rapid growth of hMSCs, Atlanta 
Biologicals, Lawrenceville, GA), 100 units/ml penicillin, 100 µg/ml streptomycin, and 2 
mM L-glutamine (Mediatech Inc., Hendron, VA). When the cells reached 80-90% 
confluence, the plates were washed twice with PBS and serum-free MEM (MEM) was 
placed on the cells (20 mls per plate).  After 48 hours of incubation, the EPI CdM was 
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collected, filtered (0.2 µm PES membrane, Nalgene MF75, Rochester, NY), and 
concentrated to 10-fold or 30-fold with a Labscale™ TFF diafiltration system with a 5 
kD cut-off filters (Millipore, Bedford, MA) or with Amicon Centricon filters (Millipore) 
with a 5 kD cut-off.  One ml vials of EPI CdM were frozen and stored at -80ºC.  Some 1x 
unconcentrated EPI CdM was aliquoted and reserved for ELISAs and cell protection 
assays with primary human cardiac endothelial cells. ELISAs for human growth factors 
were performed with commercially available kits (R and D systems).  
Myocardial ischemia-reperfusion surgery and treatment with EPI CdM 
All animal procedures conformed to the Guide of the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH publication No. 85-23, 
revised 2011) and to the IACUC guidelines for animal care approved by the University of 
Vermont. Fischer 488 rats (males, 7 weeks of age) were weighed, shaved, anesthetized 
under 4% isoflurane, and endotracheally-intubated. Rats were ventilated at a respiration 
rate of 65 beats per min under a peak inspiration pressure of 15 cm H2O (Kent 
Scientific). Body temperature was maintained at 37°C with a heated pad (Gaymar). 
Through a dermal incision, a blunt dissection of the fascia was performed and the 
intercostal muscles were separated. The heart was exposed by retraction of the 
pericardium to expose the left anterior descending coronary artery (LAD). The LAD was 
then encircled with 6-0 nylon suture. To facilitate release of suture at the time of 
reperfusion, a 0.4 cm length of PE10 tubing was placed over the LAD. The LAD was 
then occluded; this was confirmed by blanching of the anterior free wall of the LV. 
Animals were allowed to recover off the ventilator. After 2 hours, the rats were re-
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intubated under anesthesia, ventilated, and the chest wall was re-opened. Hearts were 
exposed to reveal the suture, which was released, and reperfusion was visually confirmed 
by blood flow through the LAD and “re-pinking” of the blanched area. For each rat, we 
injected 1 ml of MEM, EPI CdM,  or other treatments steadily over a period of 1.5 min 
through LV wall into the ventricle lumen (intra-arterial, 30.5 gauge needle). After the 
injection, the chest wall was closed and the rats recovered in their cages for 24 hrs prior 
to euthanization and tissue harvest. Under anesthesia, the chest of sham-operated animals 
was opened (twice) to visualize the intact pericardium, corresponding to the times of 
ischemia and reperfusion surgeries. No further manipulations or treatments were 
performed on the sham animals. 
Measurement of vascular permeability in vivo. 
At 22 hours post-ischemia, animals were injected with 0.5 ml FITC-albumin (tail vein, 5 
mg/ml). After 2 hours, rats were anesthetized, perfused with 50 ml sterile PBS to wash 
out circulating FITC-albumin from blood vessels, and whole hearts were excised into 
sterile PBS. To isolate the left ventricles with septum, the adventitial tissue, major vessels 
and left and right atria were separated. Hearts were then homogenized in PBS (2 ml/gm 
wet weight of tissue) using a Polytron dispersing tool (Euro Turrax T206 IKA 
Labortechnik; Dispersing Tool S25N-10G, outer diameter 10 mm; IKA Works Inc., 
Wilmington, North Carolina, USA) and centrifuged at 16,000 x g for 20 min. The soluble 
fraction was separated and 100 µl volumes were aliquoted to determine the amount of 
FITC extravasated into myocardial tissue. Fluorescence readings were measured in 
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duplicate at 480 nm excitation and 520 nm emission wavelengths on an HT Synergy plate 
reader (BioTek Instruments, Winooski, VT). 
Preparation of HGF/IgG complexes  
Recombinant human HGF was diluted to a working concentration of 10 µg/ml in sterile 
PBS. Mixed polyclonal IgG (non-specific) from human serum was diluted to 14 µg/ml. 
The IgG was mixed with diluted HGF in a total volume of 10 ml (1:1 molar ratio; 
HGF:IgG). The mixture was then concentrated 40-fold (from 10 ml to 250 µl) using a 
centricon device (Centricon Plus-70 Centrifugal Filter, Ultracel-PL Membrane, 30kDa, 
Millipore). This concentrated mixture was diluted in PBS to give final HGF:IgG doses of 
1x or 10x. Different concentrations of HGF were then used for treatment studies either in 
the free “uncomplexed” form or as HGF/IgG complexes. 
Statistical Analysis 
Comparisons of data from individual control and treatment groups were made by 2-tailed 
Student’s t test. For studies with comparison of multiple groups, we performed one way 
ANOVA with Bonferroni post-hoc testing. Values of p≤ 0.05 were considered 
statistically significant.  
Results 
Isolation of adult human epicardial progenitor cells and EMT into precursor cells 
The epicardial layer from adult human right atrial heart tissue consisted of a single layer 
of epithelial cells that stained positive for keratin, epithelial “intermediate filament 
protein” (Figure 1A) and negative for vimentin (mesenchymal, Figure 1A). Human 
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epicardial cells were isolated from right atrial appendages commonly removed to place a 
cardiopulmonary bypass cannula as part of cardiac surgery. The cells were successfully 
isolated from 12 out of 13 donors (Supplemental Table 1). We developed methods to 
isolate proliferating epicardial progenitor cells from right atrial appendages (for details 
see Supplemental Materials and Methods). Explant cultures were generated from minced 
right atrial appendage (Figure 1B). Once fibroblast outgrowth reached about 70% 
confluence, the medium was switched to a low serum stem/progenitor cell growth 
medium containing LIF, EGF, and bFGF. Under these conditions, floating spheroids and 
bunches of cells formed and were collected, placed into new culture dishes and expanded 
(Figure 1C). The epicardial progenitor cells had an epithelial morphology and expressed 
keratins (Figure 1D). Differentiation (EMT) of the epicardial progenitor cells into a 
mixture of transitory-amplifying precursor cells (hEPDC) was induced by culture in 
medium containing 10% fetal calf serum (Figure 1D). During EMT into precursor cells, 
the progenitor cells downregulated their expression of keratins and expressed vimentin 
(Figure 1D). By RT-PCR, we detected several mRNAs for markers of EMT: Snail, Slug, 
Twist and Smad1 (Supplemental Figure 2A). In addition, the human precursor cells 
expressed transcription factors reported to be expressed by murine epicardial cells: WT1 
(cardiac development)15,16, GATA4 (myocardial differentiation and function) 17, TCF21 
(epicardial EMT, cardiac fibroblast specification) 18, and RALDH2 (enzyme for retionoic 
acid synthesis) 19 (Figure 2A). Expression of mRNA for several epicardial-related 
transcription factors decreased as the cells differentiated (see GATA5, WT1, Isl-1, and 
Tbx18; Figure 2B) 20. In contrast, expression of mRNA for smooth muscle actin and von 
Willebrand Factor (vWF) increased (Figure 2B), indicating that some hEPDC might be 
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differentiating into vascular smooth muscle cells or myofibroblasts and others into 
endothelial cells, respectively. At 2 weeks after EMT, by immunocytochemistry, we 
detected a few cells that were positive for smooth muscle myosin or vWF, confirming 
that some of the cells were precursors of smooth muscle cells and endothelial cells, 
respectively. The majority of epicardial-derived cells were positive for prolyl-4-
hydroxylase, an enzyme involved in collagen biosynthesis and a marker of fibroblasts 
(Supplemental Figure 2B). Cell surface phenotyping demonstrated that the hEPDC were 
negative for hematopoietic and endothelial cell surface markers such as CD31, CD34, 
CD45, and c-kit, and also the vascular pericyte marker NG2. Multiple cell surface 
antigens typical of bone marrow MSCs such as CD105, CD90, CD73, CD54, CD49d, 
CD44, and CD29 were expressed by hEPDC after EMT (Supplemental Figure 3 and data 
not shown).   
                      For the second isolation method, epicardial tissue was carefully dissected 
from the surfaces of human right atrial appendages and cultured directly (Supplemental 
Figure 1 and Supplemental Materials and Methods).  Comparison by 
immunocytochemistry, cell surface phenotyping, and ELISA data indicated that the 
precursor cells derived from EMT did not differ whether the cells were rapidly induced to 
undergo EMT or were maintained for several weeks as epithelial progenitor cells and 
then induced to undergo EMT. 
EPI CdM treatment promotes vascular integrity in vivo 
To determine whether human EPI CdM could provide vascular protection in vivo, adult 
male Fischer rats underwent 2 hr of transient ischemia followed by 24 hr of reperfusion. 
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They were then treated with either MEM (vehicle control) or EPI CdM at the time of 
reperfusion. Twenty four hours after ischemia/reperfusion we quantified the amount of 
FITC-albumin extravasation in each treated animal by normalizing it to the level of 
extravasation in sham-operated animals. On tissue sections, we observed a greater level 
of FITC-albumin extravasation from vessels in the infarcted region from the left ventricle 
(LV) compared with no intact vessels outside the region of infarction, including the right 
ventricle (RV) (Figure 3A). Furthermore, heart homogenates from MEM-treated rats had 
37.8% greater FITC fluorescence than homogenates from rats treated with EPI CdM. The 
amount of extravasated FITC-albumin in the MEM-treated group was 527.4% ± 109.33 
of sham, whereas in the EPI CdM-treated group it was 359.7% ± 78.82 of sham (p ≤ 0.05, 
n=5 per group; Figure 3B).  
To investigate vascular effects of EPI CdM treatment, we performed immunoblotting on 
left ventricular homogenates. VE-Cadherin is a key junctional protein involved in 
maintenance of endothelial barrier integrity and the level of phosphorylated VE-Cadherin 
(pVE-Cadherin) is a useful indicator of increased vascular permeability.21 At 24 hr after 
MI, reperfusion, and treatment, the level of pVE-Cadherin (pY658) was significantly 
higher in the MEM-treated group of animals than in the EPI CdM-treated group (p ≤ 
0.01, n=3; Figure 3C). To examine the relative effects of EPI CdM treatment on vascular 
endothelial cells and smooth muscle cells, we next compared the levels of CD31 
(PECAM1, endothelial marker) and smooth muscle alpha actin (α-SMA) in LV 
homogenates from the MEM and EPI CdM treatment groups. Consistent with enhanced 
endothelial cell survival, we observed significantly higher levels of CD31 in animals 
treated with EPI CdM compared with MEM-treated controls (p ≤ 0.05, n=3; Figure 3C). 
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In contrast to the CD31 results, we observed equal amounts of α –SMA for the MEM and 
EPI CdM treatment groups (Figure 3C), indicating that EPI CdM protected endothelial 
cells. 
EPI CdM protects human cardiac endothelial cells during simulated ischemia 
To investigate EPI CdM-mediated protection of cardiac endothelial cells, human cardiac 
endothelial cells were purchased from Lonza (Catalog # CC-2585 and CC-7030, Passage 
1). Cell protection assays were performed under conditions of simulated ischemia (low 
glucose medium, 1% oxygen, for 24 or 48 hr). We first performed an MTS assay 
(Promega) which measures cell metabolism, a measure of cell viability (Figure 4A). 
Compared with incubation in MEM (vehicle control), EPI CdM generated from hEPDC 
of donors from 52 to 80 years of age all protected primary human cardiac endothelial 
cells from simulated ischemic injury for 24 hr (Figure 4A).  To determine the effects of 
EPI CdM on cell survival, we quantified cell number (nuclei) by dye-binding of the 
nucleic acids (cyQuant assay, Molecular Probes, Invitrogen). The CyQuant assay 
confirmed cell protection by EPI CdM (Figure 4B).  
HGF is a key vascular protective component of EPI CdM 
To identify signaling pathways stimulated in cardiac endothelial cells following exposure 
to EPI CdM, we performed phospho-receptor tyrosine kinase (RTK) arrays with lysates 
from human coronary artery endothelial cells previously exposed to MEM or 1x EPI 
CdM. We observed that c-Met, VEGFR1, VEGFR2, and Tie2 (angiopoietin-1 receptor), 
but not FGFR1 were phosphorylated after EPI CdM exposure based on array signal 
relative to that of MEM (Figure 4C). By ELISA, unconcentrated (1x) EPI CdM from 
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several different human donors contained HGF (about 3 ng/ml) (Figure 4D), 
angiopoietin-1 (ANG1, between 446 pg/ml and 1.1 ng/ml), VEGFA (between 500 pg/ml 
and 2.5 ng/ml), and SDF-1 alpha (<150 pg/ml) (Supplemental Figure 4).   
To examine the relative role of HGF and other angiogenic factors in protection conferred 
by EPI CdM, we performed pull-down assays with growth factor-specific antisera. 
Compared with non-specific PD, HGF pull-down significantly reduced the protective 
effects of EPI CdM (Figure 4E, Supplemental Figure 5). Importantly, pull-down of the 
other angiogenic factors from EPI CdM did not decrease its ability to protect endothelial 
cells under hypoxic conditions (Figure 4E).  
Protein complexes containing HGF and IgG are present in concentrated EPI CdM 
In experiments designed to neutralize HGF in 30x EPI CdM using protein A Sepharose, 
we observed an unexpected decrease in the HGF concentration of EPI CdM when it was 
incubated with non-specific polyclonal IgG alone (typically used as a control for specific 
IgG). We have previously described the presence of left-over serum carrier proteins in 
CdM preparations, due to dynamic recycling of extracellular proteins by cellular 
vesicles.22 We performed experiments to determine whether HGF interacted with IgG 
from serum in EPI CdM to form protein complexes as a consequence of concentrating it 
ex vivo. To test this idea, we first concentrated EPI CdM to varying degrees (1x to 40x).  
To determine if IgG was interacting with HGF we added a standard amount of IgG (non-
specific polyclonal IgG, 2 ug/ml) to the series of EPI CdM concentrations to use as bait 
for HGF and performed pull-down assays with Protein A Sepharose. As expected, we 
detected increasing amounts of HGF by ELISA when unmodified EPI CdM was 
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concentrated from 1x to 40x. Hypothetically, in the instance that IgG and HGF were 
interacting, we would observe a reduction in HGF level and detect HGF on the Protein A 
beads. To test our hypothesis we performed pull-down of HGF from increasing 
concentrations of EPI CdM using a non- specific IgG, and compared the levels of HGF 
with before and after pull-down at the various concentrations (Figure 5A). We then tested 
the co-precipitation of HGF with IgG from EPI CdM, by washing the beads thoroughly 
after pull-down and then incubating them in sodium deoxycholate. We performed ELISA 
on the deoxycholate-soluble fraction to determine if we could recover HGF from the 
beads. We were able to detect increasing levels of HGF after pull-down with IgG, 
corresponding to increasing EPI CdM concentration. We detected about 1.5 ng/ml HGF 
from beads with 30x CdM and a significantly greater amount from beads with 40x CdM 
(~2.8 ng/ml Figure 5B) (n=3). Although some interaction may have been present, at EPI 
CdM concentrations lower than 30x CdM we could not detect HGF from beads by 
ELISA. In order to visualize the direct interaction between HGF and IgG in solution, 
electrophoretic mobilities of human IgG (Sigma) and human HGF were compared in free 
and complexed states by native agarose (1.5%) gel electrophoresis using MES buffer (50 
mM, pH 6.7). By staining with Coomasie Brilliant Blue dye, we were able to observe a 
band shift for the HGF when loaded as a complex with IgG compared to free HGF 
(Figure 5C).  
HGF/IgG complexes provide enhanced vascular protection by activating RYK 
As the above protein interactions were observed in vitro, we were interested to learn if 
they had any physiological benefit(s). To investigate whether HGF/IgG complexes might 
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protect vascular endothelial cells differently during tissue injury than would free HGF, 
we performed ex vivo cell protection assays under conditions designed to simulate 
ischemia (1% oxygen combined with nutrient deprivation). To ensure reproducibility 
across experiments, we first produced and purified several mg of soluble, human HGF 
from stable clones of HEK293 cells that were grown in 5% serum (Figure 6A). 
Importantly, the recombinant HGF produced by this method was 100% processed by 
factors contained in serum (e.g. HGF-activating factor) as indicated by complete cleavage 
of the 90 kDa HGF protein into its subunits under reducing conditions (Figure 6A). 
Activity of HGF was further confirmed by performing an ELISA to measure activated c-
Met receptor after exposure of human cells (Supplemental Figure 6). For protection 
assays, 100 ng/ml of HGF was added to cells as HGF/IgG complexes (see detailed 
description in methods) or as free HGF combined with a concentration of IgG that 
matched that of the HGF/IgG complexes. We observed a significant increase in 
protection conferred by HGF/IgG complexes compared with uncomplexed HGF and IgG 
at individual, matched protein concentrations (p≤ 0.01, n=4; Figure 6B). Notably, 
uncomplexed HGF with IgG provided similar level of protection in culture when 
compared to free HGF alone. We therefore chose uncomplexed HGF and IgG mixture as 
appropriate control for HGF/IgG complexes in subsequent experiments. 
To determine if HGF/IgG complexes mediated their protective effects via a receptor (or 
receptors) that differed from c-Met, we performed a second phospho-RTK array with 
lysates of human coronary artery endothelial cells that were incubated for 30 min with 
HGF/IgG complexes or with a matched concentration of HGF and IgG. On the array, the 
level of c-Met phosphorylation was comparable in both the treatment groups, suggesting 
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an additional mechanism for protection mediated by HGF/IgG complexes (Figure 6C). Of 
special interest, we observed phosphorylation of RYK (a.k.a. related to tyrosine kinase) 
after treatment with HGF/IgG complexes but not after treatment with free HGF and IgG 
(Figure 6C). RYK is an “orphan” receptor tyrosine kinase with no ligand yet identified 
that promotes its phosphorylation. 23,24  We next performed a cell protection assay under 
conditions of simulated ischemia in the presence or absence of RYK neutralizing 
antibodies. Blocking RYK on coronary artery endothelial cells significantly decreased the 
protective effect of the HGF/IgG complexes (complexed HGF with anti- RYK 155.46% 
±  14.62 % of MEM, complexed HGF with non-specific control IgG, 223.46 % ± 10.307 
% of MEM, p≤ 0.01; Figure 6D, n=4), but not the protection conferred by uncomplexed 
HGF with IgG (p=0.09; Figure 6D, n=4).  
HGF/IgG complexes localize to blood vessels and promote vascular protection after 
MI 
To test whether treatment by HGF/IgG complexes was advantageous over uncomplexed 
HGF with IgG in vivo, we compared the relative level of vascular integrity after MI with 
reperfusion. We mixed HGF (10 µg/ ml) with non-specific polyclonal rat IgG (carrier) 
either in a complexed form or uncomplexed form and compared effects to MEM infusion. 
We then administered HGF/IgG complexes or uncomplexed HGF with IgG (control) to 2 
groups of rats at the time of reperfusion, 2 hours after LAD occlusion (steady injection of 
1 ml treatment with a 30 gauge needle into LV lumen at the apical end of heart). By 
FITC-albumin assay, treatment with HGF/IgG complexes significantly improved 
vascular integrity at 24 hr after ischemia-reperfusion when compared with treatment by 
free HGF and IgG or MEM (MEM, 544.1% ± 94.18 of sham, n=4; Complex, 370.2%± 
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102.86 of sham, n= 11; free HGF, 516.5%± 53.93 of sham, n=8; Complex vs. MEM, p ≤ 
0.001; MEM vs. free HGF, n.s.; Complex vs. free HGF, p ≤ 0.01; Figure 6E).  
              Immunohistochemistry using an antibody targeting the N-terminal His-tag of our 
recombinant HGF demonstrated a perivascular localization of His (HGF) when 
administered as HGF/IgG complexes, but we were unable to detect His (HGF) in tissue 
sections of control animals that received free His (HGF) and IgG (Figure 6F). For rats 
treated with HGF/IgG complexes, His (HGF) was readily detectable in larger vessels 
(Figure 6F,F’) and the microvasculature and the remaining capillary bed within the 
infarcted region (Figure 6F”).   
Discussion  
Based on their multipotent capacity for differentiation and paracrine activity, hEPDC are 
a promising cell type for cardiac regenerative medicine.10,15 However, safe and effective 
clinical use of hEPDC will require a more complete understanding of cytokines and 
growth factors secreted by hEPDC and their roles under homeostatic conditions and after 
cardiac injury.  Here we identified HGF as a factor produced by hEPDC that protected 
cardiac microvascular endothelial cells during hypoxia/ischemia. When administered 
upon reperfusion after MI, concentrated human EPI CdM prevented vascular leak and 
promoted microvascular cell survival. Previous reports demonstrated that HGF increased 
myocyte survival after cardiac injury (ischemia/reperfusion) 26 and provided vascular 
protection after lung or brain injury. 27,28  
We found that EPI CdM contained unique HGF/IgG complexes that promoted 
endothelial cell survival in a manner superior to “free” HGF. Furthermore, we determined 
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that recombinant human HGF and IgG interact in a predictable manner in vitro, and, 
could be reproducibly prepared as complexes for in vivo administration. Compared with 
free HGF, HGF/IgG complexes increased the preservation of vascular integrity after 
myocardial ischemia with reperfusion. Immunohistochemical data suggested that 
HGF/IgG complexes localized to blood vessels in a different fashion than did free HGF, 
both spatially and temporally; this may increase local concentration and/or retention time, 
thereby enhancing its protective effect(s). Exposure of vascular endothelial cells to either 
HGF/IgG complexes or free HGF promoted the phosphorylation of c-Met to the same 
extent, but only HGF/IgG complexes were able to induce phosphorylation of RYK. 
Furthermore, protection of endothelial cells by HGF/IgG complexes was substantially 
diminished when RYK was blocked by antisera.  
At present, the intracellular signaling cascade downstream of RYK 
phosphorylation has yet to be determined, but several reports describe RYK as a 
modulator of Wnt ligands and Wnt signaling. 29-32 RYK has also been shown to associate 
with Ephrins, which have known roles in vascular permeability during developmental 
angiogenesis and after injury. 33,34 In the case of reperfusion injury and endothelial cell 
protection, RYK signaling could promote intracellular signal transduction that directly 
increases cell survival. Notably, HGF/IgG appears to be the first “ligand” reported to 
induce RYK phosphorylation and may therefore provide a tool to help delineate signaling 
downstream of p-RYK. 
In the clinic, patients with MI commonly undergo percutaneous coronary intervention 
(PCI) or thrombolytic treatment (e.g. tissue plasminogen activator, TPA)35 to restore 
blood flow to occluded vessels. Unfortunately, re-canalization of macroscopic vessels 
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does not lead to improved microvascular perfusion in ~30% of cardiac patients.36 This 
phenomenon is described as “no re-flow” or “low re-flow” and the extent of no re-flow is 
a major determinant of infarct expansion after MI. 37,38 No re-flow may result from 
destruction of microscopic vessels, which we have termed “vascular rhexis" or from other 
factors such as microemboli, inflammation, release of toxic cellular metabolites, or 
oxidative stress that cause endothelial cell dysfunction and induce microvascular leaks. 
39,40 Our results indicate that HGF/IgG treatment protects against reperfusion injury after 
MI as opposed to stimulation of angiogenesis, which is a process that requires several 
days. Further administration of HGF/IgG complexes may provide additional protection or 
induce angiogenesis, but this remains to be tested. 
By simultaneously signaling through c-Met and RYK, HGF/IgG complexes have 
potential as a new therapeutic to improve vascular integrity. Infusion of HGF/IgG 
complexes may also reduce vascular rhexis and the incidence of no/low reflow after MI.  
In addition to cardiac ischemia/reperfusion injury, many other forms of tissue injury or 
disease that involve damage to vascular endothelium, such as stroke and peripheral artery 
disease, may also benefit from treatment with HGF/IgG complexes.  
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Isolation of Adult Human Epicardial Progenitor Cells and EMT into Precursor Cells 
Right atrial appendages were obtained from consenting cardiac bypass patients in a 
protocol that was approved by the IRB of the University of Vermont.  The appendages 
were transferred from the hospital to the UVM Stem Cell Core on ice in 50 ml conical 
tubes containing explant medium: Alpha MEM (Invitrogen, Carlsbad, CA), 10% FCS 
(Atlanta Biologicals, Lawrenceville, GA), 100 units/ml penicillin, 100 µg/ml 
streptomycin, and 2 mM L-glutamine (Mediatech Inc., Hendron, VA).   
Method #1 In a cell culture hood, appendages were immediately rinsed in 1X PBS and 
any extracardiac fat was manually removed with fine scissors.  The remaining tissue was 
transferred to a 100 cm2 dish) containing 1X PBS supplemented with 1 mg/mL 
collagenase/dispase (Roche Applied Science, Indianapolis, IN) in which it was minced 
into approximately 1 mm3 pieces with sterile scalpel blades.  The dish was placed into a 
sterile 37°C humidified cell culture incubator for 1.5 hours, with shaking every 10 
minutes. The resulting tissue digest was collected and centrifuged at 600 x g for 5 min.  
The pellet was resuspended and washed in 25 mls of explant medium and centrifuged 
again.  The final pellet was resuspended in 20 mls of explant medium and the digested 
fragments were split between 2 uncoated 100 cm2 dishes.  After 2-3 days, the dishes 
were supplemented by the addition of 5 mls of explant medium and then left undisturbed 
to allow for the adherence of tissue fragments.  After 5-7 days, when fibroblast outgrowth 
from the explants had almost reached confluence, the dishes were washed once by PBS 
and the explant medium was changed to a medium that favored stem/progenitor cell 
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growth: DMEM/F12 with 3% FCS and 20 ng/ml EGF, 10 ng/ml bFGF, 10 ng/ml LIF (all 
growth factors from Sigma, Saint Louis, MO), 1 x ITS plus (BD Biosciences, San Jose, 
CA), 100 units/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine.  After 2-3 
days, areas of epicardial progenitor cells could be observed to be proliferating in between 
the fibroblasts.  The progenitor cells were morphologically distinguishable from 
surrounding cell types, did not mix with surrounding cells, and formed floating spheroids 
and cell aggregates that resembled bunches of grapes as they divided upwards into the 
medium rather than horizontally.  By shaking the dishes and washing once with calcium- 
and magnesium-free PBS, the floating progenitor cells were collected.  The resulting cells 
(epicardial progenitor cells) were cultured in petri dishes (uncharged) in stem/progenitor 
growth medium for up to several weeks (in some cases up to 2 months).  The epicardial 
nature of the cells was clear as all of the cells were epithelial and expressed Keratin 
proteins. Under these conditions, the epithelial cells continued to produce floating cells. 
To induce EMT, the epicardial cells were collected, centrifuged at 600 x g for 5 min, 
resuspended in Claycomb medium (SAFC Biosciences, Sigma) with 10% FCS, 100 
units/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine, and transferred to 
new dishes.  Following adherence to culture plastic, the majority of the progenitor-like 
cells underwent EMT within 3 days into precursor cells and expanded rapidly in the 
Claycomb medium with 10% FCS.  
We examined whether long-term growth in the stem/progenitor cell medium (low serum 
with growth factors) and in uncoated petri dishes was necessary to generate the precursor 
cells at the next stage of culture. This was not the case as primary floating epithelial 
progenitor cells obtained directly from initial the feeder layer cultures could also undergo 
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EMT when plated onto typical positively-charged cell culture dishes and incubated in the 
Claycomb medium with 10% FCS.   
Method #2 : Epicardial explants were cultured for up to 7 d in explant medium to allow 
outgrowth of epithelial cells. Upon switching to the adult stem/progenitor medium as 
above, the epithelial cells similarly became refractile and formed spheres and “bunches of 
grapes”. These progenitor-like cells also expressed Keratins and could be induced to 
undergo EMT into EPDCs in Claycomb medium containing 10% FCS (as above) 
(pictured in Supplementary Figure S1). 
Characterization of Cell Surface Epitopes.   
Pellets containing 0.5 x 106 to 1 x 106 cells were suspended in 0.5 ml PBS and were 
incubated for 30 min at 4°C with monoclonal mouse anti-human antibodies that were pre-
titered for flow cytometry. All antibodies except those against CD105 and NG2 
(Beckman Coulter, Miami, FL) were purchased from BD Biosciences Pharmingen (San 
Diego, CA). After labeling, the cells were washed twice with PBS and analyzed by 
closed-stream flow cytometry (LSR II, Becton Dickinson, Franklin Lakes, NJ). 
Immunoblotting. 
The soluble fraction from above was diluted 1:1 in protein lysis buffer (20 mM Tris, pH 
7.4; 1 mM EDTA; 10 mM Sodium Chloride; 0.5% v/v Triton X-100) containing protease 
inhibitor (Complete mini # 04693116001, Roche, Basel, Switzerland) and phosphatase 
inhibitor (P0044-1ML, Sigma). Protein concentration was determined with a commercial 
Lowry assay (BioRad DC Protein Assay). For each sample, 10 µg of protein was loaded 
on a 4-12% Bis-Tris gel (Invitrogen). Proteins were transferred to a PVDF membrane and 
blocked in 5% non-fat dry milk in TPBS for 1 hour at room temperature. Primary 
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antibodies were diluted in 5% non-fat dry milk and incubated with membranes overnight 
at 4 ºC: phosphoVE-Cadherin (44-1144G pTyr658, Invitrogen; 1:500), α-smooth muscle 
actin (A5228 clone 1A4, Sigma Aldrich; 1:1000), and GAPDH (Clone 6C5, Chemicon, 
Millipore; 1:1000). Membranes were washed in TPBS for 10 min x 3 and incubated in 
HRP-conjugated secondary antibodies for 1 hr at room temperature. Membranes were 
washed for 15 min x 3 and signals were enhanced by chemiluminiscence (Perkin Elmer) 
prior to exposure on X-ray film (Kodak) 
Immunohistochemistry and Immunocytochemistry assays. 
Cells cultured in chamber slides were washed once with PBS and fixed by 10 min 
incubation in 4% paraformaldehyde in PBS. Following several PBS washes, the chamber 
slides were blocked for 1 hr with 5% goat serum with 0.4% Triton-X 100 in PBS. 
Primary antibodies were diluted into blocking solution, placed on the cells, and incubated 
overnight at 4ºC. The following primary antibodies were used: Smooth muscle myosin 
heavy chain, (SMMS-1, Dako, Carpinteria, CA 1:100), Von Willebrand Factor (F8/86, 
Dako 1:50), Fibroblast (prolyl hydroxylase) (clone 5B5, Dako 1:100), GATA 4 (G-4, 
Santa Cruz Biotechnology, Santa Cruz, CA 1:100) Cytokeratin (C2562, Sigma 1:100),  
Epicardin (TCF21,  ab32981, Abcam; 1:100), Vimentin (E2944, Spring Bioscience, 
Freemont, CA 1:200) WT1 (C-19, Santa Cruz Biotechnology  1:100), RALDH2, 
(Bioss, bs-3676R 1:200).  Following 3 x PBS washes, secondary antisera was applied in 
blocking buffer and incubated for 1 hr at RT. After 3 more washes, slides were mounted 
(Vectashield with DAPI, Vector laboratories, Burlingame, CA), cover slips were applied, 
and specimens were viewed with an epifluorescence microscope (Leica DM6000B with 
DFC350 FX camera). Immunohistochemistry was performed as described previously 
181 
 
(17). Hearts were isolated and fixed overnight in 4% paraformaldehyde. They were then 
equilibrated in 15 and 30 % sucrose consecutively (24 hr in each) followed by mounting 
in OCT. Hearts were sectioned in 10 µm serial sections, apex to base. Fixed slides were 
heated on a heated block for 20 minutes at 52ºC and washed 2 x 5 minutes in PBS. Slides 
were blocked in goat serum (5% goat serum, 0.05% Triton X100 in PBS) for 1 hour at 
room temperature followed by incubation in primary antibody overnight; mouse anti rat 
CD31 (1:50, BD Bioscience). The following day, slides were washed 2x5 minutes in 
PBS, and incubated in Alexa 594 conjugated goat anti mouse antibody. Slides were 
treated with 20 µg/ml Proteinase K in PBS for 15 minutes at room temperature and 
washed thoroughly with PBS 2 x 5 minutes. Slides were incubated in equilibration buffer 
for 1 minute at room temperature followed by incubation in working enzyme solution 
with substrate for 1 hour at 37ºC. They were then washed in stop/wash buffer for 10 
minutes at room temperature followed by mounting with DAPI and mounting medium.  
RT-PCR.   
Total RNA was isolated from cell pellets with a commercial kit (RNAqueous, Ambion, 
Austin, TX). To avoid the possibility of contaminating DNA, the total RNA samples 
were treated with DNase prior to reverse transcription (TURBO DNase, Ambion). 
Reverse transcription was performed with Superscript III (Invitrogen) in the presence of 
RNase inhibitor (RNaseOUT, Invitrogen). PCR was carried out with an Eppendorf 
Master Cycler EP thermal cycler. Control RT-PCR reactions included template samples 
in which the reverse transcriptase was omitted from the single strand synthesis reaction. 
Primer sequences and annealing temperatures are listed below. Target sequences were 
denatured at 94ºC (2 min) followed by 30 amplification cycles of 94ºC (30 s), anneal 
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temp (30 s), and 72ºC (45 s). The last PCR step extended the products at 72 C for 1 min.  
RT-PCR products were analyzed on 1% agarose gels. The following PCR primers were 
used:  SNAIL, Forward 5’ TTT ACC TTC CAG CAG CCC TA 3’,Reverse 5’ CCC ACT 
GTC CTC ATC TGA CA 3’; SLUG, Forward 5’ GAG CAT ACA GCC CCA TCA CT 
3’Reverse 5’ GGG TCT GAA AGC TTG GAC TG 3’; TWIST, Forward 5’ GTC CGC 
AGT CTT ACG AGG AG 3’, Reverse 5’ TGG AGG ACC TGG TAG AGG AA 3’; 
SMAD1, Forward 5’ CTA CCC TCA CTC TCC CAC CA 3’, Reverse 5’ GCA CCA 
GTG TTT TGG TTC CT 3’ ; GATA5 Forward 5’ CAC AAG ATG AAT GGC GTC AA 
3’ Reverse 5’ CTT CCG TGT CTG GAT GCT TT 3’ ;Wt1 Forward 5’ CGG GGG TGA 
ATC TTG TCT AA 3’ Reverse 5’ CCT GGA CCA TCC CCT ATT TT 3’; Isl-1, Forward 
5’ GTA GAG ATG ACG GGC CTC AG 3’, Reverse 5’ TTT CCA AGG TGG CTG 
GTA AC 3’ ; Tbx18 Forward 5’ GGG GAG ACT TGG ATG AGA CA 3’, Reverse 5’ 
AGC AAG AGG AGC CAG ACA AA 3’; Tbx5 Forward 5’ ACG TGC TCA GTT TTG 
CCT CT 3’, Reverse 5’ CAG TTT TGT GTT GGC ATT GG 3’ Smooth muscle alpha 
actin Forward 5’ GAA GAG GAC AGC ACT GCC T 3’ Reverse 5’ CTG ATA GGA 
CAT TGT TAG CAT A 3’ vWF Forward 5’ AAG AAC CGA AGT CCC AGG AGA 
AAG G 3’, Reverse 5’ AGA TTT CAG AGG CGT TCT AAA ACT CA 3’ GATA4 
Forward 5’ GAC GGG TCA CTA TCT GTG CAA C 3’, Reverse 5’ AGA CAT CGC 
ACT GAC TGA GAA C 3’; Mef2C Forward 5’ CTG GGA AAC CCC AAC CTA TT 3’, 
Reverse 5’ GCT GCC TGG TGG AAT AAG AA 3’ Myocardin Forward 5’ GGA CTG 
CTC TGG CAA CCC AGT GC 3’, Reverse 5’ CAT CTG ACT CCG GGT CAT TTG C 
3’ GAPDH  Forward 5’ GCT GAG TAC GTC GTG GAG T 3’, Reverse 5’ CAC CAC 




Pull down of HGF from EPI CdM. 
Monoclonal goat anti-human HGF (R & D Systems) was incubated with 30x EPI CdM 
overnight at 4 ºC on a rocking platform. The following day, 1 ml of EPI CdM was 
incubated with 250 µl of Streptavidin agarose (GE Healthcare) for 2 hr at 4 ºC on a 
rotating platform. The agarose beads were washed twice thoroughly with PBS to remove 
traces of ethanol from the stock preparation. After incubation the beads with EPI CdM 
were centrifuged at 4 ºC for 30 minutes at 800 x g to collect the “pull down” fraction that 
had separated with the pelleted beads. Sandwich ELISA (R & D Systems) was performed 
on EPI CdM after pull down to confirm depletion of HGF.   
Recombinant human HGF 
A recombinant human HGF (HGF) expression plasmid was constructed by cloning a 
human HGF cDNA from plasmid pBabe-puroHGF (B.Weinberg Lab, Addgene,# 10901) 
[29] into vector pIRES-puro3 (Clontech), with the addition of 6xHis Tag to the C-
terminus. The plasmid was introduced into HEK293 cells by transfection (Lipofectamine 
2000, Invitrogen) with puromycin selection of stable clones. For production of 
recombinant HGF, cells were grown in 150 mm2 dishes in DMEM containing 5% FBS 
with medium changes every 3-4 days. For purification, medium containing secreted and 
processed HGF was clarified by 3 min centrifugation (2934 g) and ultrafiltration. 
Heparin-sepharose affinity chromatography (GE Healthcare) was used as 1 step of 
purification. Heparin-bound factors were eluted stepwise with 1 M NaCl, diluted, and 
applied onto Ni-NTA Resin (Novagen). HGF was eluted with 250 mM of imidazole 





Figure 5- 1. Isolation of adult human epicardial progenitor-like cells and EMT into 
precursor cells 
(A) Immunohistochemistry of a section of right atrial appendage from a human donor showing a single 
layer of keratin-positive epicardial cells (Right). Epicardial cells are Keratin-positive and not Vimentin-
positive (mesenchymal marker). Arrows point to vimentin-positive cells. Inset: Note absence of vimentin 
staining in the epicardial layer (n=4 donors). (B) Explant culture of right atrial appendage to generate 
feeder layer (Left); Formation of floating spheroids and bunches of cells following switch to medium that 
favors the growth of stem/progenitor cells (right). (C) Maintenance of epicardial progenitor-like cells with 
epithelial phenotype on uncoated dishes (left), followed by EMT at 3 days after incubation of epicardial 
progenitor cells in medium containing 10% FBS (Right). (D) Epicardial progenitor-like cells express 
keratins (epithelial intermediate filament proteins) (Left) while precursors derived by EMT express 









Figure 5- 2. Characterization of epicardial and precursor markers of the isolated 
human cells 
 
Immunocytochemistry for epicardial transcription factors: WT1 (Top Left), TCF21 (Top Right), GATA4 
(Bottom Left) and RALDH2 (Bottom Right) (n=5-7 donors). (B) Several transcription factors associated 
with cardiac development are downregulated in epicardial progenitor-like cells during EMT into precursor 
cells, while others such as smooth muscle actin (SMA) and vWF are upregulated. Left lane shows 
amplification from RNA of progenitor-like cells “EPI” pictured in (1C). Middle and right lanes show 
amplification of RNA from cells after EMT and 1 or 2 weeks of culture (n=3 donors). Note: The lower 








Figure 5- 3. EPI CdM treatment improves vascular integrity after myocardial 
ischemia with reperfusion in rats 
 (A) Representative immunofluoresence images showing the extent of FITC–albumin extravasation from an 
uninjured blood vessel in the right ventricle (RV, Top) and from an injured LV vessel (Bottom). Dashed 
white line indicates infarct border at 24 hr after reperfusion. We confirmed a similar staining pattern in 
hearts of 3 different animals (n=3). (B) Treatment with 30x EPI CdM significantly decreased extravasation 
of FITC-Albumin in the LV wall of rats, 24 hr after reperfusion  (n = 5 animals per group). In each group, 
treatment animals are calculated as % of sham. (C) Western blot image of 3 representative animals per 
group showing lower levels of phospho-VE-Cadherin (pY
658
) and higher levels of CD31 in heart 
homogenates from EPI CdM-treated rats compared with MEM-treated rats. Note: α-SMA levels were 
similar in both treatment groups. (Bottom) Quantification of Western blot bands. The levels of phospho-
VE- Cadherin were higher in MEM (control) vs EPI CdM (n = 3) and CD31 levels were higher in heart 
homogenates of EPI CdM-treated rats compared with MEM-treated rats (n = 3). GM: Growth Medium; 
Con CdM: Control (EPI) CdM; PD: Pull down; Con IgG: Control IgG. Student’s t-Test: * p ≤ 0.05. Scale 





Figure 5- 4. HGF is a key vaso-protective factor in EPI CdM 
  
 (A) EPI CdM protected cultured primary human coronary artery endothelial cells for 48 hrs under 
simulated ischemia, as measured by MTS assay (n = 5 donors). Data are mean ± S.D. (B) EPI CdM 
protected cultured human microvascular endothelial cells for 48 hr under simulated ischemia, as measured 
by CyQuant assay (n = 3 donors). Data are mean ± S.D. In both experiments, survival of cells in growth 
medium (GM) was considered as 100%. (C) Receptor tyrosine kinase (RTK) array demonstrates 30 min 
exposure to 1x EPI CdM induces phosphorylation of multiple growth factor receptors of coronary artery 
endothelial cells compared with MEM treatment (n=2). (D) HGF ELISA data are for 5 different EPI CdM 
donors (D1-D5). Measurements are in duplicate. (E) Pull down (PD) of HGF from EPI CdM with an HGF-
specific antibody (2 µg/ml) decreased EPI CdM-mediated protection of microvascular endothelial cells 
during simulated ischemia (48 hr) compared to PD with a non-specific IgG antibody (*p ≤ 0.05 Control 
IgG vs Anti-HGF). In contrast, PD of SDF-1, ANG1 or VEGFA did not alter protection of microvascular 
endothelial cells (all antibodies used at 2 µg/ml) (n=3). Cell numbers were determined by CyQuant assay 
(dye binding of nuclei acids). Data are mean ± S.D.  One way ANOVA for A,B,E: *p ≤ 0.05, ** p ≤ 0.01, 





Figure 5- 5. Concentrated EPI CdM contains HGF/IgG protein complexes 
(A) Loss of HGF from EPI CdM corresponded to increasing concentration of EPI CdM. Solid line= EPI 
CdM, dashed line= EPI CdM + non-specific polyclonal IgG (3 EPI CdM donors, n=3 each). (B) 
Quantification of HGF after dissociation from Sepharose beads with deoxycholate (3 EPI CdM donors, n=3 
each). (C) EMSA (electrophoretic mobility shift assay) demonstrating the change in mobility of HGF when 
complexed with IgG. Human IgG (lane 1) migrates towards the anode at a much slower rate at pH 6.7 
compared with human HGF (lane 3). A simple mixture of the 2 proteins (free) did not affect their 
individual mobilities (lane 2). However, HGF and IgG complexes formed by concentration resulted in a 




Figure 5- 6. HGF/IgG complexes enhance vascular protection by interacting with 
RYK 
(A) Stable producer cell lines and purification of bioactive recombinant human HGF. (Left, Top) Phase 
contrast images of HEK 293 cells with genomic integration of pIRES-puro vector expressing human HGF-
His tag-F2A-GFP. (Left, Bottom)  Epifluorescence image showing GFP expression (FITC channel). (Right) 
Gel electrophoresis illustrating purification of HGF. Lane 1, Electrophoresis of eluted material under non-
reducing conditions demonstrates purity and molecular weight of single chain pro-HGF (90 kDa). Gel 
stained with Coomassie Brilliant Blue. Lane 2, Purified protein run under reducing conditions (beta-
mercaptoethanol) demonstrates the active heterodimer of human HGF (see bands at 65 kDa and 32 kDa) 
(n=4). (B) CyQuant assay demonstrates enhanced protective effects of HGF/IgG complexes when 
compared with free HGF (alone) or free HGF with IgG (Free, unconcentrated factors). For greater detail, 
please refer to Methods. Cell number was assayed after 48 hours of simulated ischemia (MEM, 68.52 %± 
4.73 of HGF; free HGF alone, 100 ± 7.27%; free HGF with IgG [Free], 113.65 ± 3.117.27% of HGF;  HGF 
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with IgG (Complex), 169.034 ± 4.004% of HGF (n=4 for all). Free HGF with IgG (Free) conferred 
protection (p≤ 0.01, vs. MEM). However, HGF/IgG complexes (Complex) protected better than did free 
HGF with IgG (Free) (p≤ 0.001). (C) Treatment of coronary endothelial cells with HGF/IgG complexes 
(Complex, Top), free HGF and IgG (Free, Middle) or MEM (Bottom) affects the level of phosphorylation 
for RYK, but not c-Met. Positive control signal (pos-ctrl) has been included for each membrane to compare 
for normalization (n=2). (D) Blocking RYK reduced protection conferred by HGF/IgG complexes (p ≤ 
0.01, n=4) but not protection by free HGF with IgG (p=.09, n=4). Note: Coronary artery endothelial cells 
were incubated under simulated ischemia for 24 hr. (E) Intra-arterial treatment with HGF/IgG complexes 
significantly decreased FITC-albumin extravasation in the LV wall of rats at 24 hr after reperfusion (MEM, 
n = 4; free HGF with IgG [Free], n=8; HGF/IgG complexes [Complex], n=11; p≤ 0.01). (F,F’) 
Epifluorescent image showing localization of His-HGF outside of blood vessels (by anti-His antibody) in 
animals treated with free HGF (F) and complex HGF (F’). HGF/IgG complexes were localized to large 
blood vessels (F, F’) and the capillary network at the borders of infarcted regions (F’’). We confirmed a 
similar staining pattern in hearts of 3 different animals. Note: The presence of HGF not localized to 
capillaries is likely indicative of leakage from damaged or dead blood vessels in the capillary bed. Data are 


















Sex Age HTN DM CAD MR AS LVEF 
M 47 + + + - - 0.45 
M 59 + - + - - Nl 
M 57 - - + - - Nl 
M 52 - - - + - Nl 
M 57 - - + - - Nl 
F 53 + - + - - Nl 
M 80 + - - - + Nl 
F 72 + - - + - 0.45 
M 53 + + + - - Nl 
M 78 - - + - - Nl 
F 72 + - + - - Nl 
F 60 + - + - - Nl 
 
 
Table 2. Patient data for epicardial progenitor cell isolations 
Abbreviations: HTN, hypertension; DM, diabetes mellitus; CAD, coronary artery disease; MR, mitral 








Figure 5- S 1. Time course of epicardial progenitor-like cell formation directly from 
human epicardial explant 
Note that this time course pertains to isolation method #2 for EPDCs (see Methods). (a) Epicardial cell 
outgrowth from epicardial explant generated by dissecting surface epicardial cell layer from right atrial 
appendage removed during bypass surgery. Outgrowth occurs over 7 d. Note epithelial morphology of cell 
monolayer. (b) Epicardial cell monolayer 1 d after switching medium to adult stem/progenitor expansion 
medium (see Methods). (c) Epicardial cell monolayer 3 d after switching medium to adult stem/progenitor 
expansion medium. Note refractile cells beginning to round up. (d) Epicardial cell monolayer 4 d after 
switching medium to adult stem/progenitor expansion medium. Note the formation of “bunches of grapes” 
due to epicardial progenitor-like cells adhering to each other and growing upward in the culture dish 
(within yellow dashes). (e) As with isolation method #1, the bunches of progenitor cells pictured in (d) 







Figure 5- S 2. Cell surface phenotype of human EPDCs after EMT and cardiac 
function at 24 hrs 
Many of the cells are positive for markers associated with human bone marrow-derived MSCs: CD105, 
CD90, CD73, CD54, CD49d, CD44, and CD29. Note that the expanding cell population is negative for 
CD45, CD34, and CD31 as well as c-kit and NG2.  The green line represents the signal from cells stained 
with isotype control antisera and the red line represents the signal from cells from the same culture stained 
with specific antisera. (Bottom) A single, injected dose of EPI CdM does not protect against vascular leak 
at 72 hr after MI and treatment. (A) At 72 hr after reperfusion, there is no difference in FITC extravasation 
as measured by FITC-albumin (n = 6 animals per group, p = 0.08). (B) Myocyte survival in the LV at 24 hr 
was determined by assay of LV residual creatine kinase (CK) activity. There was no difference in the level 
of myocyte survival as indicated by residual creatine kinase activity between the MEM and EPI CdM 




Figure 5- S 3. Additional data for proteins secreted by EPDCs 
ELISA data for VEGFA and SDF-1 alpha. Data are shown for 5 different human donors that range in 
(Middle). Pull down of HGF from EPI CdM. Using HGF specific antibody, HGF can be completely 
depleted from EPI CdM as measured by ELISA. (Bottom). Activity of purified recombinant human HGF. 
ELISA data for human phospho-HGF R/c-Met (R and D Systems) shows activity of material eluted from 
Heparin-sepharose column (HS) and Ni-NTA column (Ni-NTA material diluted 5-fold). Cultured human 












The goal of this dissertation was to advance the understanding of epicardial cell signaling 
and functions in the adult mammalian heart. I focused on evaluating the contribution of 
epicardial cells in cardiac regeneration during growth (exercise) and in response to injury. 
The studies were ultimately aimed at determining whether epicardial cells are useful for 
cardiac cell therapy and/or can serve as a source of beneficial paracrine factors for the 
treatment of myocardial ischemia/reperfusion. My dissertation research sought to define 
new methodologies for the study of epicardial cells both in vivo and ex vivo. I present 
data describing epicardial cell identification in mammals, and the isolation, 
characterization and long-term propagation of epicardial cells and their derivatives ex 
vivo. These findings are confirmed by data collected from multiple donor species. Current 
controversies and technical limitations for studying epicardial cells in vivo prompted us to 
develop a new mouse model that employed a Keratin18CreERT2 (K18 CreERT2) mouse 
for performing gene screening and targeted gene knockout in epicardial cells. This model 
constitutes a significant advance over currently available adult transgenic mouse models 
where transgene expression relies on the initiation of an injury for the re-expression of 
embryonic Cre driver genes (Zhang et al., 2013).   
Summary of interests and future directions 
Screening mesenchymal stromal cell (MSCs) from the bone marrow niche for paracrine 
factors that support stem/progenitor cell survival and function, we identified a defined 
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combination of CTGF-D4 and Insulin that promoted robust cardiac stem cell grafts to the 
heart after MI. These 2 peptides also promoted the engraftment of transplanted primary 
EPDCs after MI/R into their original subepicardial niches, where they survived, 
proliferated and initiated migration to participate in repair and remodeling. Alternatively, 
my experiments with transplantation of primed epicardial cells directly into the 
myocardium, or into regions distal to the infarct, did not demonstrate a similar level of 
graft success. I therefore infer that the most successful engraftment of EPDCs likely 
occurs when they were transplanted back into their original in vivo sites. Notably, these 
are also sites which corresponds to sites where multiple tissue repair mitogens become 
concentrated after MI (Chen et al., 2012; Mehrabi et al., 2002; Tofukuji et al., 1998; 
Tomanek et al., 2006; Tomanek and Zheng, 2002). These observations indicate that there 
are cardiac “injury niches” within subepicardial regions that border tissue with infarction 
after MI. Employing subepicardial border zone cell delivery, we transplanted cultured 
EPDCs back into these injury niches, thereby exposing them to additional signals in vivo 
to support their survival, proliferation and migration. EPDC engraftment into 
subepicardial sites was superior to other methods of administration (Hamdi et al., 2009; 
Tano et al., 2014). This observation relates to a parallel clinical consideration regarding 
the site of injection or method of administration. While direct injection into the 
myocardium with infarction affects cell viability due to necrosis, and systemically 
injected cells face the risk of non-specific embolization to the lungs, my results with 
subepicardial injections suggest it may provide a promising strategy for clinical 
applications of EPDCs (Freyman et al., 2006; Malliaras et al., 2014; Mushtaq et al., 2014; 
Nakamuta et al., 2009; Scorsin et al., 1996; Sullivan et al., 2015). Importantly, the use of 
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animal models provided a means to perform open chest manipulations for cell 
administration, which, in humans, is performed only under certain instances. However, 
more recent methods for closed-chested manipulations that are clinically performed in 
other instances significantly increase the feasibility of this method of cell administration.   
Optimizing protocols for engraftment helped us identify multiple interacting 
players in epicardial cell signaling such as LRP6, Sox9 and ETBR, with previously 
unrelated roles. Whereas these factors functionally integrated to form a novel signaling 
axis that controlled epicardial proliferation, EMT and migration, I do not rule out the 
existence of other factors with key roles in regulating these processes. For instance, my 
inhibitor screen also identified FGF to be critical for CTGF-D4 signaling on epicardial 
cells, which is consistent with observations by other groups (Masters and Riley, 2014; 
Zhou et al., 2011). Likewise, priming epicardial cells with a pharmacological Wnt 
pathway agonist “BIO” (Atilla-Gokcumen et al., 2006; Sato et al., 2004), augmented 
EPDC grafts that, in turn, provided a significant functional benefit, thereby implicating 
the classical Wnt pathway in controlling engraftment. Further studies will be needed to 
discern if these pathways function in a manner that is involved with or independent from 
the axis we describe.  
During homeostasis and after MI, the epicardial cell layer provides a population 
of migratory progenitor cells (Gittenberger-de Groot et al., 2010; Weeke-Klimp et al., 
2010; Wessels and Perez-Pomares, 2004), whose complete properties and functions have 
yet be uncovered. Importantly, the reliable targeted knockout model we generated with 
the K18CreERT2 mouse now permits specific cellular ablation of the epicardial cells in 
adults. This should help to determine whether they are required or dispensable for repair 
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after MI. To this end, I propose to compare developmental models of growth with adult 
models of hypertrophic growth to determine unifying features of epicardial fate decisions 
in the heart. Lineage-tracing using the K18CreERT2 reporter mouse model will be 
valuable to determine if EPDCs adopt different fates after EMT under different 
physiological circumstances, and the corresponding intracellular or extracellular 
molecular differences that control fate decisions (Braitsch et al., 2013; Lie-Venema et al., 
2007; Munoz-Chapuli et al., 2002; Ruiz-Villalba et al., 2015; Smart et al., 2013). Based 
on gross histological observations in my experiments with exercised and lineage-traced 
animals, and extensive genetic inheritance studies from experts in the fields of cardiology 
and fibrosis (Galindo et al., 2009), I expect distinct cell fate outcomes in the different 
physiological models. These outcomes may depend on the physiological demands of 
growth versus repair and/or remodeling in cardiac tissue.  
Among multiple functions of epicardial cells, one that has interested us and many 
other groups is their ability to secrete a range of growth factors that can be exploited for 
clinical use. By performing gene expression analysis on epicardial cells from human 
donors before and after EMT in culture, I noted gene transcription for various growth 
factors like CXCR4, VEGF-C, HGF, Endothelin-1 etc., after they underwent EMT. 
Intriguingly, I observed that exposure of epicardial cells to CTGF-D4 appeared to control 
the paracrine secretions of these cells. Specifically, CTGF-D4 stimulation of epicardial 
cells in culture increased their secretion of HGF, as measured by ELISA. I believe that 
the same LRP6/Sox9/ETBR signaling axis that controls EMT and cell engraftment may 
also control the paracrine action of epicardial cells. This hypothesis is supported by 
computational analysis indicating that HGF has Sox9 binding elements in its promoter 
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and can potentially be regulated in a manner similar to what we reported for EDNRB. 
Gene array analysis of epicardial cells after EMT also suggested increased secretion of 
immune modulatory factors like IL-6, IL-21, TGF-beta, and other macrophage and 
monocyte attractants. More recently in my discussions with other groups, unpublished 
results from their work suggest that epicardial EMT could have significant roles in 
modulating immune infiltration after MI (Cantarini et al., 2013; Lau et al., 2011; McLarty 
et al., 2011; Vinci et al., 2013). Notably, preliminary observations from my transgenic 
mouse experiments with epicardial specific ETBR knockout mice also indicate that a 
greater number of immune cells migrate into zones of MI after knockout. If these 
correlations prove to be true, our signaling axis might represent a rare example of a cell 
culture system that models the multiple effects controlled by epicardial cell functions in 
vivo. The process of EMT in adult epicardial cells requires additional investigations to 
better understand the signals that control epicardial cell fate and functions after injury. 
Furthermore, comparing cardiac function data between epicardial-specific knockout 
ETBR and control animals after MI may provide valuable information regarding the 
requirement of EMT for functional improvement after injury. 
Clinical perspective 
The ability to detect and measure cell grafts at 1 month after transplantation in our studies 
provides a valuable opportunity to evaluate whether there exists a direct correlation 
between numbers of grafted cells and improved cardiac function. To better evaluate 
functional benefits in response to administration of cells or purified factors, I believe we 
need to include other measures of cardiac function in addition to echocardiography, 
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combined with systematic multiple dosing studies. This information will be important for 
defining the initial cell numbers for engraftment and effective dosage for pure factors, in 
a patient- specific manner.  
For clinical application of epicardial cells, we need to increase their persistence in 
vivo after transplantation (Arnesen et al., 2007; Marelli et al., 1992; Ng, 2004; Penn, 
2006; Stamm et al., 2012). One strategy could involve the phenotyping of donor EPDCs 
to create a cell bank. Alternatively, I propose considering the selection of cell lines 
derived from induced pluripotent (iPS) cells or clonal lines of EPDCs after genetic 
engineering, to capture their capacity for long-term proliferation. As a next step, it may 
be possible someday to genetically or chemically control the time course of epicardial 
migration in vivo and cell fate decisions for enhanced repair after transplantation. For 
instance, a few research groups have shown the ability to reprogram fibroblasts in vivo 
into myocytes using lentiviral injections after MI (Addis and Epstein, 2013; Fu et al., 
2013; Lian et al., 2014; Sadahiro et al., 2015).  
In order to evaluate the beneficial effects of epicardial-derived factors for clinical 
purposes, it is critical to optimize their preparation and administration regimen, in 
addition to analyzing their effects in vivo. As a first step, sensitive and reliable methods 
are required to detect whether signaling complexes of HGF/IgG exist in subjects, as my 
preparations were produced in an artificial system in vitro. Performing genetic or 
chemical modifications in epicardial cells to express reporters and tags at specific regions 
in the heart after injury should help to record their behavior and myriad roles in real-time. 
Such modifications may provide new experimental strategies for understanding paracrine 
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biology, while also possibly identifying means to amplify the desirable effects of 
paracrine factors in vivo. 
Taken together, the studies herein provide unique insight into adult mammalian 
epicardial cell biology during homeostasis and after cardiac injury. Overall, these 
findings have potential to advance the use of epicardial cells and their derivatives for 
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APPENDIX I. OSTEOGENIC DIFFERENTIATION OF HUMAN 
MESENCHYMAL STEM CELLS THROUGH ALGINATE-GRAFT-
POLY(ETHYLENE GLYCOL) MICROSPHERE-MEDIATED 
INTRACELLULAR GROWTH FACTOR DELIVERY  
























Osteoporosis is defined by a reduction in the quantity and quality of bone that results in 
skeletal fragility [1]. As people age, bone resorption rates become unbalanced and bone 
resorption dominates over bone formation, which leads to reduced bone mass and altered 
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bone architecture. Human bone marrow progenitor cells known as multipotent stromal 
cells or mesenchymal stem cells (MSCs) can differentiate into osteoblasts, chondrocytes 
and adipocytes and show promise for clinical bone repair [2]. A notable recent study with 
murine MSCs showed that intracellular as opposed to extracellular signaling of vascular 
endothelial growth factor A (VEGFA) had the ability to distinctly regulate MSC lineage 
commitment toward osteoblasts or adipocytes [3]. Liu et al. (2012) demonstrated that 
murine bone marrow stromal cells were more likely to differentiate into osteoblasts when 
MSC expressed VEGFA and possessed intracellular VEGFA, compared with no change 
in osteoblast differentiation following exposure of MSCs to extracellular VEGFA. The 
investigators proposed that VEGFA regulated differentiation through an intracrine 
mechanism unique to the intracellular form of VEGFA and different from the typical 
mechanism for secreted, extracellular VEGFA and signaling through cell surface 
receptors. For patients, the intracellular delivery of VEGFA into MSCs prior to cell 
therapy could be a potential approach to speed the repair of large or complex bone 
fractures or perhaps even to treat chronic skeletal diseases such as osteoporosis [4]. In 
this work, we developed and functionally tested a specialized drug delivery system 
designed to accomplish the controlled, intracellular delivery of VEGFA in MSCs. 
  Modern drug delivery systems are designed to maintain the structure and 
bioactivity of biomolecules and to release therapeutics in a controlled and predictable 
manner. Micro-encapsulation is one of the core technologies used in polymer drug 
delivery systems [5]. Polymeric particles or microspheres for controlled drug delivery 
applications are designed to provide uniform particle dimensions, shield the drug from 
the extracellular environment, and be biocompatible [6]. Alginate microspheres have 
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attracted much attention for the development of controlled- and sustained-release drug 
delivery systems for proteins [7], cytokines [8] and cells [9, 10]. Alginate is a naturally 
occurring polysaccharide extracted from brown seaweed that is generally regarded as 
non-toxic. The fabrication of alginate microspheres is favorable for drug delivery due to 
the relatively mild yet rapid gelation process that omits the use of harsh chemicals to 
ensure stability of encapsulated biomolecules [11-14]. However, the application of 
alginate microspheres has been limited due to their relatively large diameters (10 – 100 
μm) and rapid drug-release rates (< 24 h) [15]. In addition, the anionic nature of alginate 
interferes with the encapsulation and release of charged molecules such as 
polyelectrolytes. To overcome these limitations, alginate microspheres have been refined 
by varying molecular weight and concentration, stirring conditions, degree of 
crosslinking, and chemical modification of the alginate polymer to achieve sustained drug 
release [16, 17]. 
 Poly(ethylene glycol) (PEG) is the most widely applied synthetic polymer in the 
emerging field of biomaterials for drug delivery. Recently, alginate has been modified 
with PEG for the fabrication of microcapsule coatings [18], mucoadhesive polymers [19, 
20], self-assembling nanospheres [21, 22] and hybrid microspheres [23, 24]. The ability 
of PEG to influence the pharmacokinetic properties of drugs and drug carriers has been 
used to modify many different pharmaceutical compounds and components [25]. 
Biocompatibility and stealth behavior make PEG an ideal material to avoid opsonization 
and subsequent elimination by the reticuloendothelial system [26]. In addition, PEG-
modified products are less immunogenic and antigenic; hemolysis and aggregation of 
erythrocytes may also decrease, as can the risk of embolism. However, the lack of a cell 
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adhesion ligand limits its application in targeted drug delivery systems. To address this 
issue, we developed novel PEG-modified alginate copolymer microspheres with and 
without the surface conjugation of a bioactive cell adhesion ligand.  
 Proteins containing tri-peptide arginine-glycine-aspartate (RGD) attachment sites, 
along with the integrins serving as receptors for them, constitute a major recognition 
system for cell adhesion to the extracellular matrix (ECM) [27]. Consequently, 
researchers continue to utilize RGD in order to mimic cell adhesion proteins and bind to 
integrins [28], inhibit apoptosis, angiogenesis, and tumor formation [29], coat surfaces 
for use as biomaterials [30], and enhance drug delivery systems [31, 32], including 
microspheres [33]. In this study RGD was utilized as a model cell-recognition molecule 
to demonstrate the efficacy of immobilizing ligands onto microsphere surfaces. Our 
results demonstrate that the incorporation of an adhesion ligand onto the surface of 
alginate-graft-PEG (Alg-g-PEG) microspheres containing VEGFA provides a promising 
strategy to regulate osteoprogenitor cell differentiation and bone tissue homeostasis, in 
addition to providing efficacy for the use of surface ligands for cell-targeted therapeutic 
applications in vivo. 
 Materials and methods 
 Materials 
Sodium alginate (MW = 65–75 kg/mol, 60-70% guluronic acid residues) was generously 
donated by FMC BioPolymer. Cysteine-L-arginyl-glycyl-L-aspartic acid (CRGD) was 
purchased from Genscript. Amine-poly(ethylene glycol)-thiol (NH2-PEG-SH, MW = 
1000 g/mol) and methyl-poly(ethylene glycol)-amine (mPEG-NH2, Mw = 500 g/mol) 
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were purchased from Laysan Bio. N-ethyl-N’(3-dimethylaminopropyl) carbodiimide 
hydrochloric acid (EDC), N-hydroxysuccinimide (NHS),  2,2’-dithiodipyridine,  
methanol (MeOH, anhydrous, 99.8%), biology-grade mineral oil, Span  80, Tween 80, 
ethylenediaminetetraacetic acid (EDTA), dexamethasone, ascorbic acid, β-glycerol 
phosphate, hydrocortisone, isobutylmethylxanthine, indomethacin, deuterium oxide 
(D2O), the In Vitro Toxicology Assay Kit (MTT-based), Hoechst 33342 and Alizarin red 
were purchased from Sigma-Aldrich. One molar hydrochloric acid (HCl) and 1 M 
sodium hydroxide were purchased from BDH ARISTAR®PLUS. Dichloromethane 
(DCM, 99.9%), sodium citrate, isopropanol, sodium chloride (NaCl), sodium acetate 
(NaAc), alpha-modified eagle medium (α-MEM, Hyclone), DyLight 550 Microscale 
Antibody Labeling Kit, and 20X phosphate buffered saline (PBS) were purchased from 
Fisher Scientific. Fetal bovine serum (FBS) was purchased from Atlanta Biologics and 
screened for a lot that best supported growth of human MSCs.  Penicillin, streptomycin 
and Trypsin EDTA were purchased from Corning Cellgro. AdipoRedTM was purchased 
from Lonza Inc.  Human VEGF DuoSet and human osteoprotegerin ELISA Kits were 
purchased from R&D Systems. Oligo (dT) and dNTP mix were purchased from Promega 
Inc. A Roche High Pure RNA Isolation Kit was purchased from Life Science. 
Polymerase chain reaction (PCR) primers were purchased from Integrated DNA 
Technologies. 
Alg-g-PEG-S-S-Pyridine copolymer synthesis 
First, NH2-PEG-SH (0.1 mg, 0.1 mM) was dissolved in 5 mL of de-gassed acetate buffer 
(0.1 N sodium acetate adjusted to pH 4.6 with acetic acid, 0.3 M sodium chloride, and 1 
mM EDTA) into which a solution of 2,2’-dithiodipyridine (88.124 mg, 0.4 mM) 
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dissolved in 10 mL of MeOH was added; the mixture was stirred at room temperature 
under a flowing N2 atmosphere for 4 h. The MeOH was extracted three times with DCM 
and the sample was prepared for 1H-NMR analysis [34].  
 Alginate was modified with the newly formed NH2-PEG-S-S-pyridine using EDC 
and NHS chemistry. The COOH:EDC:NHS molar ratio remained consistent at 1:8:3.2 
during the carbodiimide reactions, where COOH refers to the moles of alginate carboxyl 
groups. A 1% (w/v) alginate solution was adjusted to pH 5 with 1 N HCl. EDC was then 
added followed by NHS and the solution was mixed at room temperature for 30 min. 
NH2-PEG-S-S-pyridine and mPEG-NH2 (the control PEG graft chain) were added to 
separate alginate solutions, respectively; the target degrees of PEG modification of the 
alginate was 10 %. After 12 h of reacting at room temperature, the various alginate and 
PEG polymer solutions were placed into dialysis cassettes (MWCO 20 kDa, Pierce 
Biotechnology) and dialyzed against deionized (DI) water for 4 d; dialysis solution was 
changed every 12 h. The Alg-g-PEG-S-S-pyridine copolymer product was lyophilized 
and the powder was stored in a desiccator until use. PEG retention post-fabrication was 
verified using 13C-NMR (Bruker AVANCE III 500 MHz high-field NMR spectrometer) 
in D2O [34]. As a control, Alg-g-PEG copolymers were synthesized with this approach 
using mPEG-NH2. The polymer was dissolved in D2O and the result was verified via 
1H-NMR (Bruker AVANCE III 500 MHz high-field NMR spectrometer). 
Microsphere fabrication 
To fabricate microspheres containing VEGFA, Alg-g-PEG-S-S-pyridine was dissolved in 
phosphate buffered saline (PBS) with pH pre-adjusted to 5.0 with 1 N HCl. Non-
modified alginate (Alg) and Alg-g-PEG microspheres were fabricated using a 1% (w/v) 
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polymer solution. VEGFA was added to the copolymer solution at a ratio of 106:1 
(copolymer:VEGFA). Microspheres without VEGFA were fabricated as blank controls. 
One mL of polymer/VEGFA solution was slowly added to 6.72 mL of biological-grade 
mineral oil containing 5% (v/v) Spam 80 while mixing at 1200 rpm for 5 min at room 
temperature. Next, 400 µL of 30% (v/v) Tween 80 was added and the emulsion was 
mixed for an additional 5 min. Then, 5 mL of 1 M calcium chloride (CaCl2) solution was 
added slowly. After 30 min of mixing, 3 mL of isopropanol was added to the emulsion 
and allowed to mix for 5 min, then was centrifuged at 400 rpm for 5 min to precipitate 
microspheres. The microspheres were washed sequentially with isopropanol (x2) and DI 
water (x2), respectively, and centrifuged after each wash. The Alg-g-PEG-S-S-pyridine 
microspheres were formed in a similar fashion, however, the DI water wash was replaced 
with a 1% (w/v) CRGD solution (x2); the corresponding microspheres are here-after 
identified as Alg-g-RGD. Microspheres were flash frozen in liquid N2.  
 After lyophilization Alg, Alg-g-PEG and Alg-g-RGD microspheres were 
characterized by scanning electronic microscopy (SEM, JEOL 600; samples were sputter 
coated with 45 nm of gold). SEM micrographs of various magnifications were used to 
quantify microsphere diameters; images were analyzed using ImageJ (3 images per 
group). 
Cytotoxicity assay 
Human MSCs were isolated from bone marrow aspirates with an IRB-approved protocol. 
Human MSCs (passage 7) were seeded in 24-well tissue culture polystyrene (TCPS) 
plates at a density of 20,000 cells/well in 500 µL/well of standard MSC growth medium 
(α-MEM, 10% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin) and allowed to 
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adhere for 24 h. Cells were incubated in the presence of Alg, Alg-g-PEG, and Alg-g-
RGD microspheres encapsulating VEGFA (n = 3 per group) at concentrations of 10, 50, 
100, 500 µg/mL at 37°C and 5% CO2. After 24 h of incubation, medium containing the 
microspheres was removed, and cells were rinsed two times in sterile PBS then analyzed 
using a MTT-based In Vitro Toxicology Assay Kit following the manufacturer’s 
protocol. The optical density was measured at 570 nm using a BioTek plate reader. 
Background absorbance at 690 nm was subtracted from the measured absorbance. 
Absorbance values for the experimental and control samples were normalized to non-
modified TCPS controls [35].  
DyLight 550 labeling of human VEGFA 
Recombinant human VEGFA was cloned, expressed in HEK 293 cells, and purified in 
the Spees laboratory [36]. 1 mg/mL of purified VEGFA in PBS was used for labeling. 
The DyLight Microscale Antibody Labeling Kit was used according to the 
manufacturer’s instructions. Briefly, 100 μL of 1 mg/mL protein was mixed with a 
commercial vial of DyLight 550 reagent and incubated for 60 min in the dark after gentle 
vortexing and a quick centrifugation step to mix the sample and dye. Spin columns 
provided by the kit were then placed into microfuge collection tubes and used for 
purification of protein from unbound dye. The labeling solution was mixed with 
purification resin and centrifuged in the spin column to purify labeled protein. The 
dye:protein ratio was determined based on methods described in the labeling kit. 
VEGFA encapsulation and release 
A known amount of lyophilized VEGFA-loaded Alg, Alg-g-PEG and Alg-g-RGD 
microspheres was dissolved by immersion in 3% (w/v) sodium citrate solution to dissolve 
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the microspheres by displacing calcium ions [37]. The VEGFA concentration was 
measured with a DuoSet ELISA Development Kit. Briefly, standard series and sample 
solutions were added to a culture plate (100 µL/well) pre-coated with capture antibody 
after washing in mild detergent (0.05% Tween 20 in PBS). After 2 h of blocking and 
incubation at room temperature, the biotin-conjugated detection antibody was added and 
incubated for another 2 h. Then 100 µL poly HRp conjugated streptavidin substrate was 
incubated in each well for 20 min after washing the detection antibody, followed by 
incubation with 100 µL substrate (ABTS, Thermo Scientific.) in the dark at room 
temperature. The absorbance was measured at 450 nm with a BioRad microplate reader. 
The VEGFA concentration was determined with a standard curve, and the VEGFA 
encapsulation efficiency (mass of VEGFA encapsulated in the microspheres / mass of 
VEGFA added when forming the microspheres) was calculated.  
 A VEGFA release test was performed in a 48-well plate at 37°C.  Six mg 
lyophilized VEGFA-loaded Alg, Alg-g-PEG and Alg-g-RGD microspheres was 
dissolved in 500 µL of PBS (pH 7.4). At each time point (1, 2, 4, 8, 12, and 24 h, 
followed by collection each day for a total of 14 d) 100 µL of the PBS was removed and 
another 100 µL was added to maintain the total volume. The released VEGFA 
concentration was determined with the DuoSet ELISA Development Kit described above.  
Human MSC intracellular delivery 
Green fluorescent protein (GFP)-labeled primary human MSCs were generated by 
lentiviral transduction used to express the gene and enriched by selecting for GFP-
positive cells by fluorescence activated cell sorting (FACS) [38, 39]. DyLight 550-
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labeled VEGFA (red fluorescence) was incorporated within Alg, Alg-g-PEG and Alg-g-
RGD microspheres using the same above approach except the ratio of polymer to 
VEGFA was increased to 105:1 to increase the intensity of the visualized signal. 
Microspheres (500 μg/mL) were cultured with GFP-labeled primary human MSCs 
(100,000 cells, passage 4, green fluorescence) for 24 h in glass bottom culture dishes pre-
coated with poly-d-lysine (MatTek Corporation). Confocal laser scanning (CLS) 
microscopy (Zeiss LSM 510 META) was used to visualize the microspheres by detecting 
directly through the plate. Z-stack images were formed with the use of AimImage 
Software.  
Human MSC differentiation assays 
Colorimetric osteogenesis and adipogenesis assays 
 Human MSCs (passage 4) were seeded in 12-well TCPS plates at a seeding 
density of 50,000 cells/well. Cells were cultured at 37°C and 5% CO2 in standard MSC 
growth medium containing 100 μg/mL of VEGFA-encapsulated microspheres (Alg, Alg-
g-PEG or Alg-g-RGD) or blank microspheres not containing VEGFA. The experiments 
were done in triplicate. After 48 h, old medium was aspirated off and one plate was given 
osteogenic differentiation medium (growth medium including 1 nM dexamethasone, 50 
µg/ml ascorbic acid, 10 mMβ-glycerol phosphate) and the other plate received 
adipogenic differentiation medium (growth medium including 0.5 µM hydrocortisone, 
0.5mM isobutylmethylxanthine, 60 µM indomethacine). Cells that served as controls 
were cultured without the addition of microspheres (either with VEGFA or without 
VEGFA). Differentiation medium was changed every 3 d. After 14 d of culture in 
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differentiation medium, cells were rinsed with sterile PBS and analyzed via an Alizarin 
Red osteogenic differentiation assay [40, 41] or an AdipoRedTM adipogenesis assay 
(Sigma).  
 In addition, six different concentrations of VEGFA ranging from 0 to 20 ng/ml (0, 
0.01, 0.025, 0.05, 0.5, 20 ng/ml) were incubated with human MSCs for the control assay 
(extracellular VEGFA). The extracellular VEGFA differentiation experiment was 
conducted in 24-well TCPS plates with a seeding density of 30,000 cells/well. After 48 h, 
medium containing VEGFA was aspirated off and the plates were given either osteogenic 
or adipogenic differentiation medium. Differentiation medium was changed every 3 d. 
After 7 d of culture in differentiation medium, cells were rinsed with sterile PBS and 
analyzed via an Alizarin Red osteogenic differentiation assay [40, 41] or an 
AdipoRedTM adipogenic differentiation assay (Sigma).  
Osteoprotegerin ELISA 
 Protein analysis was performed on blank (i.e., empty) and VEGFA-encapsulated 
Alg-g-PEG microsphere-treated hMSCs after 14 days of culture in osteogenic 
differentiation medium. To determine the concentration of osteoprotegerin in the 
supernatant of culture medium, an ELISA was performed with human osteoprotegerin 
ELISA DuoSet Kit according to the manufacturer’s instruction. 
Reverse transcription polymerase chain reaction (RT-PCR) 
 
 To quantitatively determine gene and protein information from differentiated 
MSCs, we selected on experimental microsphere group, Alg-g-PEG, to detect 
osteogenesis marker via RT-PCR and ELISA. Primary human MSCs were exposed to 
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VEGFA-encapsulated Alg-g-PEG microspheres, blank Alg-g-PEG microspheres or an 
empty control (no microspheres) for 48 h and then in osteogenic differentiation medium 
for 14 days. After differentiation, half of the cells were lysed to extract RNA; RNA 
extraction was performed using a Roche High Pure RNA Isolation Kit according to the 
manufacturer’s instructions. Total RNA (0.25 µg) was reverse-transcribed in a 15 µl 
reaction using SuperScript® III CellsDirect™ cDNA Synthesis Kit (Invitrogen) 
according to the manufacturer’s instructions. The PCR reactions were conducted using 25 
µl PCR super mix (Invitrogen), 2 µl of each sample and 1 µl of each primer under the 
following conditions: 94 ˚C for 5 min, followed by 35 cycles of 3.5 minutes denaturation 
at 94 ˚C, 30 s annealing at 53 ˚C, and 60 s extension at 72 ˚C. The cycles were followed 
by a denaturation at 72 ˚C for 2 min. PCR products were separated using agarose gel with 
1% ethidium bromide. Primers used included: 5'-ATGAGAGCCCTCACA CTCCTC-3' 
(sense) and 5'-CGTAGAAGCGCCGAT AGGC-3' (antisense) for osteocalcin; 5'-
GATGACACTGCCACCTCTGA-3' (sense) and 5'-GACTGGCGGGGTGTA AGT AA-
3' (antisense) for  core-binding factor-α1 (RUNX2)；5'- GATGGATTCCAGTTC 
GAGTAT G-3' (sense) and 5'-GTTTGGGTTGCTTGTCTG TTTG-3' (antisense) for 
collagen type I; 5'-GTCAGTGGTGGACCT GACCT-3' (sense) and 5'- 
AGGGGAGATTCAGTG TGG TG-3' (antisense) for glyceraldehyde 3-phosphate 
dehydrogenase (GADPH) [42].  
Statistical methods 
All experiments were performed in triplicate; results are reported as mean ± standard 
deviation. Statistical analysis was performed on the cytotoxicity data and the 
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differentiation data, respectively, using one-way ANOVA with Tukey multiple 
comparisons (α = 0.05) via the SAS statistics program in the GLM procedure as the post-
test to compare all of the groups. A p < 0.05 is considered significantly different. 
Results 
 Synthesis of Alg-g-PEG and Alg-g-PEG-pyridine copolymers 
The copolymer reactions for the chemical modification of alginate are shown in Fig. 1. 
To synthesize Alg-g-PEG-pyridine, the oligomer NH2-PEG-S-S-pyridine was 
synthesized first. 1H-NMR spectral analysis confirmed the presence of both PEG and 
pyridine in the final product (7.1 ppm, 7.5 ppm, 7.7 ppm, 7.9 ppm corresponding to the 
hydrogen on pyridine ring and 3.6 ppm corresponding to the hydrogen within the repeat 
group in PEG) when compared to the alginate and PEG controls (Supplemental Fig. 1). 
The large peak at 1.8 ppm corresponds to the excess acetate in the reaction system; this 
by-product does not interfere with the carbodiimide chemistry and can be removed 
through dialysis in the proceeding step of the copolymer reaction. Quantification of the 
reaction yield by peak integration determined approximately 70% reaction efficiency. 
 
 The natural polysaccharide alginate was grafted with a short chain PEG decorated 
with either pyridine or methyl end groups resulting in the copolymers Alg-g-PEG or Alg-
g-PEG-pyridine. For the synthesis of Alg-g-PEG, 1H-NMR spectral analysis confirmed 
the presence of both alginate and PEG functional groups in the final purified graft 
copolymers through the appearance of new peaks and peak shifts in the Alg-g-PEG 
spectrum (Supplemental Fig. 2); 3.36 ppm corresponds to the -CH3 moiety of the PEG 
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side chain and 4.31 ppm corresponds to the shift of hydrogen atoms due to the grafting of 
the PEG side chain when compared to the alginate and PEG controls. As stated in the 
methods, the theoretical degree of PEG modification was 10 molar % of alginate 
backbone. Quantification of PEG conjugation by peak integration of the 1H-NMR spectra 
was not successful due to extensive broadening and overlapping of peaks corresponding 
to alginate in the Alg-g-PEG spectra. The synthesis of Alg-g-PEG-pyridine was 
confirmed by 13C-NMR (Supplemental Fig. 3); 132.31 ppm, 136.05 ppm, 141.37 ppm, 
143.53 ppm, 149.24 ppm correspond to carbon on the pyridine ring, 69.76 ppm 
corresponds to the carbon within the repeat unit of PEG, and 42.84 ppm corresponds to 
the carbon on the alginate. Verification of NH2-PEG-S-S-pyridine by 13C-NMR 
confirmed that the reaction was successful.  
 Fabrication of Alg, Alg-g-PEG and Alg-g-RGD microspheres 
 Complete microsphere fabrication strategies are shown in Fig. 2. Alg, Alg-g-PEG 
and Alg-g-RGD microspheres were designed to encapsulate VEGFA without interfering 
with the bioactivity and electrostatically-condensed structure of VEGFA. The mild 
gelation method by the addition of CaCl2 during an emulsion was successful in creating 
microspheres encapsulating VEGFA. The surface functionalization of microspheres 
through CRGD conjugation did not appear to affect the shape or yield of the 
microspheres. SEM photomicrographs (Fig. 3A-F) demonstrate that the microspheres 
(Alg, Alg-g-PEG and Alg-g-RGD) were spherical in shape with an average diameters and 
standard deviations of approximately 1.9 ± 1.0 µm, 0.5 ± 0.1 µm, and 1.1 ± 0.4 µm, 
respectively (Fig. 3G). VEGFA encapsulation efficiency values were 52, 22 and 35% 
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respectively for the different microsphere groups; values represent an average of multiple 
batches within a group (n = 3).  
Alg-g-PEG microspheres exhibit no cytotoxic effects 
 The viability of human MSCs in the presence of Alg, Alg-g-PEG and Alg-g-RGD 
microspheres containing no VEGFA was determined at increasing concentrations (10, 50, 
100 and 500 µg/mL, Fig. 3H). The results demonstrate that Alg, Alg-g-PEG and Alg-g-
RGD microspheres were non-toxic (cell viability > 90%) at concentrations up to 100 
µg/mL. and cell viability was greater than 75% at a concentration as high as 500 µg/mL. 
A Tukey statistical test was performed to compare the experimental groups to the control 
groups (n = 3). No significant differences were seen between experimental microsphere 
groups at the same concentration (p > 0.05).  
VEGFA in vitro release  
 VEGFA release from Alg, Alg-g-PEG and Alg-g-RGD microspheres are shown 
in Fig. 4 as the total percent of VEGFA released, determined from cumulative VEGFA 
concentrations and encapsulation efficiencies. VEGFA encapsulation efficiency values 
were 52, 22 and 35% respectively for the different microsphere groups (Fig. 3G). After 
48 h of release, the Alg, Alg-g-PEG and Alg-g-RDG microsphere groups released 573, 
802, and 1509 pg of the encapsulated VEGFA. The percentages released for the 
microsphere groups were 17.7, 54.2 and 61.1 %, respectively (Fig. 4A). All of the 
microsphere groups sustained VEGFA release for 14 d (Fig. 4B). After 14 d of release, 
the percentages released for the microsphere groups were 43.8, 100, and 98.2 %, 
respectively. When comparing the 48 h release profile with the longer 14 d release 
247 
 
profile, it is evident that a burst release within the first 12 h was followed by a gradual 
sustained release until the termination of the study. 
Microsphere internalization  
 Internalization of Alg, Alg-g-PEG and Alg-g-RGD microspheres containing 
DyLight 550 (red fluorescent) labeled VEGFA was verified after examination of CLS 
micrographs. GFP human MSCs (green) successfully internalized DyLight-labeled 
VEGFA (red) encapsulated Alg, Alg-g-PEG and Alg-g-RGD microspheres (Fig. 5). The 
red microspheres were spread throughout the cytoplasm and appeared to surround the 
nucleus. The intensity of the red signal is a qualitative visualization of microsphere 
internalization rather than a quantitative measurement.  
 Human MSC differentiation 
 The UV absorbance of Alizarin red and fluorescent AdipoRed™ assays were used 
to quantify the osteogenic and adipogenic differentiation of human MSCs, respectively. 
The extent of differentiation was normalized to cell number by measuring the 
fluorescence intensity of Hoechst nuclear staining. As shown in Fig. 6A, incubation of 
human MSCs with microspheres containing VEGFA resulted in a significant increase in 
osteogenic differentiation when compared with non-modified TCPS controls. Statistical 
analysis of the data indicated a significant difference (p < 0.04) between the experimental 
groups (Alg, Alg-g-PEG and Alg-g-RGD) and the control group (cells cultured without 
the addition of VEGFA-encapsulated microspheres). The p-values for Alg, Alg-g-PEG 
and Alg-g-RGD microsphere groups compared to the control group were 0.0001, 0.0005 
and 0.0330, respectively. For the adipogenesis differentiation assay, the Alg microsphere 
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group showed a significant enhancement compared to the control group (p = 0.02). For 
the other two groups (Alg-g-PEG and Alg-g-RGD), there were no significant differences 
for the adipogenesis assay with p-value of 0.28 and 0.57 respectively (Fig. 6B). The 
empty microspheres and pure VEGFA experimental groups did not exhibit any trends or 
significant differences for either adipogenic or osteogenic differentiation (p > 0.06) as 
shown in Fig. 6C-F. The significant differences between the experimental and control 
groups demonstrate that the VEGFA-encapsulated microspheres (Alg, Alg-g-PEG, Alg-
g-RGD) were internalized by hMSCs and that VEGFA was delivered intracellularly, 
resulting in a functional output (osteogenic differentiation).  
 The concentration of osteoprotegerin produced by differentiated MSCs was 
quantified in each of the following groups:  no microspheres (empty control), blank (i.e., 
empty) Alg-g-PEG microspheres, and VEGFA-encapsulated Alg-g-PEG microspheres 
(Fig. 7A). Osteoprotegerin concentrations after 14 d of culture in osteogenic medium 
were 205, 189, and 780 pg/mL, respectively, for the control and experimental groups. 
Further analysis of these results indicate a significant increase in osteogenic 
differentiation of MSCs after incubation with VEGFA-encapsulated Alg-g-PEG 
microspheres for 48 h (p < 0.0001). 
 RT-PCR analysis 14 days after culture indicated osteogenic differentiation in all 
the 3 treatment groups. Cells in the VEGFA-encapsulated microsphere treatment group 
showed greater message for osteocalcin and type I collagen, while all the treatment 
groups contained message for RUNX2 confirming their osteogenic identity. GAPDH was 




There is a growing demand for injectable acellular therapeutics for the enhanced 
mineralization of osteoporotic bone. This study provides the first evidence that Alg, Alg-
g-PEG and Alg-g-RGD microspheres, fabricated from graft copolymers of alginate and 
amine-terminated PEG or alginate and pyridine-conjugated PEG, may be used for the 
controlled intracellular delivery of VEGFA into living human stem/progenitor cells for 
enhanced osteogenic differentiation. Through the use of a biodegradable natural polymer, 
mild gelation methods, chemical conjugation of PEG, and immobilization of the adhesion 
ligand RGD, the applicability of controlled drug delivery by means of microspheres 
increases. The Alg, Alg-g-PEG and Alg-g-RGD microspheres were uniform in shape, of 
a moderate size to allow for internalization into human MSCs, and proved adaptable to 
surface-modification [34, 35]. The fabrication was easy to perform and translate to 
engineering applications compared to other approaches which require higher spinning 
speeds and double emulsion processes.  
VEGFA release from alginate-based microspheres was sustained over a period of 14 d, 
which is promising for targeted intracellular delivery. However, the intracellular delivery 
of VEGFA into human MSCs took place over a shorter time-span of 48 h. The non-
selectivity of the microspheres in culture with MSCs allowed uptake to occur quickly, 
and this is also believed to be the case for the internalization of microspheres during the 
differentiation assay; the microsphere concentration and duration of co-culture were 
consistent among the internalization and differentiation studies. The short time frame 
allowed for delivery also suggests that the VEGFA content of the internalized 
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microspheres was high enough to significantly affect MSC differentiation. Drug diffusion 
may be hindered by PEGylation of the alginate; an effect that has been reported for Alg-
g-PEG chains of moderate to high molecular weights [19]. The varying release kinetics 
with time suggest that the microsphere structure may be optimized further for controlled 
release applications [43]. Decreasing the variability in the diameter of the microspheres 
for all three experimental groups may result in different encapsulation efficiencies and/or 
release rates. However, microsphere size homogeneity and drug release profile 
optimization were outside the scope of this study and may be addressed through further 
investigations. Indeed, in regards to the MSC differentiation experiments, encapsulation 
efficiency was a more critical parameter compared to the in vitro extracellular release 
kinetics of the microspheres. 
 Multiple uptake pathways have been targeted as a means of delivering material 
intracellularly, namely endocytosis, in the case of cationic nanoparticles [44] or for larger 
micron-scale particles [45]. Due to the mild and quick gelation used to fabricate Alg, 
Alg-g-PEG and Alg-g-RGD microspheres, encapsulated drugs and proteins are better 
protected. Chemical conjugation of RGD onto PEG utilized disulfide bonds, which are 
covalent linkages arising from the oxidation of two sulfhydryl (SH) groups of cysteine 
connected to RGD (CRGD) and the SH terminal group on PEG (SH-PEG-NH2). 
Disulfide bonds exist commonly in eukaryotic cell proteins with the function of fortifying 
the protein tertiary structure. Due to the reversibility and relative stability in plasma, the 
disulfide bond linkage becomes attractive in designing drug delivery systems. In addition, 
the physical properties and network structure of the calcium crosslinked alginate-based 
microspheres are readily changed after alterations in pH (such as in an endosome) or in 
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the presence of calcium chelators. For the system described herein, it is hypothesized that 
the microspheres rapidly released VEGFA into the cytoplasm once inside the MSCs [46, 
47] due to the disassembly of the microspheres.  
RGD is widely utilized in tissue engineering studies and has been used in studies 
with alginate [48, 49]. In the current study RGD was used a model ligand which may be 
replaced with more relevant cell-recognition molecules for targeting MSCs in vivo. 
However, RGD has been shown to increase uptake of surface modified DNA complexes 
for intracellular delivery [50]. Although a limitation of the current study was in the 
collection of qualitative internalization results, future work will investigate RGD 
modified microspheres for enhanced MSC uptake and it may be combined with other 
cell-recognition motifs to control drug delivery for target cell populations.  
Results of the differentiation colorimetric assays did not exhibit significant enhancement 
of the RGD or PEG modification between alginate microsphere groups in promoting 
osteoblast differentiation. Alg-g-PEG microspheres were chosen to further quantify the 
significance of the intracellular delivery method of VEGFA-encapsulated microspheres. 
MSCs in the VEGFA-encapsulated microsphere treatment group showed greater message 
for osteocalcin and type I collagen compared to the control groups. These results are 
promising and warrant further investigation into the intracrine activation mechanisms of 
growth factors for regulating MSC differentiation. 
Although Alg-g-RGD microspheres resulted in the lowest Alizarin red absorbance, 
several reasons may account for this. The cells in the current study were only directed to 
differentiate for 14 d, meaning that the human MSCs cultured with Alg-g-RGD 
microspheres might still result in enhanced osteogenesis but more time is needed to 
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demonstrate that result. Another possible explanation is RGD’s influence on 
differentiation signaling. The research of Garcia et al. (2005) and Park et al. (2010) 
indicate a promotion effect of RGD in stem cell differentiation [33, 51]. In addition, it 
could also enhance chondrogenic differentiation [52]. However, other studies present 
findings in disagreement with the aforementioned work [53, 54]. The potential for Alg, 
Alg-g-PEG and Alg-g-RGD microspheres to deliver VEGFA intracellularly may be 
applied to investigate a wide array of differentiation lineages for MSCs and perhaps other 
progenitor cells.  
Of special interest, our functional tests with VEGFA-bearing microspheres 
support an intracrine mechanism for VEGFA in human MSCs and are consistent with 
results reported by Liu et al. (2012) with retroviral expression of VEGFA in murine 
MSCs. We found that intracellular delivery of VEGFA via alginate-based microspheres 
resulted in up-regulated osteogenic differentiation by human MSCs, suggesting the 
effectiveness of our drug delivery system to control the intracrine mechanism that 
balances osteoblast and adipocyte activity. Extracellular VEGFA did not alter 
differentiation of human MSCs. To carefully evaluate the function of intracellular 
VEGFA in regard to specificity for bone formation, we used adipogenesis as an 
alternative differentiation out-put. MSCs from osteoporotic bones exhibit a higher 
adipogenic capacity compared to healthy MSC donors, which is why adipogenic 
differentiation was chosen as the alternative lineage [55]. Except for the Alg microsphere 
group, in which adipogenesis by MSCs was enhanced, there was not a significant 
difference in adipogenesis for MSCs incubated with the VEGFA-encapsulated Alg-g-
PEG and Alg-g-RGD microspheres. Based on the enhanced adipogenesis we observed in 
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the VEGFA-encapsulated Alg microspheres group, Alg-g-PEG and Alg-g-RGD 
microspheres may be better suited for controlled intracellular delivery to enhance 
osteogenesis in vivo. The investigation of various cell-recognition molecules (i.e. ligands, 
antibodies, etc.) may provide a viable option for targeting a specific cell population in 
vivo for enhanced mineralization of osteoporotic bone. 
Conclusion 
This study is the first to report the fabrication and surface-functionalization of Alg, Alg-
g-PEG and Alg-g-RGD microspheres for the encapsulation and intracellular delivery of a 
bioactive growth factor, VEGFA. Alg, Alg-g-PEG and Alg-g-RGD microspheres 
containing VEGFA promoted osteogenic differentiation of human MSCs upon 
intracellular delivery after 48 h of incubation time. These significant results provide 
encouraging evidence for development of a systemic growth factor delivery system with 
potential to treat many debilitating diseases. Future work will involve manipulation of the 
surface ligand to enhance cell-targeted internalization of microspheres for intracellular 
growth factor delivery. 
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SUPPORTING INFORMATION AVAILABLE 
  NH2-S-S-pyridine was verified via 1H-NMR spectra (500 MHz, D2O) as 
shown in Supplementary Fig. 1. The peaks within the range of 7-8 ppm confirmed the 
success of the chemistry. 1H-NMR analysis of Alg-g-PEG was performed to verify the 
retention of PEG after the grafting reaction. Alg-g-PEG was synthesized using mPEG-
NH2 and sodium alginate via carbodiimide chemistry (Supplementary Fig. 2). 1H-NMR 
spectra (500 MHz, D2O) are shown, comparing the graft copolymer Alg-g-PEG to the 
homopolymer constituents: mPEG-NH2 and sodium alginate. The inset image is the 
chemical structure of the Alg-g-PEG copolymer. The alginate conjugation onto NH2-S-
S-pyridine which forms the Alg-g-pyridine was confirmed by 13C-NMR (500 MHz, 
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Figure A1- 1. Chemical modification of alginate (Alg) with two different 





The synthesis of Alg-g-PEG was conducted using carbodiimide chemistry at pH 5 and room temperature. 
To synthesize Alg-g-PEG–S-S-Pyridine, NH2-PEG-SH was reacted with 2,2’-dithiodipyridine in degassed 
acetate buffer at pH 4 and room temperature under N2 flow. Next, the modified NH2-PEG-pyridine was 






























Figure A1- 2. Schematic representation of microsphere fabrication techniques 
 
Microspheres with or without VEGFA were prepared by premixing alginate or alginate-based copolymer 
solutions with VEGFA and creating a water/oil emulsion at room temperature in the presence of 1M 
calcium chloride. An additional surface modification step was performed on Alg-g-PEG-S-S-Pyridine 
microspheres to chemically conjugate CRGD via disulfide bonds. For Alg-g-RGD microspheres, the 
conjugation of 2,2’-dithiodipyridine was used to exchange the thiol group on the cysteine-RGD (CRGD) 




























Figure A1- 3. The shape, average diameter, VEGFA encapsulation efficiency and 
cytotoxicity of alginate-based microspheres 
 
These were verified using scanning electron microscopy (SEM), an ELISA assay (n = 3), and an MTT-
based In Vitro Toxicology assay. SEM micrographs representing (A,D) Alg, (B,E) Alg-g-PEG, and (C,F) 
Alg-g-RGD microspheres were fabricated without the addition of VEGFA through a water/oil emulsion; 
micrographs shown in A,B,C have a scale bar = 10 μm while micrographs in D,E,F have a scale bar = 1 
μm. In preparation for imaging, microspheres were frozen by immersion in liquid N2 and subsequently 
lyophilized; samples were sputter-coated with 45 nm of Au-Pb. (G) Microsphere diameters were 
determined using ImageJ analysis on SEM micrographs. (H) The effect of microsphere concentration (10, 
50, 100, and 500 μg/mL) on primary human MSC viability after 24 h culture in standard MSC growth 
medium at 37°C and 5% CO2 was determined. Experimental groups were normalized to non-modified 
confluent human MSCs cultured on tissue culture polystyrene. A Tukey statistical test was performed. No 














Figure A1- 4. Quantitative release of VEGFA (%) was calculated using the 
encapsulation efficiencies of each sample group and the VEGFA concentration after 
each time point 
 
Sample aliquots were collected and VEGFA concentration was determined using an ELISA assay (n = 3). 
(A) Cumulative VEGFA release (ng/mL) from alginate-based microspheres in PBS at pH 7.4 and 37°C 


































Figure A1- 5. Confocal light microscopy images 
 
GFP-labeled human MSCs (green) after 24 h of culture with DyLight 550 labeled-VEGFA-encapsulated 
alginate-based microspheres (red) at a concentration of 500 µg/mL in standard MSC growth medium. The 
Alg, Alg-g-PEG and Alg-g-RGD images all verify the internalization of microspheres, especially compared 
to the non-modified empty Alg microsphere control. The red intensity is a qualitative visualization of 












Figure A1- 6. In vitro osteogenic (gray) and adipogenic (black) differentiation assay 
results of human MSCs after 14 days in culture with differentiation growth medium 
  
(A) and (B) represent the VEGFA-encapsulated microspheres, (C) and (D) represent empty microspheres, 
and (E) and (F) represent extracellular delivery of pure VEGFA at different concentrations ranging from 0 
to 20 ng/ml. A Tukey statistical test was performed to compare the experimental groups to the control 
groups (n = 3). ** shows a significant p-value less than 0.0005 and * shows p-value less than 0.04. For the 
control group, only standard MSC growth medium was added. The graphs illustrate a significant difference 
between VEGFA encapsulated Alg, Alg-g-PEG and Alg-g-RGD microsphere groups compared to the 
control group in the osteogenesis assay as well as for the VEGFA encapsulated Alg microsphere group in 
the adipogenesis group. No significant differences were seen (p ≤ 0.05) between control and experimental 













Figure A1- 7. In vitro osteogenic differentiation results 
 
(A) Protein results of human MSCs after 14 days in culture with differentiation growth medium. Sample 
aliquots were collected and osteoprotegerin concentration (pg/mL) in the supernatant medium was 
measured using an ELISA assay (n = 3). * indicates significantly higher result, p < 0.0001. (B) RT-PCR 
results verify production of osteocalcin andRUNX2 in MSCs after 14 days in culture with osteogenic 
differentiation growth medium. Collagen type I was upregulated for MSCs pre-treated with VEGFA-



































APPENDIX II. PRECLINICAL TESTING AND INTELLECTUAL 
PROPERTY ASSOCIATED WITH THIS PHD DISSERTATION 
 
Preclinical tests of therapeutics from Spees Lab 
(A) Intracoronary infusion of EPI CdM or HGF/IgG complexes in adult swine with 
MI. To ascertain whether EPDC CM could preserve cardiac tissue after MI in a large 
animal model, our group has performed a short-term preliminary treatment study with 10 
adult commercial swine (~65 kgs). Under anesthesia and with fluoroscopic guidance, a 
balloon catheter was advanced and inflated to completely occlude the LAD for 60 min 
prior to revascularization. At the time of reperfusion, pigs in the control group received 
additional contrast dye to confirm re-flow (n=5). Alternatively, pigs in the treatment 
groups received 16 mls of 20x EPDC CM and contrast (n=3) or 16 mls of 25x EPDC CM 
and contrast (n=2), by infusing EPDC CM directly into the LAD at the location of the 
deflated balloon. The EPDC CM was infused over 3-5 min. No anti-arrhythmic drugs 
were used and there were no adverse events following any of the treatments. All pigs 
were euthanized at 24 hr after treatment.  Hearts were removed and cut transversely from 
apex to base (1 cm slices), stained by TTC, and digitally photographed (Figure 1A). The 
weights of right and left ventricular tissue from each 1 cm slice were recorded, whilea 
areas of viable and scarred cardiac tissue were quantified (Scion Image 4.0.2) and 
multiplied by the tissue weights to estimate infarct size.  As the effects of 20x and 25x 
CM on infarct size were similar, treatment data were together (p=0.024, n=5; Figure 1B).  
 Using the same PCI-based ischemia/reperfusion MI model, a pilot study to test an 
effective intracoronary dose of HGF/IgG complexes has also been performed in adult 
267 
 
swine. From the guide catheter, at the time of reperfusion, either alpha MEM (vehicle, 
n=2) or HGF/IgG complexes (0.125 mg/50 kg pig, n=2) was infused, followed by similar 
method for tissue processing analysis as before. Initial observations by comparing Evan’s 
Blue staining and TTC areas at risk (red; viable) are presented here, in animals treated 
with HGF/IgG complexes (Figure 1C, C’).  
(B) Subepicardial engraftment of primary human EPicardial Derived Cells 
(EPDCs) into adult swine with MI. 
Preliminary results indicated that human EPDCs could be primed in CTGF-D4/Ins to for 
engraftment into immunocompromised pigs after MI, at the time of reperfusion. Human 
cells were detected at 1 week following engraftment by staining for human antigen Alu, 






























































A) Representative 1 cm slices from control (MEM) and CM-treated hearts stained 
by TTC at 24 hr after 60 min of ischemia with reperfusion. Note that the non-viable 
(white) area in the control heart extends through the 3rd section in both the LV and 
RV (far left section), whereas the infarct in the CM-treated heart does not. B) 
EPDC CM treatment significantly reduces infarct size 24 hr after MI (p=0.024, 
MEM vs. CM-treated, n=5 each). Error bars, SD of mean. C, C’) HGF/IgG 
treatment promotes myocardial rescue within the Evan’s Blue risk region. Note 
area within the yellow dashes stained red (viable) by TTC in (C’), but is within the 
risk region for low/no perfusion after MI (non-blue area delineated by yellow 
dashes in C). (D) Representative tissue section of adult swine heart 1 week after 




cell graft (human EPDC) 
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Intellectual Property  
1. Compositions and methods for cardiac tissue repair  
USPN 9,132,155 Issued: Sept 15, 2015 
U.S. Patent Application No. 14/826,613, filed on August 14, 2015 
The invention features compositions comprising epicardial progenitor cells and agents 
having cardiac protective activity isolated from epicardial progenitor cells and derivatives 
thereof, and methods for the use of such compositions. 
 
2. Compositions and Methods for Cardiac Tissue Repair (Cell-Kro) 
U.S. Patent Application No. 14/771,747, filed on Aug 31, 2015 (Mar 8, 2012) 
EU Patent Application No. 14 760 147.0, filed on Mar 8, 2013 (Mar 8, 2012) 
The invention features compositions featuring (a) one or more of connective tissue 
growth factor (CTGF) and human C-terminal CTGF peptide; and (b) one or more of 
insulin and IGF-1; and methods of using such compositions to reduce cardiac tissue 
damage associated with an ischemic event or to enhance engraftment of a cell in a cardiac 
tissue. 
 
3. Compositions and Methods for Vascular Protection against Reperfusion Injury 
after Myocardial Ischemia 
U.S. Patent Application No. 62/126,374, filed on Feb 27, 2015 
The invention features compositions featuring (a) one or more of human hepatocyte 
growth factor (HGF) and (b) one or more of Immunoglobulin G (IgG); and methods of 
using such compositions to protect vascular cells against reperfusion injury in order to 
reduce cardiac tissue damage associated with an ischemic event. 
 
 
 
